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The discovery of benzodiazepines 
Once upon a time, Leo H Stembach synthesized a senes of compounds based on the quinazohne 3-
oxides, which had been the basis of his PhD thesis in Cracow, Poland, in the early 1930s A nng system 
unknown at that time, a benzodiazepine, had been obtained No biological tests had been earned out with 
these compounds, but it was hoped that some useful activity might be discovered 
In 1955, a team at Hoffmann-La Roche Ine led by Leo Stembach, decided to study some of these 
compounds and their denvatives All, but one of these were pharmacologically inert The last one was 
not tested, instead, it was labeled Ro 5-0690 and shelved because of other research pnonties In 1957 
Lowell O Randall, one of Stembach's chemists, turned up the compound and suggested it to be tested 
He discovered the pharmacologic profile of this compound, later named chlordiazcpoxide, that included 
pronounced sedative, anticonvulsant, and muscle relaxant effects with excellent safety Following 
clinical confirmation of the useful pharmacologic profile of chlordiazcpoxide, this benzodiazepine 
compound was launched in 1960 under the trade name Librium for the treatment of psychosomatic 
disorders, anxiety and related symptoms It was followed in 1963 by a second benzodiazepine named 
diazepam (Valium) When Libnum and Valium became known to physicians, their populanty was 
almost instantaneous and their commercial success was assured In rapid succession many other 
benzodiazepine denvatives appeared leading to the so-called "benzodiazepine boom" in the 1960s and 
1970s Benzodiazepines were generally accepted as a clear improvement upon older psychotropics such 
as barbiturates, were regarded to be of equally therapeutic efficacy, seemed to show only few side-effects 
and seemed to exhibit limited risk in overdosing This has led to a dramatically increase in use during 
1970s, which would be a happy end if the fairy-tale ended here 
Unfortunately, almost simultaneously some concern was growing about the increasing quantity of 
benzodiazepines consumed This concern is still fed in the 21st century by high prevalence rates of long-
term benzodiazepine use, while associated complications become increasingly clear This way, the long-
term use of once a promising therapeutic agent of which the synthesis had been described in a thesis in 
the early 1930s, could become an illness the treatment of which will be evaluated in this thesis 
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In this chapter, the study is put in a wider perspective by discussing the background of (long-term) 
benzodiazepine usage First, the actual prevalence rate of benzodiazepine use is presented, followed by 
the indications and guidelines for benzodiazepine treatment Subsequently, the pharmacological 
effects of benzodiazepines and the long-term therapeutic efficacy are considered Thereafter, the 
different side-effects of long-term benzodiazepine use are discussed, classified as dependence, 
psychomotor functioning and cognitive decline, falls and accidents, and finally suicide/mortality, 
followed by some economic aspects of benzodiazepine use (costs) Factors are summarised that might 
explain or contribute to the observed discrepancy between guidelines and clinical practice Finally, 
some aspects of treatment modalities for the discontinuation of long-term benzodiazepine use are 
mentioned briefly with respect to the gaps in the literature addressed by this thesis 
Prevalence of benzodiazepine use 
Benzodiazepines belong to the most presenbed drugs in Western countries In 1998, when this study 
started, approximately 11 6 million prescriptions for benzodiazepines were issued in The Netherlands, 
most of them (89%) by general practitioners, and in the case of repeat prescriptions 89% were issued 
without even any patient-doctor contact ' " The demographic characteristics of benzodiazepine users 
show that two-thirds are female and half are aged 65 or over M Over the past 5 years, the absolute 
number of benzodiazepine prescriptions has increased by one million, although a slight decrease was 
found when corrected for population growth and senescence ' In the same period, benzodiazepine use 
in other Western countnes also slightly decreased or stabilised 6 7 
The number of benzodiazepine users in the Netherlands was estimated at 1 9 million in 1998, 
which corresponds to a prevalence rate of 12 2% At least one-third can be considered long-term users 
(prevalence 4 2 - 5 3% a year) This group received on average 13 prescriptions a year, with an 
amount of 311 defined daily dosages according to therapeutic dosages of the World Health 
Organisation (WHO) ' However, reported prevalence rates of long-term benzodiazepine use differ 
considerably, which is partially explained by different definitions of long term use 7 In this thesis, 
long-term benzodiazepine use is defined as use for at least three months for the following reasons 
firstly, the likelihood of spontaneous discontinuation of benzodiazepine use dramatically decreases 
after this penod β " Secondly, this time window corresponds well with guidelines on the maximum 
duration of benzodiazepine treatment12 2 0 Based on our definition, we estimated the actual prevalence 
rate of long-term benzodiazepine use in the population to be about 3%, ι e , 72 patients in an average 
Dutch general practice 
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Indications and guidelines 
In the Netherlands, benzodiazepines are registered for 'the symptomatic treatment of pathological 
anxiety, tension and insomnia' In addition, 'benzodiazepines should be used for short-term treatment 
of insomnia only if patients are severely disabled or suffenng extreme distress' " The Dutch Health 
Care Insurance Council (College voor Zorgverzekeringen) has indicated the use of benzodiazepines 
for 'short-term treatment (two weeks) of severe insomnia' and 'pathological anxiety and tension', 
which is 'severe, disabling or subjecting the patient to unacceptable distress' These indications are 
subject to certain limitations, for example (a) pharmacological treatment of insomnia is justified only 
in cases of poor daytime functioning, (b) benzodiazepines can be prescribed to make patients with 
generalised anxiety disorder (GAD) accessible for cognitive-behavioural therapy, and (c) 
benzodiazepines arc only indicated as a temporary adjuvant for anxiety disorders other than GAD 
The guidelines of the Dutch Society of General Practitioners (Nederlands Huisartsen Genootschap) 
advise prescribing benzodiazepines for short-term treatment of insomnia only if basic sleep advice 
does not give any reliefl4 In addition, general practitioners should be cautious in using 
benzodiazepines for anxiety disorders, and should agree a piion with patients on the date of 
cessation According to the Guidelines of the Dutch Society of Psychiatrists (Nederlandse 
Vereniging voor Psychiatrie), benzodiazepines have a limited place in the treatment of generalised 
anxiety disorder, uncomplicated panic disorder, and uncomplicated social phobia 16 Finally, none of 
the Dutch guidelines consider benzodiazepines as a first treatment option for any disorder 
The Dutch guidelines correspond well with guidelines in other Western countries According to 
the recommendations of the US Food and Drug Administration and the US National Health and 
Medical Research Council, benzodiazepine use should not exceed tour months l718 The American 
Psychiatric Association raises 'senous questions' about the long-term use of benzodiazepines lg In the 
United Kingdom, the Committee on the Safety of Medicines staled that (a) benzodiazepines are 
indicated for the short-term relief (two to four weeks only) of anxiety that is severe, disabling or 
subjecting the individual to unacceptable distress, (b) the use of benzodiazepines to treat short-term 
mild 'anxiety' is inappropriate and unsuitable, and (c) benzodiazepines should be used to treat 
insomnia only when it is severe, disabling or subjecting the individual to extreme distress In addition, 
the lowest dose should be used and treatment should not be continued beyond four weeks ,0 
Pharmacological effects of benzodiazepines 
Benzodiazepines exert their effects by binding on the gamma-armnobulync acid receptor type A 
(GABAA receptor) The GABAA receptor complex is a glycoprotein that consists ol five subumts, 
which together form a CI channel This receptor can be activated by the interaction of two gamma-
aminobutync acid (GABA) molecules, leading to an allostenc modulation, which results in a CI 
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influx in the neuron and causes inhibition of that neuron Benzodiazepines bind to a specific site at the 
GABAA receptor, and exert their effect by enlarging the inhibitory effects of GABA GABA is the 
most frequently used inhibitory neurotransmitter in the central nervous system it is used by 
approximately 40% of the neurones This might explain the broad effects of benzodiazepines 
Benzodiazepines exert anxiolytic, sedative/hypnotic, muscle relaxant, anticonvulsant, and 
amnesic effects Different benzodiazepines have different pharmacokinetics, ι e, rate of absorption 
(Tmax), eliminiation half-life (V,), forming of (in)active metabolites and the apparent volume of 
distribution, and different pharmacodynamics, ι e, the affinity to the receptor (potency) 
Benzodiazepines are classified as being either hypnotic or anxiolytic depending on the rale of 
absorption and elimination half-life This classification, however, is rather arbitrary as in certain 
circumstances the duration of action depends more on dosage than on the elimination half-life 
An important issue in the long-term use of benzodiazepines is the development of tolerance to 
the differential effects of benzodiazepines Tolerance is defined as a reduced response to a certain 
dosage or the need for higher dosages to obtain a certain effect Tolerance can be scientifically 
established by comparing the dose-response curves of long-term benzodiazepine users with those of 
benzodiazepine-naive controls Most studies on the development of tolerance for the effects of 
benzodiazepines in humans, however, have been confined to healthy subjects receiving treatment for 
several weeks 2 7 1 0 Studies including long-term benzodiazepine users are scarce, while dose-response 
studies for most benzodiazepine effects, including the anxiolytic properties, are lacking altogether 
Nonetheless, many reports present data, which are suggestive for the development of tolerance This 
issue will therefore be dealt with in the following sections on therapeutic efficacy and adverse effects, 
looking at each effect separately 
Long-term therapeutic efficacy 
Benzodiazepines have been proven to be effective for the short-term treatment of both insomnia and 
anxiety However, long-term use of benzodiazepines is controversial because of the associated side-
effects (see below) and the apparent development of tolerance to the therapeutic action Furthermore, 
it remains unclear to what extent the suppression of withdrawal symptoms are mixed up with long-
term efficacy Also significant is the fact that most long-term benzodiazepine users report high levels 
of psychopathology32 and high levels of residual anxiety3354, which suggests only partial efficacy 
Moreover, the observation that the severity of these symptoms decreases in patients who lowered their 
daily dose by taking part in a discontinuation programme1516, suggests that long-term benzodiazepine 
use might even increase their psychopathology level For these patients, continued benzodiazepine 
treatment might obstruct a more appropnate therapy In addition, recent treatment studies show that 
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previous or co-morbid long-term benzodiazepine use independently predicted a poorer 
pharmacological and psychological treatment outcome in patients with anxiety disorders 37 39 
Tolerance to the sedative and hypnotic effects of benzodiazepines is reported to develop after 
treatment lasting only a few days or weeks " , A 1I Sleep laboratory studies show a return to baseline 
values within one to four weeks of treatment with benzodiazepines 40 Nonetheless, most patients claim 
that some benefit remains and may insist on continuing with the medication Schneider-Helmert et al 
(1988) found that patients reported sleeping longer while taking the drug than after discontinuation It 
has been suggested that this misperception might be due to the amnesic effect of benzodiazepines A 
recent meta-analysis on the treatment efficacy of benzodiazepines and Zolpidem drew attention to the 
lack of well-controlled evidence regarding the efficacy of long-term exposure to benzodiazepines in 
patients with pnmary insomnia42 Oswald et al (1982) evaluated the self-reported effects of 
lormetazepam 2 mg, nitrazepam 5 mg, and placebo during treatment week one and treatment week 24 
in 100 patients complaining of poor sleep not diagnosed as having pnmary or secondary insomnia 
Compared to placebo both benzodiazepines significantly improved the quality of sleep in the first 
week, but not in the last week of treatment Sleep latency significantly decreased in patients treated 
with benzodiazepines compared to those treated with placebo in the first as well as the last week of 
treatment However, the graphs show that for patients receiving nitrazepam this effect was not found 
consistently throughout the whole treatment penod 4:s 
Recent studies have questioned the anxiolytic efficacy of prolonged benzodiazepine 
treatment3144 Moreover, hardly any randomised controlled treatment trials have been carried out on 
the continuous therapeutic value of benzodiazepines for chronic anxiety Only two controlled studies 
addressing this aspect have been published Rickels et al (1983) concluded that a significant 
number of patients with generalised anxiety disorder benefited from prolonged diazepam treatment, 
and that tolerance to the anxiolytic effect did not develop over a 22 week period A closer inspection 
of this data raises numerous questions It shows that 50% of patients were already using 
benzodiazepines before entering the study, which meant the baseline anxiety severity was unknown, 
30% dropped out, because of fear of addiction, and 50% maintained improvement after switching to 
placebo The study of Schweizer et al (1993) randomised 106 patients diagnosed with panic disorder 
during an eight-week treatment penod with either alprazolam (n=37), Imipramine (n=30), or placebo 
(n=35), after which they were offered a six-month maintenance phase46 Both alprazolam and 
Imipramine were supenor to placebo after eight weeks of treatment All the patients who completed 
the maintenance phase were panic free after eight months This phase was completed by 27 (73%) 
patients on alprazolam, 11 (37%) on Imipramine, and 10 (29%) on placebo Dunng the maintenance 
phase, neither tolerance nor increase of daily dosage was observed ^ This study suggests long-term 
efficacy of alprazolam in panic disorder, although no significant differences between the three groups 
were detected dunng the maintenance phase due to low patient numbers at follow-up A subsequent 
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report of this study on the discontinuation of alprazolam showed that one third of the users could not 
discontinue alprazolam 
Side-effects 
The side-effects of benzodiazepine use are discussed below For the purpose of discussion, these 
effects are categonsed as dependence, psychomotor functioning and cognitive decline, falls and 
accidents, and suicide / mortality 
Dependence 
Directly after their introduction in the 1960s, the potential of benzodiazepines lo induce a state of 
physical dependence was described in chronic psychiatric patients who abruptly discontinued high-
dose benzodiazepine treatment (300 - 600 mg chlordia/epoxide a day) 4 8 4 9 In the early 1970s, the first 
case reports appeared in the scientific literature of patients who had escalated their benzodiazepine 
dosage beyond the upper limit of the recommended therapeutic range At that time, however, little 
notice was taken of these reports, partly because of the many reports on, and the widespread 
perception of, the safety of benzodiazepines In 1978, for example, Marks estimated the dependence 
risk with benzodiazepines as approximately one case per five million patient months 'at risk' for all 
recorded cases, and probably less than one case per 50 million months in therapeutic use 54 This 
conclusion was almost entirely based on patients who had escalated their dose beyond therapeutic 
levels 
The first study of physical dependence in normal-dose benzodiazepine usage was by Covi et al 
(1969, 1973), who desenbed a withdrawal syndrome after discontinuation of 20-week 
chlordiazcpoxide treatment " , 6 Malelzky & Klotter (1976), who reported a survey of 50 patients on 
therapeutic doses of diazepam, found that some patients had difficulty in discontinuing their diazepam 
use, experiencing anxiety, tremor, and insomnia " Concern about the dependence liability of 
benzodiazepines grew subsequently This was reflected, for example, in a paper by Lader (1978) 
entitled "Benzodiazepines - The opium of the masses9" and a paper by Tyrer (1974) entitled 
"Benzodiazepine Bonanza" ,H w In the years thereafter, both authors came forward with accumulating 
evidence for the existence of normal-dose dependence 
Tyrer conducted his studies within a clinical context substituting placebo (or propranolol) for 
diazepam or lorazepam ^ The studies of Lader were laboratory based 6I These studies unequivocally 
proved that normal-dose dependence, as manifested by a physical withdrawal syndrome, was a real 
entity and supervened even if the dosage was tapered off Moreover, the withdrawal symptoms of 
patients withdrawing form high- and low-dose usage were identical ω Table 1 shows the symptoms of 
the benzodiazepine withdrawal syndrome 
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Benzodiazepine withdrawal symptoms 
Less frequently 
Diarrhoea 
Hypersensitivity to sensory stimuli 
Depersonalisation / derealisation 




Loss of interest 





Confusion / incoherence 
Delusions 
Hallucinations 
Although normal-dose benzodiazepine dependence was generally accepted, the prevalence rate 
of withdrawal symptoms remained controversial. Reported prevalence rates of withdrawal symptoms 
after discontinuation varied widely (range 0 - 100%) mainly because of different study populations or 
type of assessment.45566063 66 A well-controlled study of Busto et al (1986) established that about 15-
25% of long-term (over 12 months) users develop a definite withdrawal syndrome.676* Generally, the 
withdrawal syndrome is relatively mild, although a small percentage of patients experience major 
distress. Most symptoms diminish two weeks after benzodiazepine discontinuation, but prolonged 
withdrawal syndromes for over a year have been described.6970 Large-scale prospective studies 
evalualing the epidemiology of benzodiazepine withdrawal, however, have not been carried out. 
The literature on benzodiazepine dependence mainly concentrates on physical dependence. 
However, the term dependence also involves certain psychological phenomena induced by the 
repeated taking of a substance. ' 7 The WHO proposed a psycho-physiological-biological model in 
1981 for dependence on psycho-active substances, which led to the general substance dependence 
criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R/1V) and the 
International Classification of Diseases (ICD-10) (see table 2). 
A recent literature review on the definition of benzodiazepine dependence showed that the DSM 
and ICD substance dependence criteria had only been used in a small number of the 250 papers 
reviewed.71 Definitions of benzodiazepine dependence that emphasised the physical aspects were still 
predominant. Two research groups found, independently of each other, that benzodiazepine 
dependence can be regarded as a multidimensional concept, including both physical and psychological 
aspects. In 1997, the first study was published that assessed the prevalence of benzodiazepine 
dependence according to the DSM-III-R and ICD-10 substance dependence criteria.76 Past-year 
prevalence rates were found in primary care and psychiatric outpatients of 40% and 63% respectively 




Cntena for benzodiazepine dependence according to DSM-IV and ICD-10. 
DSM-IV: 
Three (or more) of the following have been expenenced or 
exhibited at any time in the same 12-month period 
ICD-10: 
Three or more of the following have been expenenced or 
exhibited at some time dunng the last year 
Tolerance 
Withdrawal 
Persisterli desire or repeated unsuccessful efforts lo cut 
down or control use 
Substance taken in a larger amounl or over a longer 
penod of time than was intended 
Great deal of lime involved in obtaining or using the 
substance or recovering from its effects 
Important social, occupational or recreational activities 
given up 
Continued use despite knowledge of persistent or 
recurrent physical or psychological problems caused or 
exacerbated by the substance 
Tolerance 
Physiological withdrawal by reducing or ceasing intake 
Loss of control 
Progressive neglect of alternative pleasures or interests, 
increased amount of time necessary to obtain or take the 
substance or lo recover from its effects 
Persistent use despite evidence of harmful physical or 
mental consequences 
Craving 
Psychomotor functioning and cognitive decline 
Experimental studies clearly showed that initial administration of benzodiazepines negatively affected 
psychomotor performance.77 Many of the performance-impairing effects of benzodiazepines 
diminished after repealed administration of benzodiazepines for just a few weeks.78'79 However, acute 
challenge tests on long-term benzodiazepine users showed that tolerance does not fully develop for 
most measures of psychomotor performance. Especially high-dose users and elderly users experienced 
psychomolor-impairing effects after prolonged use.80 82 
Benzodiazepines also cause anterograde amnesia, which means benzodiazepines impair recall of 
what happened or what is learned under drug influence.84"86 Studies where no effect of 
benzodiazepines on amnesia was found mostly assessed patients at a specific time of day without 
taking into account when the previous dose of medication was taken, since the amnesia only lasted a 
certain number of hours after drug intake. Challenge tests on long-term benzodiazepine users indicated 
that tolerance did not develop for anterograde amnesia.83'87 88 Verwey et al (2000) evaluated a clinical 
aspect of anterograde amnesia by prospectively evaluating the presence of anterograde amnesia in 
people who tried to commit suicide with benzodiazepines.89 They found considerable memory 
impairments, also in patients who did not seem to be sedated, and suggested the efficacy of psychiatric 
consultation could be impaired because patients did not remember the content of the consultation. 
Several authors reported a global cognitive deterioration in benzodiazepine users.9091 Some 
researchers are even concerned for prolonged cognitive and generalized intellectual impairment long 
after benzodiazepine use has been discontinued.92'94 Rickels et al (1999) found that cognitive functions 
improved for many long-term benzodiazepine users after discontinuation of benzodiazepine intake. It 
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is not clear whether the cognitive functions fully recovered after discontinuation since no control 
group was included u Rummans et al (1993) found that detoxified benzodiazepine dependent patients 
had significantly more difficulty with tests on learning, and short-term and delayed recall, than the 
alcohol-dependent and the control group 95 In addition, Tata et al (1994) found significant impairment 
six months after discontinuation of long-term benzodiazepine use in patients' verbal learning and 
memory, psychomotor, visuo-motor, and visuo-conceptual abilities compared with controls The 
latter two studies, however, did not match the detoxified benzodiazepine users with controls for the 
level of anxiety, which might have acted as a confounder Kihc et al (1999) found no impairment in 
explicit memory 3 5 years after treatment with alprazolam compared with patients treated with 
placebo The difference they found in the weeks immediately after withdrawal was explained by 
interference of the drug with practice effects on the tests and habituation of anxiety after repeated 
exposure to the test situation 97 
Recently, a significant association was found between dementia and former use of 
benzodiazepines in a nested case-control study98 Furthermore, m a large population-based 
longitudinal study, chronic benzodiazepine use was associated with an accelerated decline in a global 
cognitive test (Mini Mental Stale Examination) and two attention tests (Trail Making Test, part B, 
Digit Symbol Substitution Test) compared to non-users over a four-year penod This study controlled 
for potential confounders, including the level of depressive symptoms and anxiety, but not for 
psychiatric diagnosis " 
Falls and accidents 
Benzodiazepines have been associated with a higher incidence of falls, which are presumed to be 
caused by their sedative and myorelaxant effects A recent meta-analysis on the association between 
psychotropic drug use and falls in the elderly found an increased nsk of 20 - 48% for users of 
benzodiazepines l00 Five studies directly evaluated the relationship between the use of 
benzodiazepines and falls leading to hip fractures Four of these studies used a case-control design' ' 
ltM, while the fifth was a prospective cohort study 10, Three of the four case-control studies found a 
significant increased nsk of falls leading to hip fractures in benzodiazepine users '01 '0 The four-year 
prospective cohort study compnsed 9516 patients, and found a relative nsk ratio of 1 6 for the use of 
long-acting benzodiazepines 105 A study especially designed to examine differences between short 
(temazepam) and ultra-short (tnazalom) acting benzodiazepines did not find any differences between 
these agents with respect to the relative nsk of falls 106 Moreover, benzodiazepine dosage and 
simultaneous use of two different benzodiazepines seems to contnbute more to an increased nsk of 
falls leading to hip fractures than elimination half-life 
The delelenous effects of benzodiazepines on a wide variety of driving-related performance 
tasks as well as actual dnving performance have been demonstrated '07108 Although an association 
between the use of benzodiazepines and traffic accidents could not always be confirmed m 
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epidemiologic studies - three studies did not find a significant association" "" - most epidemiologic 
studies confirmed that the use of benzodiazepines was associated with an increased nsk of traffic 
accidents"2"9 A recent review of case-control studies in this field suggests the use of 
benzodiazepines approximately doubles the nsk of motor vehicle accidents, placing elderly and high-
dose users at the highest nsk"" Although the highest nsk ratio was found in the first week of 
benzodiazepine use, the nsk ratio for long-term benzodiazepine use remained also significant "8 A 
recent study also found a greater nsk of traffic accidents associated with benzodiazepine use in people 
younger than 65 A dose-response relationship was evident, while the increased nsk was significant 
for long-acting benzodiazepines used as anxiolytics, as well as for short-acting hypnotics ' " 
It is not clear whether the relationship between benzodiazepine use and falls and accidents is a 
causal one, since depression, anxiety, and insomnia also have an impact on driving behaviour and 
falls l20 However, a study of psychotropic drugs and accidents in general practice found that 
benzodiazepine users had a significantly higher risk of having an accident compared with controls, 
while no elevated nsk was found compared to the controls in the periods benzodiazepine users were 
(temporarily) not taking the drugs l21 
Suicide / mortality 
Benzodiazepines are generally thought to be safe in overdose l22 Death after benzodiazepine 
intoxication is rare, and caused by respiratory depression with aspiration of gasine contents 121 
However, benzodiazepines are involved in almost half of suicide attempts 124 Over a ten-year penod, 
1576 fatal poisonings in the United Kingdom were attnbuted to benzodiazepines Within this period, 
the number of suicides based on an overdose of paracetamol was 2002, and for amitryptiline 1083 
The fatal toxicity index of benzodiazepines was calculated at 5 9 deaths per million prescriptions, 
when analyses were restneted to adult deaths classified as suicides, undetermined deaths, and 
accidents caused by benzodiazepines alone or together with alcohol '^ 
Costs 
Benzodiazepines are low-pnced drugs the median pnee for a 30-day treatment period of the 
recommended dosage in the Netherlands vanes from € 2 24 for diazepam to € 7 26 for medazepam 
and clobazam An exception is kctazolam, which is priced at € 18 76 n Due to the high prevalence rate 
of benzodiazepine usage, however, the pharmaceutical costs for benzodiazepines were estimated at € 
95 million per year in 1998 Moreover, benzodiazepines had the 7th highest annual increase in drug 
costs in the Netherlands ' The costs of associated side-effects, such as falls and traffic accidents, are 
difficult to estimate Henngs et al (1994) estimated the costs for treatment of hip fractures associated 
with the use of benzodiazepines in 1994 at € 15 9 million per year in the Netherlands 126 
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Discrepancy between guidelines and clinical practice 
The prevalence of long-term benzodiazepine use contrasts with current guidelines on treatment with 
benzodiazepines Many factors are thought to contnbute to this situation These factors include the 
characteristics of the drugs themselves, the users, the prescribing physicians, as well as certain 
practical or regulatory aspects There is little scientific evidence, however, about the extent to which, 
if any, these factors contnbute to prolonged use 
A major drug-related factor is the dependence liability of benzodiazepines, which can result in 
craving, drug-seeking behaviour, dose escalation, and a withdrawal syndrome after discontinuation 
Moreover, the temporary increase of symptoms of anxiety and insomnia as part of the withdrawal 
syndrome may persuade both patient and doctor to continue treatment Scientific evidence to support 
this hypothesis is, however, not available 
Long term benzodiazepine users are less concerned about the dependence liability and other 
side-effects of benzodiazepines than the prescribing physicians Patients also report a high level 
of usage satisfaction '29 Satisfaction however, is primarily a subjective factor and could be a 
consequence of dependence Moreover, the view of patients might be affected by their benzodiazepine 
use For example, patients might not remember nocturnal awakenings due to anterograde amnesia 
induced by the use of benzodiazepines41130 In addition, the excellent initial efficacy of 
benzodiazepines might persuade patients to continue their usage despite decreasing effects in the long 
term It has also been suggested that benzodiazepine intake is a coping mechanism for stress and 
anxiety, which might decrease the likelihood of discontinuation n l ' " Neurotic or dependent 
personality traits, frequently found to be associated with long-term benzodiazepine use"'1 n5, have also 
been suggested to contribute lo a prolonged use of these agents Although many patient factors are 
thought to contribute to continued benzodiazepine use a survey in England reported that 50% ot long-
term users expressed a desire to stop taking the medication However, the majority were uncertain 
whether or not their general practitioner wanted them to continue taking the drugs P7 ' " 
Physicians also contribute to prolonged benzodiazepine use Despite the lack of evidence for 
such, some physicians are convinced of the long term therapeutic value of benzodiazepines 
Furthermore, a survey in the Netherlands showed that a minonly of the long term benzodiazepine 
users were judged by their GPs to be able to discontinue benzodiazepine use l2'' Moreover, Cormack 
and Howells (1992) found that 19 of 24 interviewed GPs expected to save consultation time by 
prescnbing benzodiazepines If alternative treatments have been med repeatedly in the past, 
physicians might think they have nothing else to offer '112 m The attitude and capability of individual 
physicians vary widely, and probably contnbute to prolonged benzodiazepine use if they are not 
interested in psychiatry or do not consider long-term benzodiazepine use a major issue in daily 
practice n 9 Cnpwell (1988), for example, pointed out that some GPs cannot tolerate the emotional 
distress of their patients, as they may believe they have neither the time nor the skills to explore this 
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distress.'40 Intervention in prescription policy, by giving information to general practitioners, resulted 
in a decrease in benzodiazepine prescription.M1 ]A Moreover, Catalan & Gath (1985) found that bnef 
counselling is as effective as benzodiazepines, and no more time-consuming in the long term than 
writing a prescription.143 
Some practical aspects also contribute to a prolonged use of benzodiazepines. Repeat 
prescriptions, for example, are mainly issued without patient-doctor contact. Moreover, in 10% of 
such cases, the GP does not know the patient uses benzodiazepines.129 Such strategies limit the 
opportunity to evaluate and discuss the necessity of continued treatment with patients. Moreover, in 
the case of psychiatric co-morbidity, psychiatric screening may prevent long-term benzodiazepine use 
when alternatives are first choice. Finally, a substantial proportion of long-term users started 
benzodiazepine treatment during hospital admission and continues treatment thereafter thinking they 
need il on a long-term basis. 
Treatment modalities to discontinue long-term benzodiazepine use 
The discrepancy between current guidelines and clinical practice stimulated the development of 
several treatment strategies to discontinue long-term benzodiazepine use. Because chapter 3 deals 
specifically with the available knowledge on benzodiazepine discontinuation strategies, this section is 
limited to some definitions and to the major gaps in literature addressed by this thesis. 
Treatment strategies for discontinuation of long-term benzodiazepine usage can be divided into 
so-called 'minimal interventions' and systematic discontinuation programmes. Minimal interventions 
invite patients to quit their long-term benzodiazepine usage of their own accord by making them aware 
of the side-effects. This type of intervention is successful with about one-fifth of patients. Long-term 
follow-up data about 'minimal' interventions is, however, not available. 
Systematic discontinuation programmes are more extensive interventions in which patients 
discontinue their doses gradually and are guided a by physician. Two-thirds of patients successfully 
discontinue their benzodiazepine use with the aid of these programmes. To increase the effect, these 
programmes have been combined with either psychological or pharmacological treatment. Certain 
methodological issues, however, prevent a clear interpretation of these results. Firstly, systematic 
discontinuation programmes have never been compared with standard treatment in a randomised 
controlled fashion. Secondly, these programmes have mainly been tested in second-line settings, while 
most benzodiazepine users receive their prescriptions from general practitioners. Thirdly, long-term 
effects are largely unknown as follow-up data are scarce, and available follow-up studies have 
considerable methodological limitations. Fourthly, although some small, uncontrolled trials suggested 
that the addition of psychological treatment enhances the success rale of discontinuation, it has never 
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been examined in a randomised controlled trial. Finally, the associated economic consequences of 
these programmes have not yet been evaluated. 
To tackle the problem of long-term benzodiazepine use in general practice, advisory boards in 
both the Netherlands and the United Kingdom suggest a minimal intervention to start off with, and to 
only offer a more intensive, systematic discontinuation programme to those patients who fail to stop 
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Objeclives and structure of the thesis 
Study objectives 
The focus of this thesis is the outcome of different strategies aimed at the reduction of long-term 
benzodiazepine use in general practice. The main objectives are: 
• To summarise the available knowledge on strategies to discontinue long-term benzodiazepine 
use in the literature. 
• To evaluate the long-term outcome on benzodiazepine prescription of a 'minimal' intervention 
strategy to cut down long-term benzodiazepine use in general practice. 
• To evaluate the short- as well as the long-term outcome on benzodiazepine consumption and 
psychological functioning of a systematic discontinuation programme, with or without 
simultaneous group cognitive-behavioural therapy, as strategies to discontinue long-term 
benzodiazepine use. 
• To provide insight into factors that affect the outcome of the different benzodiazepine 
discontinuation strategies examined, especially with respect to the seventy of benzodiazepine 
dependence. 
• To evaluate the two systematic discontinuation programmes economically with no treatment at 
all. 
All data, except the literature review presented in chapter 3, were collected within the Benzorcdux 
project. The general structure of this project is therefore briefly presented here. 
Design of the Benzoredux Project 
The Benzoredux Project was carried out to evaluate a stepped care approach to reduce long-term 
benzodiazepine use (longer than three months) in general practice. The first step was the so-called 
'minimal' intervention strategy, i.e., a letter from the general practitioner (GP) containing advice to 
discontinue benzodiazepine use of their own accord. Patients who continued benzodiazepine 
consumption after this intervention were motivated to participate in the consecutive, more intensive 
step, i.e., a benzodiazepine lapering-off programme with or without simultaneous group cognitive-
behavioural therapy. 
The Benzoredux Project was carried out in 30 general practices in the Netherlands, with a total 
of 58 GP's. All long-term benzodiazepine users were identified in these practices through a 
computerised search in the GP prescription administration system (practice pharmacy records). All 
long-term benzodiazepine users meeting the in- and exclusion criteria received the minimal 
intervention. Three months later, patients were sent a second letter inviting them to make an 
appointment to evaluate the effect of this intervention. All patients included in the minimal 
The 'minimal' intervention strategy of the Benzoredux project will be elaborated in a second thesis by WJMJ Gorgels 
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intervention, whether or not they visited their GP after three months, were followed up for 21 months 
based on anonymous pharmacy records since no informed consent was required At the end of the 
follow-up penod, the results were compared with a control group matched among others for 
benzodiazepine use at the beginning of the study penod This control group was composed 
retrospectively in additional general practices in order to avoid bias by a more restncted policy 
regarding benzodiazepine use of GP's taking part in a benzodiazepine discontinuation project 
At the evaluation consultation three months after the minimal intervention, patients were asked 
to give their consent If they had stopped their benzodiazepine use, informed consent was requested 
for two additional follow-up assessments, one directly after giving informed consent and one at the 
end of follow-up, ι e , 18 months after the baseline assessment, and 21 months after receiving the 
initial letter For patients still using benzodiazepines, informed consent was requested for participation 
in a consecutive benzodiazepine discontinuation study 
This second study consisted of a randomised controlled tnal on the differential efficacy of 
tapenng off long-term benzodiazepine use combined with group cognitive-behavioural therapy, 
tapenng off alone, and a no-intervention control group given usual care The patients were assessed in 
three different ways Firstly, a computensed extraction of all drug prescnption data from the GP 
information system (= computerised medical records) was earned out This extraction was comparable 
to the follow-up of all patients selected and included for the minimal intervention Secondly, a self-
report assessment was earned out at baseline, at end of treatment (i e , 3 months after the start of the 
randomised controlled tnal), and at 18 months follow-up Thirdly, patients were asked to fill out five 
three-week cost-dianes to evaluate the medical consumption at baseline and 3, 6, 12 and 18 months 
after the start of the tnal 
Figure 1 shows a flow chart of the study, including the number of patients in each stage The 
setting of the study, the selection and recruitment of patients, and the assessments and analyses will be 
desenbed in more detail in Parts II, III and IV of this thesis Each chapter has been written as a 
separate article Consequently, although they discuss different topics, the chapters overlap each other 
is some areas The study received ethical approval of the University Medical Centre Nijmegen and 
was earned out between 1998 and 2001 The Benzoredux Project was funded by the Dutch Health 
Care Insurance Council (College voor Zorgverzekenngen, project OG97-015) 
Outline of the thesis 
This thesis consists of four parts The first part presents a systematic review of the literature on 
benzodiazepine discontinuation strategies In chapter 3, we focus on the discontinuation success rates 
of the different methods identified to discontinue long-term benzodiazepine use, and the factors related 
to discontinuation outcome Moreover, we address the most important areas where knowledge is 
lacking 
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Objectives and structure of the thesis 
Part II deals with the long-term term outcome of the first stage of the Benzoredux project, i.e., 
the 'minimal' intervention strategy. Chapter 4 evaluates the clinical outcome with respect to 
benzodiazepine consumption among all patients that received the minimal intervention (n=2004). A 
more detailed evaluation of relapse into benzodiazepine usage after this intervention is presented in 
chapter 5 concerning those patients who gave informed consent (n=109) for the additional follow-up 
assessments. 
Part III addresses the short-term efficacy of the two taper-off strategies using a randomised 
controlled design for patients who were not able to discontinue benzodiazepine use by themselves. 
Chapter 6 deals with the short-term outcome of this randomised controlled trial (n=180). Special 
attention is paid to the feasibility of these programmes in general practice and the added value of 
group cognitive-behavioural therapy. In chapter 7 we carry out a cross-validation of the 
Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ) on the baseline data of the 
randomised controlled trial to establish the clinical utility of this questionnaire in benzodiazepine 
taper-off programmes. In addition to previous studies on the Bendep-SRQ, we also investigated the 
predictive validity and time course during benzodiazepine withdrawal. 
Part TV evaluates the long-term efficacy of the two taper-off strategies. Long-term outcome of 
the two taper-off strategies with respect to benzodiazepine prescription, prescription for other 
psychotropic drugs, and psychological functioning is presented in chapter 8. In chapter 9, the results of 
a prediction analysis on long-term outcome is presented. Finally, the cost-effectiveness of both taper-
off strategies is compared with the no-intervention control group in chapter 10. 
In conclusion, chapter 11, summarises the main research findings of this thesis, and the 
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Background - Success rates of benzodiazepine discontinuation outcome vary substantially in literature. 
Aims - To syslemalically review outcome and associated variables of various methods to discontinue 
chronic benzodiazepine use. 
Method - Systematic literature review and meta-analysis of 60 papers identified using MEDLINE and 
PSYCHLIT from 1966-2003. Success rates were calculated at a patient level and the impact of the 
identified variables was tested. 
Results - The abstinence rate was 22% for minimal interventions and 63% for systematic 
discontinuation programmes. The latter was influenced by transfer to a long-acting benzodiazepine 
before discontinuation, dose level, hospitalisation and diagnosis. Limited evidence suggested a 
positive effect of adding carbamazepine and imipramine, while tapering off benzodiazepines. The 
addition of psychotherapy was poorly investigated. Long-term results are limited due to 
methodological differences. 
Conclusions - Although the heterogeneity in patient groups and study methodology, robust 
discontinuation rates were found. Long-term effects remain to be established. 
38 
Strategies to discontinue long-term benzodiazepine use a systematic review and meta analysis 
Introduction 
Since the early 1960s benzodiazepines have become widely available reaching prescription peaks in 
the 1970s ' Then, more and more data were reported indicating the disadvantages of long-term 
benzodiazepine use, such as the risk of dependence, a higher nsk of accidents and falls, and cognitive 
disturbances2 Although long-term therapeutic use of benzodiazepines is controversial, limited 
evidence suggests long-term efficacy in specific diagnostic groups such as panic disorder and social 
phobia3 4 The prevalence of these disorders, however, is relatively low in the light of the widespread 
use of benzodiazepines in the population 5 
Problems with stopping benzodiazepines in patients after long-term use initiated the 
development of treatment strategies to discontinue long-term benzodiazepine use Discontinuation 
studies suggest a successful discontinuation with low potency benzodiazepines, a longer half-life, use 
of low dosages, a shorter duration of use, less personality disturbances, and less psychopathological 
symptoms In this meta-analysis success rates of benzodiazepine discontinuation strategies and the 




An initial search of the databases Medline and Psychinfo (2003) was performed for the period 1966 to 
April 2003, using the keywords "benzodiazepine(s)" in combination with "withdrawal", 
"detoxification", "dependence", "discontinuation" or "long-term" This search was extended by a 
manual search of the reference lists of the included papers Papers were included in the review if they 
met the following criteria (a) evaluation of benzodiazepine discontinuation strategies, (b) presentation 
of outcome of discontinuation for each treatment arm separately or presentation of follow-up results, 
and (c) long-term benzodiazepine use defined as daily use for over three months (or longer) Review 
papers, double publications, animal research, clinical trials evaluating the efficacy of benzodiazepine 
treatment for a fixed period, and case reports less than five cases were excluded from this meta-
analysis 
Assessments 
ROV and JEC independently reviewed the selected studies by completing a coding form After the 
studies were coded twice, discrepancies in the two coding forms were resolved by consensus after 




In the coding form, the intervention type was added by distinguishing between minimal 
interventions and systematic discontinuation programmes Minimal interventions were defined as 
simple interventions applicable to large groups of patients, e g an advisory letter or a meeting in 
which long-term benzodiazepine users are advised to stop their use Systematic discontinuation 
programmes were defined as treatment programmes guided by a physician or psychologist The 
treatment programmes were subcategonsed into systematic discontinuation alone or combined with 
either psychotherapy or pharmacotherapy Psychotherapy was divided into three groups (anxiety 
management, cognitive behavioural therapy or other) based on the terminology used in the original 
articles Outcome data were classified as end of treatment outcome versus outcome at follow-up 
divided in 3 follow-up categones 3-6 months, 6-12 months or longer than one year 
Furthermore, the coding form consisted of the following items inclusion cnlena (minimal 
duration of benzodiazepine use [3, 6 or 12 months] and diagnosing benzodiazepine dependence 
[yes/no]), results at post treatment outcome and at follow-up, year of publication, randomised 
controlled inai (RCT) [yes/no], domain of use (i e psychiatric diagnosis or symptoms of included 
patients), steps of taper [abrupt, fixed, symptom guided], taper-off after transfer to a long-acting 
benzodiazepine [yes/no], history of benzodiazepine use (dose, type, duration of use), hospitalisation 
[inpatient/outpatient treatment], and setting [primary care, psychiatric clinic, addiction clinics] 
Mean equivalent benzodiazepine dosages were obtained from the articles or calculated in 
diazepam equivalents 6 If no information was available to calculate the dosage in diazepam equivalent, 
the dosages were categonsed as low (within the therapeutic range, or < 15 mg), high (above the 
therapeutic range, or > 30 mg) or medium (patients using benzodiazepines within and above the 
therapeutic range, or 15-30 mg) 
Statistical analysis 
Success rates were calculated at a patient level for each intervention type per coded variable Studies 
were weighted for the number of patients evaluated at outcome and results were separately described 
over controlled and uncontrolled studies 
The estimation of the success rate of systematic discontinuation programmes without additional 
treatment was conducted by putting all treatment arms evaluating such programmes together The 
success rates of systematic discontinuation combined with psychotherapy, respectively 
pharmacotherapy was compared to the success rates of all control groups lumped together as well as to 
the control groups of studies evaluating that particular therapy (fe control groups of all studies 
evaluating Imipramine) 
Since success rates could be biased by publication year, inclusion criteria or study design 
(uncontrolled versus controlled) these variables were analysed Subsequently, we analysed the effects 
of the coded variables by means of Pearson's chi-square tests Since these variables could also be 
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related, all results were controlled for possible two-way interaction effects using additional Pearson 
chi-square tests over the confounding variables. Only significant confounding effects are presented. 
Results 
The initial search yielded 4855 reference titles. Of these, 664 papers were identified with a possible 
relevance to discontinuation of long-term benzodiazepine use. After screening of the abstracts, and if 
necessary the full text, 606 papers were excluded (table 1) and 58 papers met the inclusion criteria. A 
manual search of the references of these papers yielded another 5 papers of possible relevance, of 
which two papers were included, resulting in a total of 60 papers: five papers on minimal interventions 
and 55 papers on systematic discontinuation (of which four papers exclusively reported follow-up 
data). These 55 papers were divided into systematic discontinuation without additional treatment 
(n=21) and systematic discontinuation combined with either psychotherapy (n=ll) or 
pharmacotherapy (n=23). Although follow-up data were presented in 30 study reports, in only five the 
duration was longer than one year.6"10 A full list of references included in this review can be obtained 
through the corresponding author. 
Table 1 
Reasons of not included papers 
Excluded on abstract / (ull text (n=606): 
Case report (n<5) 
No success rate reported 
Overlap of patient sample with earlier reported studies 
Traditional review benzodiazepine dependence 
Review epidemiology / phenomenology BZ dependence 
Treatment study (with discontinuation phase) 
Animal research 
Experimental research benzodiazepine dependence 
Multiple drug use treatment studies 
Other (mainly letters / editonals) 
The characteristics of the included papers are summansed in table 2. Age and gender distribution of 
patients recruited in the minimal intervention studies is comparable to that of long-term 
benzodiazepine users in the population. With the exception of two studies in an elderly 
population"12, the systematic discontinuation studies included patients with a somewhat lower age 
and a relatively high proportion of men. The number of dropouts was low in all study types, minimal 
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Overview of the design and characteristics of the selected studies 
Subject of selected studies 
Ν Ν 
(studies) (patients) 
Total Dropout Completers 
Sex ratio Mean age 
M F (years) 
Minimal Intervention: 
Uncontrolled 
Controlled with usual care 
Systematic Discontinuation alone: 
Uncontrolled 
Controlled with other discontinuation scheme 
Controlled with usual care 
Systematic Discontinuation with Psychotherapy: 
Uncontrolled 
Controlled with SD alone 
Controlled with other psychotherapy 
Controlled with other discontinuation scheme 
Systematic Discontinuation with Pharmacotherapy: 
Uncontrolled 
Controlled with SD alone 
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One study did not randomise the patients over the two conditions 
Three studies exclusively reported data at follow-up 
One study exclusively reported data at follow-up 
Minimal interventions (appendix A) 
A total of 800 patients were investigated in Five studies; 572 patients actually received a minimal 
intervention and 228 patients were included in control groups receiving usual care. All minimal 
intervention studies were conducted in primary care with patients using various benzodiazepines in 
low dosages. The follow-up period varied from 6 to 12 months with one study not reporting the 
duration of the follow-up period. The mean success rate was 16% (90/572) with a range of 5% to 
38%: the lowest success rale was obtained in the only study having a 12-month follow-up period and 
the highest success rate in a study evaluating a selected group of patients, namely the visitors of an 
informative meeting in stead of all patients invited to visit this meeting.' I4 The mean success rate 
over the three remaining randomised controlled trials was 22% (66/298), significantly supenor to the 
mean discontinuation rate of 9% (20/228) in the usual care control groups (χ2=16.9; df=l; p<0.001). 
No long-term data (>1 year) have been reported. 
Systematic discontinuation without additional therapies (appendices B, C and D) 
Of the 21 studies, 3 studies were excluded as they only reported follow-up success rates. The 
remaining 18 studies (998 patients) evaluated systematic discontinuation programmes without 
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additional therapies at the end of treatment None of these studies included a usual care control group, 
while only one study used a randomised controlled design evaluating 2 different discontinuation 
programmes (abrupt cessation versus one week of lorazepam replacement therapy) A substantial 
number of studies evaluating systematic discontinuation combined with additional psychotherapy or 
pharmacotherapy also included a treatment arm consisting of systematic discontinuation alone (five 
studies, 92 patients) or systematic discontinuation combined with placebo (16 studies, 416 patients) 
Although such treatment arms also evaluate systematic discontinuation without additional therapies, 
they differ methodologically from each other and the 18 uncontrolled studies Therefore, we first 
tested the difference in success rates between these three conditions (success rates uncontrolled 68% 
(674/998), controlled 48% (44/92), controlled with placebo 57% (237/416), which appeared to be 
significant (χ2=24 4, df=2, p<0 001) Factors that might be associated with discontinuation success arc 
therefore analysed in these three groups separately 
In table 3 an overview of success rates per study type and prognostic factors are shown Firstly, 
we checked for confounding factors influencing the success rales These factors were the year of 
publication or inclusion criteria (minimal duration of benzodiazepine use and diagnosing 
benzodiazepine dependence) Comparing the success rales of 4 consecutive 5-year periods showed a 
significant trend towards a less favourable outcome in time 1981-1985 68% (120/176), 1986-1990 
67% (263/390), 1991-1995 63% (286/455), 1996-2003 59% (286/485) (χ2=8 6, df=3, p=0 04), which 
could be explained by an increase in controlled studies over time The minimal duration of use tor 
inclusion in the study showed no meaningful association with outcome since studies exclusively 
including patients using benzodiazepines for over one year had significantly higher success rates 
(66%, 449/682) than those including patients using benzodiazepines at least three (63%, 301/602) or 
six months (56%, 125/222) (χ2=6 6, df=2, p=0 04) Moreover, success rates of studies in which 
participants had to fulfil the criteria of benzodiazepine dependence (67%, 126/187) did not differ from 
those including patients based on a specific duration of use only (63%, 829/1319) (χ2=1 5, df=l, 
p=0 23) 
Transfer to long-acting benzodiazepines gave a significant 9% improvement in the success rate 
(see table 3) Subsequent analyses showed confounding with hospitalisation and dose level Transfer 
to long-acling agents resulted in significantly higher success rales in outpatient treatment 
(p=0 003), but not in inpatient treatment (p=0 87) It also resulted in higher success rates in patients 
using medium (p=0 002) or high dosages (p=0 02), but not in patients using low dosages (p=0 56) 
With respect to the mode of discontinuation three steps of taper were distinguished abrupt 
cessation, fixed taper-off schemes lasting from 1 to 8 weeks and symptom-guided taper-off methods 
which vaned in time from 1 week to 15 months Improved success rates for symptom-guided taper-off 
methods were identified Abrupt cessation (58%, 84/116) and gradual taper (62%, 654/1063), 
however, did not differ significantly (χ2=0 9, df=l, p=0 35) The comparison of abrupt cessation and 
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Table 3 
Associations with success rate of systematic discontinuation without additional treatment 
Uncontrolled Controlled Controlled with placebo Total group 
18 studies / 998 patients 5 studies / 92 patients 19 studies / 416 patients 42 studies /1506 patients 
Outcome categories Success % (n/N) Statistics Success % (n/N) Statistics Success % (n/N) Statistics Success % (n/N) Statistics 
è 
Variables 
Transfer to long-acting BZ 
Steps of taper 
Dose (diazepam eqv.) 
Duration of use 
Hospitalisation 
Setting 






< 15 mg 
15 -30 mg 
> 30 mg 
< 5 years 
5 - 1 0 years 
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gradual taper was confounded by hospitalisation gradual discontinuation was significantly better 
compared to abrupt cessation among inpatient treatment (50% versus 90%, χ2=19 5, df=l, p<0 001), 
but not in an outpatient setting (59% versus 58%, χ2<0 1, df=l, p=0 86) In contrast to our 
expectations, this finding was not confounded by dose level 
Dose level was not associated with success rate However, after controlling for hospitalisation, 
high dose users in the outpatient sample had significantly lower success rates (23%, 10/34), compared 
to low (61%, 371/609) or medium dose users (58%, 241/419) Moreover, the higher success rate of 
high dose users in the sample of uncontrolled studies (see table 3) could be explained by confounding 
with hospitalisation as most high dose users in this condition were treated as inpatients The duration 
of benzodiazepine use before discontinuation was not related to outcome The average duration of use 
was 6 9 years (s d ± 3 3) 
Hospitalisation (i e inpatient versus outpatient treatment) showed a significant difference in 
success rates in favour of inpatient treatment Setting had a significant effect on the success rate, 
achieving lower success rates in addiction clinics compared to primary care and psychiatric care 
However, subsequent analyses showed that these effects were due to interaction with the other 
variables studied 
Due to a lack of adequate psychiatric diagnosing in most studies, we defined psychopalhology 
as a "domain of use" variable Based on inclusion cntena and/or patient characteristics, we classified 
them as suffering from insomnia, from anxiety disorders, from neurotic disorders (defined as including 
patients with a combination of insomnia, anxiety disorders, and/or depression) and patients diagnosed 
as multiple drug users Although patient numbers are low and considerable overlap exists in diagnoses 
of each category, the selective use of benzodiazepines for insomnia tended to be associated with a less 
favourable outcome The fact that multiple drug users achieved comparable success rates as other 
patient groups could be explained by confounding as multiple drug users more often received inpatient 
treatment 
Systematic discontinuation combined with psychotherapy (appendix C) 
Eleven studies were identified using psychotherapy to facilitate systematic benzodiazepine 
discontinuation programmes Fifty-nine patients received no additional psychotherapy (control groups) 
and 201 patients received additional psychotherapy The median number of patients per treatment 
condition was 12 The success rates ranged from 0% to 100% (overall success rate 54%, 109/201) 
Discriminating between different types of psychotherapy or group versus individual therapy failed due 
to low patient numbers and due to predominance of one large study evaluating the effect of additional 
individual cognitive-behavioural therapy (CBT) in multiple drug users l 5 
Two of the 11 studies compared systematic discontinuation without additional treatment to 
systematic discontinuation combined with psychotherapy in a randomised controlled design The first 
study was conducted in patients with panic disorder and found a significantly higher success rate 
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among patients receiving additional group CBT. The second study was conducted among multiple 
drug users and found a significant lower success rate among patients receiving additional CBT.'5 
Systematic discontinuation combined with pharmacotherapy (appendix D) 
Twenty-three studies evaluated the effect of systematic discontinuation combined with 
pharmacotherapy. We excluded five studies from analyses. Four small, uncontrolled studies (up to 17 
patients per study) evaluated the use of drugs that have also been examined in larger controlled trials. 
The fifth study was excluded, because it reported outcome data at 6 months follow-up only. Table 4 
presents the end of treatment results per agent of the remaining studies, as well as compared to the 
control groups within the aggregated studies (within studies control group) as compared to all 18 
control groups of these studies lumped together (overall control group) 
Table 4 
Success rates of systematic discontinuation with pharmacotherapy 
Active drug Control group 
No of Within studies Overall 
Success % (n/n) 
43% (15/35) 
59% (60/101) 
7 1 % (43/61) 
92% (54/59) 
48% (11/23) 





3 1 % (4/13) 
8 1 % (30/37) 
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Number of studies is > 18, since some studies had more than 2 treatment arms 
Four drugs (carbamazepine, melatonin, sodium valproate and imipramine) were significantly 
better compared with systematic discontinuation alone as shown by the aggregated results of the 
studies evaluating these drugs (within studies control group). Carbamazepine and imipramine were 
also significantly better when compared to the overall control group of all studies lumped together, 
whereas melatonin and sodium valproate were not. The significant effects of melatonin and sodium 
valproate, therefore, can be explained by a relatively low success rate in the control group in the 
studies evaluating these drugs. Although addition of hydroxyzine yielded a relatively high success 
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Long-term follow-up studies 
To evaluate long-term results, all treatment arms of the systematic discontinuation studies of appendix 
B, C and D were grouped together Sixteen studies reported results at 3-6 months follow-up, nine 
studies at 6-12 months follow-up and five studies reported follow-up data for over one year The 
success rates of studies reporting a follow-up duration of less than one year did not differ significantly 
(3-6 months follow-up 57%, 338/598 versus 6-12 months follow-up 59%, 180/304) (χ2=0 6, df=l, 
p=0 44), while both categories had significantly higher success rales compared to studies reporting 
follow-up data for over one year (44%, 145/329) (χ2=17 9, df=2, p<0 001) 
A closer inspection of these data showed that all outcome data of studies reporting results with a 
duration of follow-up of less than one year were measured cross-sectionally The success rates of 
studies reporting results for over one year varied widely depending on outcome criteria for 
benzodiazepine use Point prevalence of abstinence as measured dunng the month before follow up 
assessment revealed success rates of 54% and 58%7 9, while longitudinal monitoring yielded much 
lower success rates of 15% and 25% 6 1 0 The long-term success rate of 94%, reported by Ashlon 
(1987), seemed the most favourable8 Investigating these data more thoroughly wc found that 5 
successfully treated patients relapsed and discontinued their benzodiazepine use after a second 
attempt, giving a continuous abstinent rate of 82% (41 of 50 patients) 
Discussion 
Main findings 
The main finding of this meta-analysis was that 22% (66/298) of patients were able to discontinue 
benzodiazepine use after a minimal intervention, whereas 63% (955/1506) manages to discontinue 
benzodiazepine use with the aid of a systematic discontinuation programme Although outcome of the 
minimal interventions has only been tested in primary care, patient groups were comparable to the 
'average' benzodiazepine user in the population suggesting a high generahsabihty Follow-up data for 
discontinuation over one year are lacking Systematic discontinuation studies have been tested in 
various settings However, the age and gender distribution of these studies show selective recruitment 
towards younger, male patients The impact of the predefined variables and additional therapies on 
outcome of systematic discontinuation will be discussed below Follow-up success rates of systematic 
discontinuation studies depended highly on the type of measurement cross-sectional measures 
resulted in high and longitudinal measures in low success rates This discrepancy suggests intermittent 
usage patterns in patients after taking part in a systematic discontinuation programme, which has also 
been reported by Couvée et al (2002) 17 The main limitation interpreting the success rates of 
systematic discontinuation studies, especially the low success rates at follow-up, is the lack of studies 




The heterogeneity of the included studies implies that large generalisations may not be possible In an 
attempt to overcome this problem, success rates were separated by some pre-defined variables, known 
or suggested to be associated with discontinuation success (see below) The clinical impression that 
patients with specific disorders - for example panic disorder, substance use disorder or borderline 
personality disorder - have more difficulty than others could not be examined due to the lack of 
information in the selected studies Although specified diagnoses of psychiatric condition were not 
reported in the studies of this meta-analysis, a distinction was possible between patients with 
exclusively insomnia, with exclusively anxiety disorders, with neurotic disorders (insomnia, anxiety or 
depressive disorder or a combination) or substance use disorders, being aware that these four 
categones are also not mutually exclusive Moreover, one might argue if the diagnosis at study start 
reflects the underlying disorder adequately, since psychiatric symptomatology is known to be affected 
by benzodiazepine treatment "' 
Variables associated with successful outcome of systematic discontinuation 
Transfer to a long-acting agent (most often diazepam) before systematic discontinuation yielded 
higher success rates for patients using benzodiazepine dosages of over 15 mg diazepam equivalent and 
for patients treated in an outpatient setting The theoretical advantage of the transfer to long-acting 
agents is the occurrence of less severe withdrawal symptoms caused by a more gradual blood level 
decrease and as a consequence a supenor effect on outcome 
Symptom-guided benzodiazepine withdrawal indicated to result in the highest success rates, but 
this method was dominated by the results of one centre 8 Fixed gradual discontinuation programmes 
were supenor over abrupt cessation m an inpatient setting However, both strategies resulted in 
comparable success rates in an outpatient setting Although no head-to-head compansons have been 
conducted comparing abrupt and gradual discontinuation, Petrovic et al (2002) showed significant 
supenor effects of abrupt cessation with lorazepam 1 mg replacement for one week compared to 
abrupt cessation in a randomised controlled fashion 12 Moreover, it is well-known from controlled 
tnals that abrupt discontinuation of short-acting benzodiazepines leads to lower success rates " 
High dose users (over 30 mg diazepam equivalent daily) had significantly lower success rates 
compared to low or medium dose users in an outpatient setting Since no differences were found 
between low or medium doses we may conclude that for the majonty of patients treated within the 1-
30 mg range, dose level has no cntical influence on success rates When treated as inpatients, dose 
level was not associated with success rate The duration of treatment with benzodiazepines did not 
cntically influence outcome 
Success rates were comparable in pnmary care and psychiatric care, while significantly lower 
success rates were achieved in addiction climes Studies evaluating inpatient treatment showed an 
important difference in favour of outpatient treatment This might indicate that a controlled 
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environment, with no patients "lost-to-follow-up", leads to higher success rates. Two diagnosis groups 
could be identified having lower success rates: multiple drug users and patients suffering from 
insomnia, although the latter finding was based on only two studies. 
Addition of psychotherapy 
The addition of psychotherapy did not result in higher success rates in the whole group of long-term 
benzodiazepine users, although definite conclusions are hampered as most studies had low patient 
numbers and a poor methodological quality. In addition, two well-designed randomised controlled 
trials suggest different efficacy in different diagnostic patient groups. The addition of CBT proved to 
be efficacious in patients diagnosed with panic disorder, but not in substance abusers. This 
discrepancy may be explained by the fact that additional psychotherapy only affects the success rate 
when it is based on the treatment of the underlying disease. 
Addition of pharmacotherapy 
The addition of the psychoactive drugs carbamazepine and Imipramine significantly increases the 
success rates compared to systematic discontinuation alone based on the aggregated results of 4, 
respectively 2 randomised controlled trials. Sodium valproate and melatonin showed also higher 
success rates than systematic discontinuation alone. However, both agents were tested in single 
controlled trials with low patient numbers per treatment arm (up to 18 patients) and with a relatively 
low success rates in the control groups. Therefore, replication of these results is suggested before 
using sodium valproate and melatonin in clinical practice. 
Clinical implications 
Whether long-term benzodiazepine use must be discontinued should be balanced on diagnosis, current 
symptoms, side-effects, treatment history and alternative treatment modalities. If one decides to 
discontinue long-term benzodiazepine treatment, the following guidelines based on the results of this 
meta-analysis can be given. 
We advice a first treatment in primary care starting with a minimal intervention by providing 
general information to patients and encouraging them to stop the use of benzodiazepines by 
themselves. If patients are unable to stop their benzodiazepine use this way, a systematic 
discontinuation programme should be offered to them, since 63% of the patients can be successfully 
discontinued. The results suggest that patients must be transferred to a long-acting agent and tapered-
off a by fixed discontinuation programme. 
If this strategy fails, patients could be referred for second line treatment At this stage it remains 
unclear which treatment options should be used. We suggest the following options, depending on local 
circumstances and patient characteristics. Patients could be offered a symptom-guided taper-off 
scheme offering specialised care to prevent significant deterioration or relapse of the underlying 
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disease during or after discontinuation. Patients using high dosages (> 30 mg diazepam equivalent) 
might be offered inpatient treatment. Adding carbamazepine or Imipramine could be offered or a 
psychotherapy programme during discontinuation aimed to treat the underlying disease. In case of 
substance abusers, we suggest to start with inpatient treatment in a specialised treatment setting. 
Future research 
Future research should acknowledge the gaps in literature identified in this review, for example head 
to head comparisons of systematic discontinuation programmes with different taper rate and direct 
comparisons over settings. Special attention should be paid to diagnostic evaluation before and after 
tapering-off, stepwise programmes for treatment resistant patients and long-term follow-up studies. As 
the high prevalence of long-term use of benzodiazepines concerns a public topic, a cost-effectiveness 
analyses should guide the long-term treatment with benzodiazepines as well as the discontinuation of 
this treatment to shed more light on the economic costs. 
50 
Strategies to discontinue long term benzodiazepine use a systematic review and mela analysis 
References 
Article 
1 Lader M History of benzodiazepine dependence Journal of Substance Abuse and Treatment 1991, 8 53 59 
2 Taylor S, McCracken CFM, and Wilson KCM Exlenl and appropnaleness of benzodia7epine use British Journal of 
Psyihiatry 1998, 173 433 438 
3 Schweizer E, Rickeis Κ, Weiss S, et al Maintenance drug trealmenl of panic disorder I Results of a prospective, 
placebo-controlled comparison of alprazolam and Imipramine Archives of General Psychiatry 1993,50 51 60 
4 Otto MW, Pollack MH, Gould RA et al A comparison of the efficacy of clonazepam and cognitive behavioral group 
therapy for the treatment of social phobia Journal of Anxiety Disorders 2000, 14 345 358 
5 Zandstra SM, Fuhrer JW, Van de Lisdonk EH, et al Different study criteria affect the prevalence of ben/odia/epine use 
Social Psychiatry and Psychiatric Epidemiology 2002, 37 139-144 
6 Zitman FG and Couvée JE Chronic benzodiazepine use in general practice patients with depression an evaluation of 
controlled Irealmenl and taper-off Report on behalf of the Dutch Chronic Benzodiazepine Working Group British 
Journal of Psychiatry 2001, 178 317 324 
7 Golombok S, Higgitt A, Fonagy P, et al A follow up study of patients treated for benzodiazepine dependence British 
Journal of Medical Psychology 1987, 60 141 149 
8 Ashton H Benzodiazepine withdrawal outcome in 50 patients British Journal of Addiction 1987, 82 665 671 
9 Rickels K, Case WG, Schweizer E, et al Long-term benzodiazepine users 3 years after participation in a discontinuation 
program American Journal of Psychiatry 1991, 148 757-761 
10 Holton A, Riley Ρ, and Tyrer Ρ Factors predicting long-term outcome after chronic benzodiazepine therapy Journal of 
Affective Disorders 1992, 24 245 252 
11 Petrovtc M, Pevemagie D, Van Den NN, et al A programme lor short-lemi withdrawal from benzodiazepines in 
genalnc hospital inpatients success rale and effect on subjective sleep quality International Journal of Geriatra 
Psychiatry 1999, 14 754 760 
12 Petrovic M, Pevemagie D, Manman A, et al Fast withdrawal from benzodiazepines m genatnc inpatients a randomised 
double-blind, placebo-controlled trial European Journal of Clinical Pharmacology 2002, 57 759 764 
13 O'Leary M A novel approach to tackling the benzodiazepine problem in general practice Psychiatric Bulletin WW), 
13 180 181 
14 Morgan JD, Wnghl DJ and Chrystyn H Pharmacoeconomic evaluation of a patient education letter aimed at reducing 
long lerm prescribing of benzodiazepines PharmtHy World and Science 2002, 24 231 236 
15 Vorma H, Naukkannen H, Sama S, et al Treatment of oul-palient with complicated benzodiazepine dependence 
comparison of two approaches Addiction 2002,97 851 859 
16 Olto MW, Pollack MH, Sachs GS, et al Discontinuation of benzodiazepine treatment efficacy of cognitive behavioral 
therapy for patients with panic disorder American Journal of Psychiatry 1993, 150 1485-1490 
17 Couvée JE, Timmermans EAY and Zitman FG The long term outcome of a benzodiazepine discontinuation programme 
in depressed outpatients Journal of Affective Disorders 2002, 70 133-141 
18 Birkcnhaeger TD, Moleman P, and Nolen WA Benzodiazepines for depression'' A review of the literature 
International Journal of Psychopharmacology 1995, 10 181-195 
19 Rickeis K, Schweizer E, Case WG, et al Ixmg-term therapeutic use of benzodiazepines I Effects of abrupt 
discontinuation Archives of'General Psychiatry 1990, 47 899 907 
20 Drake J Temazepam Planpak' a multicentre general practice inai in planned benzodiazepine hypnotic withdrawal 
Current Medical Research Opinion 1990, 12 390 393 
21 Garfinkel D, Zisapel N, Wainstetn J et al I^audon M Facilitation of benzodiazepine discontinuation by melatonin a 












Cormack et al 
(1994) 
Bashir et al 
(1994) 
Morgan et al 
(2002) 
Interventions (η)* 
Visitors of the meeting invitated by letter for 








Advisory consultation followed by offenng 
relaxation therapy & counselling 
Usual care 
Advisory letter 
Advisory letter + information sheet 
Usual care 
Personal advice + self-help booklet 
Usual care 
Advisory letter 
Results end of treatment 
Ratio* (% stopped) 
Results follow-up 
Ratio' (% stopped) 
12/32 (38%) 
9 months 
1 21/112 (19%) 
2 11/115 (10%) 
6 months 
1 2 3 / 6 5 (35%) 
2 13/75 (17%) 
3 6 / 6 9 (9%) 
6 months 
1 9 / 4 6 (20%) 
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Appendix Β 
Systematic discontinuation programmes without additional treatment 
Authors 
Petursson el al 
(1981) 




Harrison el al 
(1984) 
Tapering-off scheme(s) (η) 
Placebo-controlled, double-blind, fixed 
discontinuation in 2 or 4 weeks 
Fixed discontinuation with weekly visits (median 3 
weeks) 
Fixed discontinuation with two weeks 100%, two 
weeks 50% and finally two weeks 25% 
Fixed discontinuation in 10 days (range 2-18) 
Results 
End of treatment 














Rickels et al 1 Abrupt discontinuation 
(1986) 2 Failed abrupt, followed by fixed 
discontinuation in 4 weeks 
3 Not accepted in study protocol 
4 Abrupt outside study protocol 
1 3 8 / 5 9 (64%) 
2 Not reported 
3 Not reported 
4 Not reported 
6 - 12 months 
All patients together 
3 2 / 6 2 ( 5 1 % ) 
Ghodse et al Abrupt discontinuation for 24-48 hours, followed 14 / 25 (56%) 
(1987) by diazepam substitution and fixed disconlinuaion (10 abrupt, 14 gradual) 
if necessary to restrain withdrawal symptoms 
Ashton et al 
(1987) 
Symptom-guided discontinuation m 1 week to 125 4 9 / 5 0 (9B%) 
months 
Not evaluated 
10 - 42 months 
4 4 / 47 (94%) 
Golombok et al 
(1987) 
Symptom-guided discontinuation Nol reported 
1 - S years 
2 5 / 4 6 (54%) 
Soyka el al 
(1988) 
Fixed discontinuation every 5 days steps 50%, 2 0 / 2 0 (100%) 
25%, 12% of the original dose 
Not evaluated 
Rickels el al 
(1990) 
Abrupt discontinuation 2 9 / 4 7 (62%) 
5 weefcs 
2 0 / 4 7 (43%) 
Schweizer et al 
(1990) 
Fixed discontinuation 25% a week in the firet 2 3 9 / 6 3 (62%) 
weeks and 4x 12 5% in Ihe last two weeks 
5 weeks 
3 4 / 6 3 (54%) 
Drake Fixed discontinuation with dose reductions every 2 6 / 4 4 (59%) 
(1991) 2 weeks from 10 mg to 5 mg to 2 mg 
Randomised allocation to 
Murphy et al Fixed discontinuation 25% reduction every 2 4 4 / 6 8 (65%) 
(1991 ) weeks after randomised allocation to lorazepam, 
diazepam or bromazepam 
3-6 months 
23 / 44 (52%) 
Rickels et al 
(1991)* 
Brenner et al 
(1991) 
DuPont et al 
(1992) 
Abrupt & fixed discontinuation in 4 weeks 
Fixed discontinuation with 50% of the previous 
dose every 5 days 










End of treatment 5 years 
Holtonetal Fixed discontinuation two weeks 100%, two 36/41 (81%) 6/41(15%) 
(1992)* weeks 50% and finally two weeks 25% 6 months follow-up 
26/41 (63%) 
McDuffetal Fixed discontinuation (average 7 8 weeks, range 7/15(47%) Not evaluated 
(1993) 2 - 22) according to dose and patient, early 
reduction steps were typically greater than 
subsequent ones 
Habraken et al 
(1997) 
Schweizer et al 
(1998) 
Pelrovic et al 
(2002) 
Double-blind 
1 Fixed discontinuation in 5 weeks 3x 25% a 
week followed by 2x 12 5% a week 
2 No-intervention 
Abrupt & fixed discontinuation in 4 weeks 
1 Abrupt discontinuation 




1 10/10 (50%) 
2 16/20 (80%) 
12 months 
1 17/27(63%) 
2 Control group 
Not evaluated 
Not evaluated 
Rickels el al 1991 is the long-term follow-up of patients included of different short-term studies of Rickels & 
Schweizer, 
Holton et al 1992 is the long-term lollow-up study of Tyrer et al 1983 
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Appendix C 
Systematic discontinuation programmes with psychotherapy 
Authors 
Comnack et al 
(1983) 
Treatment arms (n) 
11-13 weeks AMT without structured tapenng-off 
Results 
End of treatment 
Ratio* (%) 






and non-consent patients 
12 months 
Nathan et al 1 Fixed discontinuation + relaxation and stress 1 1/4 (25%) 1 0 / 4 (0%) 
(1986) managementtraining 
2 Fixed discontinuation + psychoanalytic 2 0 /3 (0%) 2 -
psychotherapy 
Higgitt et al 
(1987) 
Sanchez-Craig 
et al (1987) 
Schmaus et al 
(1987) 
Crouch et al 
(1988) 
Joughin et al 
(1991) 
Otto et al 
(1993) 
Elsesser et al 
(1996) 
Chamey et al 
(2000) 
Vorma et al 
(2002) 
1 Fixed discontinuation alone 
2 Fixed discontinuation + AMT 
1 Fixed discontinuation + CBT 
2 Abrupt discontinuation + CBT 
Abrupt discontinuation + individual psychotherapy, 
relaxation - , occupational - and physical training 
Fixed discontinuation + AMT 
Fixed discontinuation + inpatient AMT and outpatient 
group therapy 
1 Fixed discontinuation alone 
2 Fixed discontinuation + group CBT 
1 Fixed discontinuation + AMT 
2 Fixed discontinuation + CBT 
Fixed discontinuation + group and individual therapy 
1 Fixed discontinuation alone 
2 Fixed discontinuation + CBT 
1 3 /6 (50%) 
2 8 /10(80%) 
1 9 /23(39%) 
2 11/19(42%) 
1 7 / 7 (100%) 
2 7 / 7 (100%) 
4 / 1 2 (33%) 
2 1 / 2 1 (100%) 
1 4 /16(25%) 
2 13/17(80%) 
1 5 /10(50%) 
2 7 /9 (78%) 
3 months 
6/12(50%) 
1 10 /37 (27%) 
2 5 / 3 9 (13%) 
12 months after baseline 
Combined results 
4 /16 (25%) 
12-months 
1 5 /23(22%) 
2 8 /19 (42%) 
3 months 
6 / 9 (67%) 
6 months 
14 /21 (67%) 
Three months 
1 5 /16(31%) 








Systematic discontinuation programmes with pharmacotherapy 
Authors 
Tyreretal (1981) 
Schweizer et al 
(1986) 
Lader et al 
(1987) 
Ries et al 
(1989) 
Ashton et al 
(1990) 
Udelman et al 
(1990) 
Cantopher et al 
(1990) 
Treatment arms (η) 
1 
2 
Abrupt discontinuation + propranolol 60-120 mg 
Abrupt discontinuation + placebo 
Abrupt and fixed discontinuation + buspirone 20 mg 
1 
2 
Fixed discontinuation + buspirone 20-30 mg 
Fixed discontinuation + placebo 







Fixed discontinuation + buspirone 10 mg 
Fixed discontinuation + placebo 
Fixed discontinuation + buspirone 15 mg 
Fixed discontinuation + placebo 
Abrupt discontinuation + propranolol 80 mg 
Fixed discontinuation alone 
Results 
End of treatment 
Ratio* (%) 
4 11/20(55%) 
5 7 / 2 0 (35%) 
9 / 1 5 (60%) 
1 5 / 1 3 (38%) 
2 6 / 1 1 (55%) 
9 / 9 (100%) 
1 4 / 1 1 (36%) 
2 11/12(92%) 
3 2 1 / 3 6 (58%) 
4 17/36(47%) 











1 4 / 1 5 ( 2 7 % ) 
2 11/16(69%) 
Rickels et al 1 Fixed discontinuation + placebo 1 2 6 / 4 5 (58%) 
(1990) 2 Fixed discontinuation + Imipramine 100-300 mg 2 1 1 / 1 4 (79%) 
3 Fixed discontinuation + buspirone 25-45 mg 3 1 1 / 1 3 (85%) 
4 Fixed discontinuation-ι-carbamazepme 200-600 mg 4 12/13(92%) 
Garcia-
Borreguero et al 
(1991) 
1 Fixed discontinuation alone 1 





Di-Costanzo et al 
(1992)· 
Lader et al 
(1993) 








Fixed discontinuation + carbamazepme 400-800 mg 
Fixed discontinuation + placebo 
Fixed discontinuation + carbamazepme (6-8 μg/ml) 
Fixed discontinuation + placebo 
Fixed discontinuation + alpidem (100-150 mg) 
Fixed discontinuation + placebo 





















Schweizer et al 
(1995) 
1 Fixed discontinuation + progesteron 900-3600 mg 









Tyreretal (1996) 1 Fixed discontinuation+ dothiepin 150 mg 
2 Fixed discontinuation + placebo 
1 11/36(31%) 
2 17/41(41%) 
Kandier et al 
(1996)· 
Abrupt discontinuation + carbamazepme 800 mg 15/17(88%) 
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Lemome et al 
(1997)· 
Romach et al 
(1998) 
Garfinkel et al 
(1999) 
Rickeis et al 
(1999) 
Retrovie et al 
(1999) 
Rickeis et al 
(2000) 



















Fixed & abrupt discontinuation + hydroxyzine 50 mg 
Fixed & abrupt discontinuation + hydroxyzine 25 mg 
Fixed & abrupt discontinuation + placebo 
Fixed discontinuation + ondansetron 2 mg 
Fixed discontinuation + placebo 
Fixed discontinuation + Melatonin 2 mg 
Fixed discontinuation + Placebo 
Fixed discontinuation + trazodone 100-500 mg 
Fixed discontinuation + sodium valproate 0 5-2 5 mg 
Fixed discontinuation + placebo 
Fixed discontinuation in 1 week 
Abrupt discontinuation + 1 week trazodone 50 mg 
Fixed discontinuation + Imipramine 150 mg 
Fixed discontinuation + buspirone 30 mg 
Fixed discontinuation + placebo 
Fixed discontinuation + paroxetine 20 mg 










43 / 49 (88%) 
36 / 45 (80%) 
37 / 45 (82%) 
14/18(78%) 




18 /24 (75%) 













66 / 97 (68%) 
Sw months 
24 / 30 (80%) 
Three months 
1 16 /30(53%) 
2 11 /14(78%) 








Foreign language (Italian / German / French) 
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Background - Minimal intervention strategies to decrease long-term benzodiazepine use in family 
practice have not yet been evaluated in large studies with a blinded control condition and a long 
follow-up penod 
Methods - The intervention evaluated in this study consisted of a letter with a discontinuation advice 
sent to long-term benzodiazepine users, followed by an invitation to consult the family physician after 
three months Prescription data were extracted from the physicians electronic medical dossier Primary 
endpoints were the amount of benzodiazepine prescription and the percentage of subjects without 
prescription (quitters) The course of long-term benzodiazepine users in practices receiving no 
intervention served as a control condition Duration of follow-up was 21 months 
Results - The experimental group consisted of 2425 long term benzodiazepine users, 1707 of whom 
were adressed by letter The control group consisted of 1821 long term users In the short term (6 
months) a reduction in benzodiazepine prescription of 24% was observed in the experimental group, 
versus 5% in the control group (p<0 01) A comparably large reduction was still present at the end of 
the follow-up Of the users in the experimental group 536 (24% of study completers) quit completely 
at short term, versus 183 (12%) in the control group (p<0 01) Of the quitters 42% in the control group 
and 56% in the experimental group remained benzodiazepine prescription free in the follow-up penod 
(p<0 01) 
Conclusion - This minimal intervention is an effective strategy to decrease long term benzodiazepine 
use in family practice 
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Introduction 
Benzodiazepines are very effective drugs in the short-term treatment of anxiety and insomnia. 
However, with few exceptions, the use of benzodiazepines is recommended to be restricted for a short 
period,1"3 as longer use may lead to benzodiazepine dependence and is associated with an increased 
risk of traffic accidents,3 8 non-accidental falls with associated hip fractures, '' and cognitive 
impairments.12'14 In contrast to these recommendations, a prevalence range of long-term 
benzodiazepine use of 0.6-2.9% was found in the family practice, depending on the design of the study 
and the time frame of the assessment of use.' 
10-40% of the long-term benzodiazepine users in family practice care was able to quit their 
benzodiazepine use as a result of minimal intervention strategies such as sending a letter, offering a 
special consultation, or offering family physician support combined with a self-help booklet. 
Although sending patients a letter with discontinuation advice proved to be as effective as a group run 
by a psychologist,19 a consultation with the family physician or sending information sheets in addition 
to a discontinuation letter,16'17 the former intervention has not been evaluated in large samples with a 
substantial number of family physicians, a blinded control condition and a long-term follow-up, 
necessary to estimate the result of lasting intervention effects. 
In the Benzoredux study, a family practice based intervention study, we created the opportunity 
to assess the short- and long-term effects of a benzodiazepine discontinuation letter in a large family 
practice care population in The Netherlands. In the Dutch Health Care system the family physician 
functions as a gatekeeper for secondary medical specialist care and all patients (70% in National 
Health Plan, 30% private insurance) are linked to one family physician, often for many years, allowing 
excellent opportunities for longitudinal research. 
Methods 
Study design 
This prospective controlled intervention study in family practice received approval of the Committee 
on Research involving Human Subjects (known as CMO Amhem/Nijmegen) The follow-up duration 
was 21 months and the study was carried out between August 1998 and December 2001. 
Experimental group 
We considered patients in 30 family practices, covering the primary care of 118,082 people. In these 
practices the electronic medical dossier (EMD) was used for patient administration and prescriptions. 
In the Netherlands 91% of the family physicians use a commercially available EMD.20 
Benzodiazepine users were selected from the EMD if they were actually using agents with the ATC 
(Anatomical Therapeutical Code) codes: N05BA, N05CD and N03AE01.2' Current users met the 
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cntena for long term use if 1 ) the prescnptions for benzodiazepines covered a penod of more than 
three months and 2) the amount of prescribed pills dunng the last three months before study inclusion 
was sufficient for 60 days use according to the family physician's prescription Long term users were 
excluded if they met one of the following cntena current treatment for mental illness in secondary 
care, drug or alcohol dependence, psychotic episodes in medical history, suffering from epilepsy, 
having a terminal disease, or not having mastered the Dutch language Additionally, subjects were 
excluded for specific individual reasons brought up by the family physician (severe co-morbidity, 
psychosocial conditions, high age, severe disability or having moved away from the practice, figure 1) 
Intervention 
The intervention consisted of a letter, with the advice to gradually discontinue benzodiazepine use, 
sent by the family physician (DL=discontinuation letter), followed by a written invitation to arrange an 
appointment with the family physician after 12 weeks in order to evaluate actual benzodiazepine use 
(EC=evaluation consultation) The letter used by Cormack et al served as a model because of the 
proven short-term effectiveness 17 The median time between sending the discontinuation letter and the 
evaluation consultation was 14 weeks 
Assessments 
Prescnption data were automatically extracted from the family physician's EMD We used the sum of 
the prescribed daily doses (PDD) of all benzodiazepine prescnptions presenbed within 3-month time 
penods (each 3-monlh penod consisted of 91 days exactly) FDD's were calculated according to the 
recommendations of Zitman and Couvee 22 Baseline recorded prescnption covered the three months 
before sending the DL, follow-up recorded prescription covered the subsequent 3-month penods after 
the DL was sent Other patient assessments were age, gender and type of health insurance (pnvate or 
National Health Plan) 
Control group 
At the end of the follow-up 19 control practices were selected from the LINH network This network 
reflects a valid sample of all Dutch family practices in which 3-monthly automated EMD extractions 
provide a longitudinal database of prescnptions, consultations and referral data 21 Practices were 
selected on the basis of two cntena 1 ) the EMD system of the practice corresponded with one of the 
EMDs in the experimental practices, 2) EMD data about prescriptions and consultations had been 
extracted from 1/1/1998 The practices corresponded on average with the expenmental practices 
regarding location and organisational type We extracted the benzodiazepine prescription data of the 
selected practices covering the study period from the LINH database Dunng the study penod, the 
family physicians of the control practices were not aware of their later inclusion in the control group in 
order to avoid Hawthorne effects 24 ' ' The same definitions as in the expenmental condition were used 
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in the control condition for long-term use and time penods 
Statistical analysis 
Statistical comparisons were performed over three time periods baseline (last 3 months before DL), 
short term evaluation (the period of 4-6 months after DL) and the end of the follow-up (the period of 
19-21 months after DL) This was done for the experimental group as a whole, for the subjects in the 
experimental group who received the DL (DL intervention group), for the subjects in the experimental 
group who did not receive the DL (DL excluded group) and for the control group 
Quitters were defined as subjects for whom no benzodiazepine prescription was prescribed in 
the penod of 4-6 months after DL was sent Relapse among quitters was defined as any new issue of a 
benzodiazepine prescnption in the follow-up period following the short term evaluation Any analysis 
of benzodiazepine precnption was performed among subjects who completed the study (subjects in 
practice till 21 months after the DL was sent ) Differences in the amount of benzodiazepine 
prescription were analysed with student t-tests and the signed rank test (in case of non-normal 
distribution) In compansons of prevalences of quitters Chi-square tests were performed Two sided 
p-values were used, with alpha is 0 05 
Within the follow-up penod 260 DL intervention group subjects received a more intensive 
follow-up consisting of a maximum of 5 measurements at different moments with questionnaires 
concerning the subject of benzodiazepine dependence, personality, mood, general health, quality of 
life, medical costs and a memory test Of these subjects 104 reported at the EC that they had quit 
benzodiazepine use The other 156 subjects gave informed consent to participate in a 6-week 
benzodiazepine tapenng-off trial, starting at least six months after the DL was sent (N=128 on active 
treatment and N=28 in a regular care control condition) For our assessment of the effects of the DL, 
and in order to avoid selection bias, we included these 156 subjects in the follow-up analysis assuming 
that they would have continued their use in the same amount as in the short term evaluation period of 
4-6 months after the DL was sent (last observation carried forward method) This has a conservative 
influence on the effect sizes of the comparison The 104 quitters at the EC, were accepted 
unconditionally as they had not received any intervention aimed at preserving abstinence, allowing for 
relapse, thus also a conservative measure 
Results 
Subjects, lost to follow-up and data completeness (figure 1) 
Three experimental and three control practices were excluded from the analysis because no complete 
recovery of data could be attained Furthermore 170 experimental group subjects were excluded 
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deleted by the family physician, probably after deregistration due to having moved away from the 
practice or death. This left 2425 subjects in the experimental group versus 1821 subjects in the control 
group at baseline. At the end of the 21 month follow-up 93% (2248/2425) of the experimental group 
versus 87% (1585/1821) of the control group subjects were still in the practice (p<0.01). Lost to 
follow-up subjects in the experimental group were younger (66 years versus 72 years in the control 
group) and less of the female gender (65% versus 72% females in the control group). 
Baseline characteristics (table 1) 
No clinically significant baseline differences between the experimental group and the control group 
were observed in age, gender, insurance type or number of different benzodiazepines prescriptions at 
baseline. In the experimental practices oxazepam had been prescribed relatively more than in the 
control practices (p<0.01). Compared to the DL excluded group, the patients in the DL intervention 
group were younger, more were female and were less often on a National Health Plan. Also a lower 
percentage of subjects received prescriptions of more than one different benzodiazepine in the 3-
month baseline period (all p<0.05). 
Baseline benzodiazepine prescription was not significantly different between the control and the 
expenmental group (p=0.27, p=0.43 when adjusted for age, gender and insurance type) (table 2). To 
subjects in the DL intervention group at baseline significantly less benzodiazepines were prescribed 
compared to the DL excluded group subjects (p<0.01). The prescription of benzodiazepines till date of 
intervention appeared stable: in the periods of 7-9 months and 4-6 months before the intervention the 
mean PDD number was 72 (SD:78){median:45) and 76 (78) {52.5} in the control group and 76 
(92)(45) and 78 (88){45} in the experimental group respectively (not in table). 
Table 1 
Baseline characteristics 
Control group Experimental group 
Total DL Intervention DL Excluded 
group group 
Ν long term benzodiazepine users 
Age (yr) (mean (SD)) 
Gender (% Iemale) 
Health insurance (% National Health) 
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26 3 % 
23 6 % 
11 4 % 






35 8 % 
20 7 % 
11 7 % 
31 8 % 
18 1 % 
1707 
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1 2 . 2 % 
29.8 % 
16 4 % 
718 
59 9 ( 1 6 6) 
6 4 6 
83 3 
34 0 % 
19 1 % 





Benzodiazepine prescription of quitters and non quitters in PDD1 



















































































Baseline: mean ±sd 
(3 months before DL)3 median 
Short term evaluation: mean ±sd 
(4-6 months after DL) median 
End ol lollow-up: mean ±sd 
(19-21 months after DL) median 
1. PDD = number of 3-month prescribed daily doses. 
2. Subjects with complete 21-month follow-up only. 
3. DL refers to the date of sending the discontinuation letter (DL Intervention group) or equivalent time point in case no letter was sent (DL excluded group and control group). 
4. If yes, relapse refers lo quitters who restart benzodiazepines during follow-up, if yes, relapse refers to remaining benzodiazepine prescription free till the end of follow-up. 
Note: Mean (±sd) baseline PDD of the subjects that 'relapse / continue abstinence': in the control group 53 ±58 / 49 ±51 ; the total expenmenlal group. 48 ±62 / 41 ±35; 
the DL intervention group: 49 ±62 / 40 ±34; the DL excluded group: 42 ±37 / 42 ±35. 
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Evaluation of the mean benzodiazepine prescription (table 2) 
In all four groups (control, experimental total, experimental DL intervention, experimental DL 
excluded), a significant reduction in benzodiazepine prescription in the first 6 months after the DL was 
sent was observed (difference short-term evaluation with baseline: p<0.0l in all groups). The 
reduction of benzodiazepine prescription was significantly higher in the experimental group (24%) as 
compared to the control group (5%) (p<0.01). Among the subjects of the DL intervention group this 
reduction was in percentage the highest (32%) and in the DL excluded group it was 8%. In the 15 
months following the short-term evaluation a further decrease in benzodiazepine prescription was 
observed in the control group (4%, p<0.01), and the DL excluded group (12%, p<0.01). No 
differences between end of follow-up values and short-term evaluation values were observed in the 
total experimental group (3%, p=0.14) and in the DL intervention group (2% increase, p=0.4). 
Table 2 
Mean benzodiazepine prescription per 3 months periods in FDD1 
Number of patients2 
Baseline 
PDD 3 months before DL3 
Short term evaluation 
PDD 4-6 months after DL 
End of follow-up 











































1 PDD = number of prescribed daily doses per 3-month period 
2 Subjects with complete 21 -month follow-up only 
3 DL refers to the date of sending the discontinuation letter (DL Intervention group) or equivalent time point in case no letter 
was sent (DL excluded group and control group) 
Evaluation of complete discontinuation (table 3) 
Of the experimental group 536 subjects (24%) did not receive any benzodiazepine prescription in the 
period 4-6 months after the DL (quitters), versus 183 subjects (12%) in the control group (p<0.01). 
The crude Odds ratio for quitting, being a member of the experimental group was 2.4 (95%-c.i.: 2.0 -
2.9). Adjustment for age, gender, insurance, baseline benzodiazepine prescription and benzodiazepine 
type did not change the Odds ratio nor the 95% confidence interval boundaries. Of the 536 
experimental group subjects the majority (N=446, 83%) had actually received the DL. The percentage 
of short term discontinuation in the DL intervention group was 28% (446/1601) and in the DL 
excluded group 14% (90/647).Non-quitters had a significantly higher baseline benzodiazepine 
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prescription than quitters (table 3, all 4 groups p<0 01) Among the non-quitters in the expenmental 
group a reduction in benzodiazepine prescription in the first 6 months was observed of 11% (p<0 01), 
whereas no reduction was observed among non-quitters in the control group The reduction in 
benzodiazepine prescription in the 7-21 months follow-up was 7% in both the expenmental and the 
control group of non-quitters (separate p<0 01) 
Of the quitters 42% in the control group and 56% in the expenmental group remained 
benzodiazepine prescription abstinent till the end of follow-up (difference control-
expenmental p<0 01) In both groups of quitters more than half of the subjects who relapsed, did so 
within the first 3 months The PDD level at 21 months of the subjects who relapsed was significantly 
lower compared with their baseline level, 60% of the baseline level in the control group and 48% in 
the experimental group respectively (separate p<0 01) Baseline PDD of continued abstinent subjects 
was not significantly different from the mean baseline level of quitters who relapsed 
Discussion 
The present study firmly demonstrated that a minimal intervention strategy with a discontinuation 
letter induces a substantial and lasting reduction of benzodiazepine use among long term 
benzodiazepine users in family practice 
The effectiveness of the intervention was evident on both major endpoints a reduction of 24% 
(versus 5% in the control group) in the amount of benzodiazepine prescnption and a doubled chance 
of quitting (24% versus 12%) in the first 6 months For the non-quitters in both the control and the 
expenmental group, the course in follow-up after 6 months was charactensed by a slow, further 
decline, indicating that the gain of the intervention established in the first 6 months was preserved 
Using our strict definition of relapse, about half of the quitters were able to remain benzodiazepine 
prescnption free till the end of the study Relapse occurred significantly more often in the control 
group which suggests a long term intervention effect Furthermore, quitters who relapsed in use, fell 
back to dosage levels that might indicale a shift from continuous to intermittent use 
The discontinuation letter used in the present study was based on a letter developed by Cormack 
e a and our short term results were comparable 17 The advantages of our study were that we included 
much larger numbers of family physicians and long term benzodiazepine users from different pnmary 
care settings, used a blinded control group and established the long term efficacy of the intervention 
Benzodiazepine discontinuation is easier when using lower doses Indeed, in our study, the 
baseline PDD of quitters was about half the baseline PDD of non-quitters 
Fifty percent of all long term users received at baseline benzodiazepine precnption for an 
average daily dose equal or less than 0 5-0 6 DDD Benzodiazepine prescnption of up to 9 months 
before the intervention showed the consistency of use in this group and the results in the control group 
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indicated that only 5% of these users could obtain long term abstinence without an intervention. In 
which content this consistency reflects benzodiazepine dependence is not clear. Recently, using 
substance dependence criteria of the ICD-10 and DSM-IIIR, prevalence of benzodiazepine 
dependence was estimated at 40-52% of all benzodiazepine users in family practice in the 
Netherlands.6 
Concerning the validity, first, there was a statistically significant difference between the 
experimental and control group in baseline benzodiazepine type, mainly for the use of oxazepam. 
Benzodiazepine type however was not critically related to the outcome as the crude Odds ratio of 
quilling was not affected after adjustment by benzodiazepine type. Second, in the absence of a valid 
control group for the DL intervention group only, the exact effect-size of the discontinuation letter 
intervention could not be determined. However it can be expected that family physicians in daily care 
will differ in the application of the exclusion criteria for this intervention. We consider it a major 
strength of this study that we surpassed the individual physician's level of choice by evaluating all 
experimental group long term users, regardless of having been included in receiving the letter, leading 
to a more pragmatic effect-size of the intervention. Third, a small percentage of the intervention group 
subjects received a second intervention (trial) aimed to reduce benzodiazepine use in the follow-up 
period. We believe that this may only have had a minor influence on our overall results. Actually, 128 
subjects received an active treatment in this tnal which is only 5% of the total experimental group. For 
these subjects in the analysis, the pre-trial level of benzodiazepine prescription was carried forward to 
serve as follow-up scores, which we believe is a conservative approach as this was a group motivated 
to undertake further action to quit. In addition, this trial couldn't have influenced the percentage of 
quitters and continued abstinent subjects. 
We conclude that the present strategy is an effective and practical tool which can be used to 




1 Ashlon H Guidelines for the rational use of benzodiazepines When and what to use Drugs 1994,48 25-40 
2 Committee on the Safety of Medicines (CSM) Benzodiazepines, dependence and withdrawal symptoms Current 
Problemi 1988,21 1 2 
3 Lader ΜΗ Limitations on the use of benzodiazepines in anxiety and insomnia are they justified7 European 
Neuropsychopharmacology 1999,9 Suppl 6 S399 S405 
4 Amencan Psychiatric Association Benzodiazepine dependence, toxicity and abuse A task force report of the American 
Psychiatric Association Washington DC Amencan Psychiatric Association, 1990 
5 Tyrer Ρ Benzodiazepine dependence a shadowy diagnosis BunhemSocSymp 1993,59 107-119 
6 Kan CC, Brctcler MH, and Zitman FG High prevalence of benzodiazepine dependence in out-patienl users, based on 
the DSM-HI-R and ICD-10 criteria Acta Psyduatnia Siandtnaiica 1997,96 85-93 
7 Barbone F, McMahon AD, Davcy PG et al Association of road traffic accidents with benzodiazepine use Lautet 
1998,352 1331 1336 
8 Hemmelgam B, Suissa S, Huang A, et al Benzodiazepine use and the nsk of motor vehicle crash in the elderly Journal 
of the Amencan Medical Association 1997,278 27 31 
9 Ray WA, Griffin MR, Schaffner W, et al III Psychotropic drug use and the nsk of hip Iraclure New England Journal 
of Medicine 1987,316 363-369 
10 Wang PS, Bohn RL, Glynn RJ, et al Hazardous ben/odiajcpinc regimens in the elderly effects of half life, dosage, and 
duration on nsk of hip fracture American Journal of Psychiatry 2001,158 892 898 
11 Henngs RM, Smcker BH, De Boer A, el al Benzodiazepines and the nsk of falling leading to femur fractures Dosage 
more important than elimination half-life Archives of Internal Mediane 1995,155 1801-1807 
12 Curran HV Benzodiazepines, memory and mood a review Psychopharmacotogy 1991,105 1 8 
13 Tata PR, Rollings J, Collins M, et al Lack of cognitive recovery following withdrawal from long term benzodiazepine 
use Psychological Medicine 1994,24 203-213 
14 Verwey B, Eling P, Wienljes H, et al Memory impairment in those who attempted suicide by benzodiazepine overdose 
Journal of Clinical Psychiatry 2000,61 456-459 
15 Zandstra SM, Purer JW, Van de Lisdonk EH, et al Different study entena affect the prevalence of benzodiazepine use 
Social Psychiatry and Psychiatric Epidemiology 2002,37 139-144 
16 Cormack MA, Owens RG, and Dewey ME The effect of minimal interventions by general practitioners on long- term 
benzodiazepine use Journal of the Royal College of General Practitioners 1989,39 408-411 
17 Cormack MA, Sweeney KG, Hughes-Jones H, et al Evaluation of an easy, cost-effective strategy for cutting 
benzodiazepine use in general practice British Journal of General Practice 1994,44 5-8 
18 Bashir K, King M, and Ashworth M Controlled evaluation of bnef intervention by general practitioners to reduce 
chronic use of benzodiazepines British Journal of General Practice 1994,44 408-412 
19 Cormack MA, and Sinnolt A Psychological alternatives to long-term benzodiazepine use Journal of the Royal College 
of General Practitioners 1983,33 279-281 
20 Wolters I, Van den Hoogen H, and De Bakker D Evaluatie invoenng Elektronisch Voorschrijf Systeem 
Monitonngsfa.se de situatie m 2001 Utrecht NIVEL, 2002 45-46 
21 WHO Collaborating Centre for Dnigs Statistics Methodology Guidelines ATC classification and DDD assignment 
Oslo WHO/NCM, 1996 
22 Zitman FG, and Couvee JE Chronic benzodiazepine use in general practice patients with depression an evaluation of 
controlled treatment and taper off report on behalf of the Dutch Chronic Benzodiazepine Working Group British 
Journal of Psychiatry 2001,178 317-324 
23 De Bakker D, Jabaaij L, Abrahdmse H, et al Jaarrapport LINH 2000 Contactfrequenties en verrichtingen m het 
Landelijk Infornane Netwerk Huisartsenzorg (LINH) Utrechi/Nijmegen NIVEIVWOK, 2001 
24 De Burgh S, Mant A, Mattick RP, et al A controlled trial of educational visiting to improve benzodiazepine presenbing 
in general practice Australian Journal of Public Health 1995 19 142-148 
25 Holm M Intervention against long-term use of hypnotics/sedatives in general practice Scandinavican Journal of 
Primary Health Care 1990,8 113-117 
26 Linden M, Bar T, and Geiselmann Β Patient treatment insistence and medication craving in long-term low-dosage 
benzodiazepine presenpuons Psyihologital Medicine 1998,28 721-729 
74 
Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice 
27 Rickels K, Schweizer E, Case WG, et al Long-term therapeutic use of benzodiazepines. I. Effects of abrupt 
discontinuation. Archives of General Psychiatry 1990,47:899-907 
28. Rickels K, Case WG, Schweizer E, et al Long-term benzodiazepine users 3 years after participation in a discontinuation 





Predictors of relapse after discontinuation of long-term benzodiazepine 
use by minimal intervention: 2-year follow-up study 
Richard C Oude Voshaar, Wim J M J Gorgels, Audrey J J Mol, Anton J L M van Balkom, 
Mannus H H Breteler, Eloy H van de Lisdonk, Jan Mulder, Frans G Zitman 
Family Practice 2003, 20(4) 370-372 
Abstract 
Introduction 
Method Design and recruitment 
Measurements 
Analyses 
Results Recruitment, participation and dropouts 
Characlenslics of the study participants 
Long-term outcomes 
Predictors of benzodiazepine use during follow-up 







Background - Minimal intervention strategies to cut down benzodiazepine use in general practice are 
effective in 1 out of 5 long-term benzodiazepine users Long-term results, however, are not available 
Objective - To evaluate the relapse rate over a two-year penod and to search for predictors of relapse 
among patients who quit benzodiazepine use based on a minimal intervention, ι e a letter containing 
advice to quit from their GP 
Methods - Prospective monitoring of GP medical records and two additional assessments of 109 
patients who quit their long-term benzodiazepine use of their own accord Cox-regression analyses 
were performed to search for independent predictors of relapse 
Results - Of the 285 patients who quit benzodiazepines in the short-term, 109 patients (38%) gave 
informed consent for the follow-up study After 819 ±100 days of follow-up, 53 (49%) patients had 
remained completely abstinent, while 3 out of 5 patients who relapsed showed better usage patterns 
Two independent predictors of relapse were identified use of high dosage (more than 10 mg 
diazepam equivalent) before receiving the letter (RR = 24 [1 2 - 47]) and poor general health 
perception (RR = 0 98 [0 97 - 0 99]), the latter made only a marginal contribution to the prediction 
model 
Conclusion - Short-term success rates after a minimal intervention were maintained well during long-
term follow-up Patients using high dosages before the intervention had the highest nsk of relapse and 
should be monitored more closely by the GP 
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Introduction 
Several guidelines advise benzodiazepine prescription only in limited circumstances and for short 
periods of time ' 2 ' Nevertheless, a review study including some recent data on the Dutch population, 
points out that 2 to 3% of the population use benzodiazepines chronically This proportion of long-
term users has hardly changed over the past 10 years in the Netherlands The majority is treated, ι e 
receive prescriptions for benzodiazepines, in primary care About 20% of long-term users in primary 
care successfully quit their benzodiazepine use in the short term with the aid of a minimal 
intervention 6 Examples of minimal interventions are a letter containing advice to quit, an advisory 
consultation, or an informational meeting 6 7* 9 1" These interventions are especially attractive in the 
context of general practice, where time is limited and consultations often last no more than 10 
minutes The long-term effects of minimal interventions have not yet been evaluated Such 
evaluations are essential to predict the outcome of implementation and to identify patients who are at 
most nsk of relapse so that they can be monitored more closely 
Therefore, we carried out a long-term prospective follow-up study on patients who successfully 
stopped their benzodiazepine use of their own accord after receiving a letter containing advice to quit 
from their general practitioner Our purpose was (a) to estimate the rale of relapse in the long-term 
and to desenbe the patterns of relapse, (b) to search for clinical predictors of relapse and (c) to 
monitor psychological functioning and switches to other medication 
Methods 
Design and recruitment 
Long-term benzodiazepine users (n = 2964) were identified by means of a computerised search for 
benzodiazepine prescriptions at 30 general practices in rural and urban areas of the Netherlands, at 
which 58 GPs were covering primary care for about 118 000 patients Long-term use was defined as 
benzodiazepine use for at least three months with an amount sufficient for at least 60 days of 
consumption according to the prescription rules Exclusion criteria were current psychiatric treatment 
(n=281), current treatment for drug or alcohol dependence (n=82), medical history of psychosis 
(n=80), epilepsy (n=53), insufficient mastery of the Dutch language (n=59), and terminal illnesses 
(n=26) Furthermore, some people were excluded specifically at the GP's request because of severe 
co-morbidity or for current psychosocial reasons (n=379) 
The remaining 2004 benzodiazepine users received a letter from their GP containing advice to 
quit gradually (=discontinuation letter, see appendix) They were invited to the surgery in a second 
letter sent three months later At this consultation, the study procedures were explained and informed 
consent to participate in the study was sought if they had been able to achieve complete abstinence 
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since receiving the discontinuation letter Patients who were still using benzodiazepines were asked to 
participate in a RCT, comparing tapenng-off with or without group psychotherapy The results of this 
RCT are reported elsewhere The study received ethical approval from the University Medical Centre 
Nijmegen and was performed from 1998 to 2001 
Measurements 
The use of benzodiazepines and other prescribed drugs was monitored prospectively in the medical 
records for a mean (±sd) duration of 819 (±100) days Benzodiazepine use relapse was defined as 
receiving a prescription during follow-up In addition, patients were assessed by self-report 
questionnaires directly after giving informed consent (baseline) and in a follow-up assessment after a 
mean (±sd) follow-up of 659 (±43) days Both assessments took place at the participants' homes by 
trained research assistants We assessed the use of caffeine, nicotine, and alcohol (including the 
detection of problem drinkers based on the 18-item list of Cornel)12, psychological well-being (GHQ 
12-item version)1 , mood (the scales depression, anger, fatigue, vigour and tension of the 32-item 
shortened profile of mood states, POMS)14, and quality of life on eight different health domains 
physical functioning, role functioning - physical problem, role functioning - emotional problem, 
vitality, mental health, social functioning, pain and general health (Medical Outcome Study Short-
Form 36, SF-36)15, and the personality characteristics negativism, somatisalion, shyness, 
psychopathology and extraversion (Dutch shortened MMPI, NVM) " 
Analyses 
Patients' prescription patterns during follow-up were classified according to Couvée et al (2002) to 
provide detailed information for those patients who relapsed This classification system is based on 
general guidelines on the adequate maximum duration of treatment with benzodiazepines 17 It 
describes systematically 14 prescription patterns with pattern 1 benzodiazepine-free, to pattern 14 
benzodiazepine use during more than 95% of the follow-up period at a higher dosage than at the 
beginning of the study Based on these prescription patterns, four outcome categories can be 
established category A, success, B, partial success, C, minor success, and D, failure 
Predictors of relapse were analysed by means of Cox regression analysis, with time to relapse 
as the dependent variable, and the following independent variables daily dosage (dichotomised at 10 
mg diazepam equivalent), half-life (dichotomised at 24 hours), potency (presence of a 4-aryl group), 
self-reported hypnotic or anxiolytic use, use of antidepressants (yes/no), use of pain medication 
(yes/no), and the variables measured at the baseline assessment Variables with univanale nsk ratios 
of p<0 10 were entered into the multivariate Cox regression analysis using a backward elimination 
procedure 
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To compare the clinical status of patients who remained abstinent to those who relapsed, 
repeated measure ANOVAs were performed with one within subject factor with 2 levels (baseline 
versus follow-up assessment) and one between subject factor (relapse yes/no) with all continuous 
variables measured at both assessments. Categorical data were analysed by means of chi-square tests. 
Results 
Figure 1 
Recruitment and participations of long-term benzodiazepine users in the trial 
All long-lerm BZ users 
η = 2964 
Letter wilh a stop advice 
η = 2004 
Consulted GP 
η = 1321 
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η = 265 
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η = 109 
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1 6 (2 7) 
' Self-reported daily benzodiazepine dosage at baseline was 6.6 ±4 3 mg diazepam equivalence 
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Recruitment, participation and drop-outs 
Figure 1 shows the progress of the total population during the trial 2964 long-term users were 
identified, the GP advised 2004 persons to stop their benzodiazepine use, 1321/2004 (66%) visited 
their GP in order to evaluate the effect of the letter Of those patients, 285/1321 (22%) had 
successfully stopped their use and of the stoppers 109/285 gave informed consent (figure 1) 
Participants (n=109) and non-participants (n=176) did not differ with respect to age (63 ±4 3 years) 
and gender (69% female sex) However, participants had been using significantly higher 
benzodiazepine dosages before receiving the discontinuation letter (6 6 ±4 3 versus 5 1 ±4 5 mg 
diazepam equivalent, p<0 01) Based on the prescription records the year prior to the study, 94 (87%) 
patients received prescriptions for daily use, while 15 patients intermittently received prescriptions for 
periods of less than 60 (n=5) or 90 (n=10) days One patient was lost to follow-up from the medical 
records, which left 108 évaluable patients In five patients, the duration of follow-up was limited to an 
average of 488 days (range 183 - 671) (two moved, three died) Eighteen (17%) patients did not 
complete the follow-up assessment (see figure 1 ) The rate of relapse did not differ between patients 
who completed the follow-up assessment and those who did not (p = 0 16) 
Characteristics of the study participants 
Psychopalhological dysfunction was relatively mild Based on a cut-off score of 2/3 on the General 
Health Questionnaire 12-item version, 23% of the patients were classified as psychiatric cases The 
scores on other questionnaires showed no or only small deviations from norm scores (see table 1) 
Half of the patients (50%) used alcohol, 32% used nicotine and 74% drank caffeine 
Long-term outcomes 
After quitting benzodiazepine use of their own accord, 53/108 (49%) patients remained completely 
abstinent during the 2-year follow-up, while 55/108 patients relapsed after a median period of 
abstinence of 243 days (P25 = 97 days, P75 = 459 days) Based on the classification of Couvée et a! 
(2002)17, 79 (73%) patients were classified as success, 4 (4%) as partial success, 5 (5%) as minor 
success, and only 20 (19%) as failure Of the 15 patients who received prescriptions for intermittent 
usage before sending the letter, 14 (93%) ended up in category A (success) Table 2 presents a more 















































2 Benzodiazepine use one episode < 15 days 
3 Benzodiazepine use > one episode < 15 days 
4 Benzodiazepine use one episode > 15 days and < 30 days 
5 Benzodiazepine use > one episode > 15 days and < 30 days 
Β Partial success 
6 Benzodiazepine use one episode > 30 days and < 60 days 
7 Benzodiazepine use > one episode > 30 days and < 60 days 
8 Benzodiazepine use one episode > 60 days and < 90 days 
9 Benzodiazepine use > one episode > 60 days and < 90 days 
C Minor success 
10 Benzodiazepine use > 90 days no use at lime of follow-up 
11 Benzodiazepine use > 95% of follow-up lime, lower dose 
D Failure 
12 Benzodiazepine use > 90 days and use at time of follow-up 
13 Benzodiazepine use > 95% of follow-up time, same dose 
14 Benzodiazepine use > 95% of follow-up time, higher dose 
Predictors of benzodiazepine use during follow-up 
Four variables were related univariately to relapse: baseline benzodiazepine dosage, and three 
dimensions of the SF-36: general health perception, vitality and mental health. The multivariate Cox 
regression analyses (model: chi-square = 8.8. df=2, p=0.01) yielded daily benzodiazepine dosage as 
the strongest independent predictor (RR 2.4 [1.2 - 4.7], ρ = 0.02). Figure 2 shows the survival curves 
of patients using 10 mg diazepam equivalent or less versus those using more than 10 mg of diazepam. 
General health perception (range 0 - 100) also had independent predictive value, but made only a 
marginal contribution to the model (RR 0.98 [0.97 - 0.99], ρ = 0.04). 
Secondary outcome measures 
Psychological functioning (GHQ-12, POMS, SF-36) showed minor, non-significant improvement at 
follow-up. Moreover, improvement was independent of benzodiazepine use relapse or benzodiazepine 
outcome classification according to Couvée et al. There was no increase in the use of psycho-active 
agents (caffeine, nicotine, alcohol). The prescription of antidepressants remained stable (baseline and 
follow-up 19%), while the prevalence rate of pain medication decreased from 44% at baseline to 36% 
at follow-up, for those patients who remained abstinent. Patients did not switch from benzodiazepines 
to other hypnotics; only one success category patient had received a prescription for Zolpidem during 
follow-up. 
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Figure 2 
Survival time until relapse stratified by baseline benzodiazepine dosage 
Discussion 
This is the first study in which a prospective longitudinal monitoring was employed to evaluate the 
long-term outcome of a minimal-intervention benzodiazepine discontinuation strategy. Half of the 
patients who had quit successfully in the short-term after minimal intervention remained abstinent for 
two years. Only 19% of the patients who relapsed were classified as failures after two years, while the 
other patients showed belter usage patterns than before the intervention. We observed no switches to 
the use of alternative hypnotic drugs (zolplicon, Zolpidem), antidepressants or pain medication. These 
good long-term results contribute positively to the proposals of Russell & Lader (1993) and many 
others (f.e. Oude Voshaar et al 2001) to use a minimal intervention strategy as a first step to cut down 
long-term benzodiazepine use. 
The major limitation of our study was the low participation rate, which increases the risk of 
significant selection bias. However, our short-term evaluation three months after sending the letter 
revealed a success rale of 22% (285/1321). This is fairly comparable with the success rates reported 
by others and suggests that the patients who responded to this evaluation were representative of all 
patients who received the discontinuation letter.6'7 Some selection bias has obviously occurred, as 
participants in the follow-up study were using significantly higher dosages before receiving the 
discontinuation letter compared with non-participants. However, as a lower dose level appeared to be 




As we did not include a control group we can not compare our results with the natural course of 
benzodiazepine use. It is not likely that the success rate of 22% can be explained by the natural course 
of benzodiazepine use after a minimal intervention, because the mean duration of benzodiazepine use 
in our sample was 6.8 years (see table 1). Moreover, our long-term success rate is substantially higher 
than the short-term success rate of 6% in the no intervention control group of the minimal intervention 
study of Cormack et al (1994).6 
In contrast with the literature on the psychological functioning of long-term benzodiazepine 
users, the patients in our sample were functioning relatively well.' ' "0 This may be a reflection of the 
fact that these patients were able to quit successfully of their own accord. The patients who relapsed 
did not show any deterioration in psychological functioning and there was no relationship between 
psychological functioning at follow-up and the outcome according to the classification of Couvcc et 
al (2002)." It is possible that the instruments used to measure changes in psychological functioning 
were not sensitive enough in our population. 
The best predictor of relapse appeared to be high dosage use (>10 mg diazepam equivalent per 
day). Poor general health perception also predicted relapse, i.e. patients who perceived themselves as 
being less healthy were at greater risk of relapse. As the latter variable contributed only marginally to 
the model, we recommend closer monitoring only in high-dose users after they have quit of their own 
accord. 
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Dear (Air Mrs-MissJ, 
For some time now I have been prescnbmg [name(s) of the benzodiazepine(s) used} for you This 
medication belongs to the group of benzodiazepines By means of this letter, I would like to see whether 
we can alter the routine of prescribing this medication and taking it 
Many general practitioners are worried about the long-term use of this medication, because the 
body can become accustomed to it, which means that it no longer has the desired effect Some people 
become addicted to the tablets or capsules, which leads to anxiety or sleeping problems if they forget to 
take a dose These anxiety and/or sleeping problems are not usually the original problems for which the 
medication was prescribed Instead they are temporary withdrawal symptoms Benzodiazepines also 
have other drawbacks For example, users run a higher risk of having accidents and tests have shown that 
the medication can affect a person's memory 
In view of the above, I would like to advise you to gradually cut down your use of {name(s) of the 
benzodiazepine(s) used) and if possible to stop using the medication altogether When you do so, your 
body will have to adjust to the new situation, which means that you may suffer temporarily from 
agitation, tenseness and sleeping problems If you find that these symptoms occur, please try to 
persevere, because before long they will disappear and you will feel better Gradually (step-by-step) 
cutting down the dose involves the least nsk of these symptoms Therefore, try to take a little less each 
week and only take a tablet or capsule if you have to do something that you are very apprehensive about 
Once you have managed to cut down, you will probably be able to stop altogether Many people who 
managed to stop taking the medication informed us that it made them feel much better than before they 
started taking it 
I hope that this letter will encourage you to cut down In about three months time, you will receive 
an invitation to make an appointment to visit me at the surgery Then, if you wish, we can talk about this 
issue at greater length 
Yours sincerely, 
(Name-GP) 
1 The text of this letter is based on a letter used by M A Cormack et al (Bntish Journal ol General Practice 1994 44 5 8) 
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Tapering off long-term benzodiazepine use with or without group CBT: 
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Background · Benzodiazepine withdrawal programmes have never been experimentally compared 
with a non-intervention control condition 
Aims - To evaluate the efficacy and feasibility of tapering off long-term benzodiazepine use in general 
practice, and to evaluate the value of additional group cognitive-behavioural therapy (CBT) 
Method - A 3-month randomised, controlled tnal was conducted in which 180 people attempting to 
discontinue long-term benzodiazepine use were assigned to tapenng off plus group CBT, tapering off 
alone or usual care 
Results - Tapenng off led to a significant higher proportion of successful discontinuations than usual 
care (62% ν 21%) Adding group CBT did not increase the success rate (58% ν 62%) Neither 
successful discontinuation nor intervention type affected psychological functioning Both tapering 
strategies showed good feasibility in general practice 
Conclusions - Tapenng off is a feasible and effective way of discontinuing long-term benzodiazepine 
use in general practice The addition of group CBT is of limited value 
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Introduction 
The evaluation of withdrawal programmes of long-term benzodiazepine use has been limited, as none 
of the reported studies included a control condition to correct for the number of people able to 
discontinue those drugs without any support, and none of them identified all long-term users before 
starting recruitment, limiting generalisibihty (see chapter 3) ' In this study, we recruited participants 
known to their GP to be long-term benzodiazepine users, and included a control group receiving usual 
care Because Cormack et al (1994) found that after wntten advice from their general practitioner 
18% of people using benzodiazepines quit by themselves, this intervention was used as a pre-
selection 2 Our objectives were to investigate the effects of tapering off long-term benzodiazepine use 
in patients who did not quit after wntten personal advice to do so, the value of additional group 




The study was a randomised, controlled trial comparing tapenng off long-term benzodiazepine use 
alone with tapenng off combined with group CBT and with a control group receiving usual care In 
order to include only those who were unable to quit of their own accord, all who were long-term users 
were sent a letter by the participating general practitioner in which they were advised to discontinue 
their benzodiazepine use The study received ethical approval from the University Medical Centre, 
Nijmegen, and look place from 1998 to 2001 
Retirement 
Long-term benzodiazepine use was identified by means of a computerised search for benzodiazepine 
prescriptions at 30 general practices (58 doctors, 118 082 patients) The practices were chosen to 
maximise the variety of locations throughout the Netherlands - 12 were urban (Amsterdam, Nijmegen 
and Almere) and 18 rural (villages nearby Nijmegen) - and of organisation type (4 health centres, 11 
group practices and 15 solo practices) 'Long-term use' was defined as benzodiazepine use for at least 
three months with an presenbed amount sufficient for at least 60 days of consumption in accordance 
with the recommended dosage Exclusion cntena were current psychiatnc treatment, cunent 
treatment for drug or alcohol dependence, medical history of psychosis, epilepsy, insufficient mastery 
of the Dutch language, or terminal illness Furthermore, some people were excluded specifically at the 
general practitioner's request because of severe co-morbidity or for psychosocial reasons People who 
met this definition of long-term benzodiazepine use were sent a letter by their GP advising them to 
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quit gradually and inviting them to the surgery three months later to evaluate the effect of the letter. 
At this consultation the doctor enquired whether the patient had been able to achieve complete 
abstinence and if not, whether the patient would participate in this study. All participants provided 
written informed consent. 
Sample size and randomisation 
The aim was to increase the success rate after the pre-selection procedure (i.e. the letter from the 
general practitioner) from an expected 55% through tapering off alone, to 80% by combining tapering 
off with group CBT.3 Based on a chi-squared test, this effect size required a sample size (two sided α 
= 0.05, β = 0.20) of 52 participants in each experimental group, or 62 participants based on a 
corrected chi-squared or Fisher's exact test.4 Participants were randomised in a ratio of 2 :2 :1 to 
achieve maximum discriminative power between the two experimental groups. Computerised 
randomisation took place after at least ten participants within a geographic cluster had given informed 
consent, in order to form CBT groups with a minimum of four participants at a location near to the 
participants' homes. 
Intervention 
Tapering off - Participants who were not using diazepam were transferred to an equivalent dose of 
diazepam for two weeks by their own doctor using the conversion table of Zitman & Couvée (2001 ).' 
For participants taking more than one benzodiazepine, the dosages were added together. The daily 
dose of diazepam was reduced by 25% a week during four weekly visits. In accordance with 
Schweizer et al (1990) participants had the opportunity to divide the last step into two steps of 121/2% 
for four days. The last visit took place two weeks after the last reduction step. The general 
practitioner filled in a case record form to monitor progress and any adverse events during the 
intervention period. Two months later, we evaluated participant and doctor satisfaction and the 
feasibility of the withdrawal programme by means of a postal questionnaire. 
Group cognitive-behavioural therapy - The participants who were randomised to tapering off 
combined with group CBT attended five weekly 2-h sessions of group CBT in addition to the dose 
reduction visits to their general practitioner. The sessions started halfway through the tapering-off 
period and finished two weeks after the conclusion of the withdrawal programme. The aim of the 
group therapy was to support the participants during the tapering-off proces and to prevent relapse 
thereafter. 
The therapy programme included: 
(a) psycho-education concerning the advantages and disadvantages of long-term benzodiazepine use; 
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(b) teaching and practising relaxation exercises by means of progressive relaxation, 
(c) cognitive restructuring of the interpretation of withdrawal symptoms 
The sessions were led by registered psychologists, expenenced in CBT, who received training 
and a detailed manual of the therapy The therapists documented participation and reasons for non-
participation at each session Tape recordings of a random sample of sessions 3 and 5 were judged by 
an independent assessor using previously defined criteria, and did not show any protocol violations 
Two months later, we evaluated patient satisfaction with the group therapy by means of a postal 
questionnaire 
Usual care - Participants in the usual care control group were informed about the randomisation by 
letter They did not receive any help with benzodiazepine reduction 
Measurements 
Participants received a baseline assessment after giving informed consent, and they received an 
outcome assessment three months after the start of the intervention Structured interview assessments 
were carried out at the participants' homes by a trained research assistant, who explored the self-
reported use of benzodiazepines, administered the 15-words test, and assessed the circumstances of 
filling in the self-report questionnaires 
Primary outcome measure - The primary outcome measure was the proportion of participants who 
successfully discontinued long-term benzodiazepine use, defined as no benzodiazepine use at the 
outcome self-report assessment We checked self-reported discontinuation of benzodiazepine use in 
the general practitioner's prescription database, which showed that less than 5% of the participants 
who reported successful discontinuation had received a benzodiazepine prescription in the month 
before the outcome assessment 
Secondary outcome measures - Secondary outcome measures were the reduction in daily 
benzodiazepine dosage by participants who did not successfully discontinue drug use, the use of 
alcohol (including the number of problematic drinkers, based on the 18-item list of Cornel et al, 
1994) , psychological well-being assessed by the General Health Questionnaire 12-item version 
(GHQ-I2)8, memory (delayed recall of the 15-words test)9, mood (the scales of depression, anger, 
fatigue, vigour and tension of the 32-item shortened Profile of Mood States, POMS)10, and the 






LONG-TERM BENZODIAZEPINE USERS 2964 
Based on prescription databases, 58 doctors in 30 general practices had 
an average of 51 patients using benzodiazepines For over 3 months 
Patients excluded 960 
Current psychiatre treatment 281 
Current treatment for drug or alcohol dependence 82 
Medical history of psychosis 80 
Epilepsy 53 
Insufficient mastery of the Dutch language 59 
Terminal illnes 26 
Excluded at instigation of the G Ρ 379 
PATIENTS ELIGIBLE FOR PRE-SELECTION 2004 
All 2004 patients received the letter containing advice to stop BZD use 
and were invited to visit the GP 3 months thereafter by a second letter 
Did not consult GP 683 
Slopped use of their own accord 285 
PATIENTS ELIGIBLE FOR TRIAL 1036 
Refused to participate 842 
Withdrew consent 14 
RANDOMISED 180 
TAPERING OFF ONLY 73 
Did not start taper protocol 22 
Discontinued of their own accord 16 
Refused to discontinue 6 
Discontinued BZD use according to 
CRF 46 (63%) 
TAPERING OFF + GROUP CBT 73 
Did not start taper protocol 21 
Discontinued of their own accord 7 
Refused to discontinue 14 
Did not attend group CBT 18 
Withdrew before Ihe start of CBT 2 
Personal reasons 16 
Discontinued BZD use according lo 
CRF 38 (52%) 
OUTCOME ASSESSMENT 60 
Lefttnal 13 
Dissatisfied with treatment 1 
Somalie / psychological problems 2 
Not motivated for other reasons 5 
Lost to follow-up 5 
Discontinued BZD use 37 (62%) 
USUAL CARE 34 
OUTCOME ASSESSMENT 57 
Lefttnal 16 
Dissatisfied with treatment 3 
Somatic / psychological problems 5 
Nol motivated for other reasons 5 
Lost to follow-up 3 
Discontinued BZD use 33 (58%) 
OUTCOME ASSESSMENT 34 
Lefttnal 10 
Dissatisfied with treatment 1 
Not motivated for other reasons 4 
Lost to follow-up 5 
Discontinued BZD use 5(21%) 
Abbreviations 
GP, general practitioner BZD, Benzodiazepine(s) CBT Cognitive Behavioural Therapy CRF Case Record Form 
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Statistical analysis 
To check for baseline differences between the three groups, a series of univariate analyses of vanance 
(ANOVAs) or non-parametric equivalents were performed on psychiatric status and demographic 
variables. The primary outcome measurements were analysed with a chi-squared test (number of 
participants who discontinued successfully). A forward logistic regression analysis with correction for 
treatment group was performed to identify independent predictors (all baseline characteristics) of 
discontinuation success. 
The dosage reduction in participants who failed to discontinue diazepam was analysed with 
one-way ANOVA (dosage quotient at outcome and baseline after natural log-transformation). 
Repeated measures ANOVAs were performed on the other secondary outcome variables for 
continuous variables and chi-squared tests for dicholomous variables. Significant main effects were 
further analysed with pairwise comparisons. 
Analyses were performed on an intent-to-treat basis. In the case of a missing outcome value, the 
last observation was carried forward to serve as the outcome measurement (whole sample, n=180). 
The analyses were repeated after excluding all those who had left the study at the outcome assessment 
(completers sample, n=141). A substantial number of participants had discontinued their use of 
benzodiazepines before the intervention started. For this reason, we also carried out a per protocol 
analysis on the participants who had been fully compliant with both the treatment programme and the 
outcome measurement (per protocol sample, n=78). We excluded the control group from this analysis, 
because only data on the experimental groups were available at the start of the intervention. 
Results 
Study profile 
Of the 2964 persons identified as long-term users of benzodiazepines, 2004 were advised to stop their 
benzodiazepine use; 1036 were eligible for the trial (figure 1). The participation rate was low: 180 out 
of 1036 (17.4%). Participants (n=180) and non-participants (n=876) did not differ with respect to age, 
gender or benzodiazepine dosage used. Of the 146 participants assigned to one of the withdrawal 
programmes, 23 discontinued their benzodiazepine use while waiting for the intervention to begin. In 
order to start therapy groups with at least 4 participants, the mean (±sd) delay between baseline 
assessment and intervention was 71 (±45) days (range 0 - 223 days). Thirty-nine participants refused 
to take part in the outcome assessment. The numbers leaving the study at this stage did not differ 
significantly across the three groups (χ2=1.85; df=2; p=0.40). Of the 85 participants compliant with 
the entire intervention programme (tapering off alone or tapenng off with group CBT), 78 were 
assessed at outcome. 
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Characteristics of the study participants 
Comparisons of the three groups did not reveal any significant differences in baseline characteristics 
(table 1). In addition, no significant difference in baseline characteristics was observed between those 
leaving the study and those completing the study. In the sample as a whole, the decile scores on the 
15-words test did not differ from the norm. Subanalyses revealed that participants who were using 10 
mg diazepam equivalent or more per day (n=35) had significantly worse scores than the participants 
who were using less than 10 mg per day (t=2.25; df=178; p=0.03) and the norm population (t=5.93; 
df=34;p<0.001). 
Table 1 
Characteristics of the study participants (n=180) at baseline assessment 
Background characteristics: 
Age (years) m e a n ( s d ) 
Gender (female)· η (%) 





Llivmg alone· η (%) 





Dosage (mg diazepam eq )· mean (s d ) 
Patients using > 10 mg diazepam eq · η (%) 
Duration of use (months): mean (s d.) 
Secondary outcomes 
GHQ-12 score, mean (s d ) 






Delayed recall (15-words test) mean (s d ) 
BWSQ score· mean (s d ) 
Patients using alcohol 
η (%) 
Units ol alcohol/ week mean (s d ) 
Problem dnnkers' η (%) 
Tapering off only 
(n=73) 










6 1 (9.B) 
12(16) 
160(116) 
2 4 (3 2) 
12 8 ( 5 8) 
11 1(5 1) 
12 4 ( 6 3) 
15 0 ( 4 3) 
12.0(5 4) 
6 7 (3 0) 
7 0 (7 0) 
42 (58) 
9 2 (8 3) 
5(12) 
Tapering off + CBT 
(n=73) 










7 1 (9 5) 
17(23) 
157(120) 
2 6 (3 4) 
14.1 (6 2) 
12 3 ( 5 7) 
12 4 ( 5 3) 
15 0 ( 4 6) 
12 5 ( 4 8) 
7 4 (3.2) 
6 3 (6.5) 
38 (52) 














5 3 (5 0) 
6(18) 
178(106) 
2 2 (2 9) 
13 7(6.7) 
11 9 ( 5 4) 
12 4 ( 5 5) 
14 1 (4 5) 
11 9 ( 5 1) 
6 β (2 8) 
5 8 (6 0) 
17 (50) 












0 4 4 
0 4 0 








Abbreviations CBT, cognitive-behavioural therapy, BWSQ, Benzodiazepine Withdrawal Symptom Questionnaire7; GHQ-12, 
General Health Questionnaire 12-item version4 
1 Based on the sum score of the list of Cornel et al (1994)3 Percentages are of those using alcohol in their group 
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Benzodiazepine usage 
The proportions of participants who successfully discontinued benzodiazepine use differed 
significantly between the three groups in the intent-to-treat analysis (table 2). Subsequent pairwise 
comparisons revealed that the two experimental groups did not differ significantly from each other in 
the inlent-to-treat analysis (whole sample p=0.51; completers sample p=0.68). However, the two 
experimental groups were significantly more successful than the control group: tapering off alone 
(whole sample p<0.001; completers sample p=0.001) and tapering off combined with group CBT 
(whole sample p=0.002; completers sample p=0.002). Corroborating these findings, the per protocol 
analysis did not show any significant difference between the two experimental conditions (p=0.53). 
Logistic regression analysis yielded benzodiazepine dosage as the only independent predictor of 
successful discontinuation (OR=4.5, [95% CI 2.0-10.2]). Patients who used 10 mg diazepam 
equivalents or more had a significantly lower chance of successful discontinuations than patients 
using less than 10 mg (35% v. 64%, p=0.009). 
Among those failing to quit, dose reduction differed significantly across the three groups 
(whole sample F2 io2=3.33, p=0.04; completers sample F2,62=3.98, p=0.02). Tukey HSD posi hoc tests 
showed a significant difference in dosage reduction between tapering off combined with group CBT 
and usual care (whole sample p=0.03; completers sample p=0.02). 
Table 2 
Benzodiazepine use at 3-months' follow-up 
Tapering off only Tapering off + CBT Usual care Ρ value 
Successful discontinuation: η (%) 
Intent to treat sample 
Whole sample with LOCF(n=1 BO) 37 (51%) 33 (45%) 5 (15%) ρ = 0 002 
Completers sample (n=141) 37 (62%) 33 (58%) 5 (21%) ρ = 0 002 
Per protocol sample 
Completers sample (n=7B) 27 (57%) 20 (65%) - p = 0 5 3 
Failure to discontinue: median % dose reduction 
Intent to treat sample: 
Whole sample with LOCF (n=105) 23% 37% - 3 % p = 0 04 
Completers sample (n=66) 35% 53% - 5 % p = 0 0 2 
Per protocol sample. 
Completers sample (n=31 ) 40% 72% - p = 0 02 
Abbreviations: CBT, cognitive-behavioural therapy; LOCF, last observation carried forward 
Secondary outcome measures 
We used repeated measure ANOVAs across the three groups to evaluate the effects of the severity of 
withdrawal symptoms, psychological distress, mood, memory and problem alcohol use. There was a 
significant time-effect only for the delayed recall of the 15-words lest, which indicated an 
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improvement. However, no significant interaction effects emerged for any of the secondary outcome 
measures, thus these measures were fairly comparable in the three groups (table 3). Moreover, 
comparing participants who successfully discontinued benzodiazepine use with those who failed to do 
so did not result in significant time χ outcome interaction effects for any of the secondary outcome 
measures. Neither the prevalence of alcohol use, nor the amount consumed by alcohol users, changed. 
Table 3 
Secondary outcome measures at 3 months' follow-up in the intent-to-treat sample (LOCF, n=180) 
GHQ-12 score mean (s d ) 






Delayed recall (15-words tesi) mean (s d ) 
BWSQ score: mean (s.d.) 
Patients using alcohol 
η (%) 
Units of alcohol / week mean (s d ) 
Problem drinkers η (%)' 
Tapering off only 
1 β (2 5) 
12 6(5.2) 
1 1 5 ( 5 5) 
12 7 ( 6 4) 
14 9 ( 4 9) 
11 4 ( 4 9) 
7 2 (2 9) 
6 2 (6 8) 
42 (58) 
10 0(11 0) 
5(12) 
Tapering off +CBT 
2 4 (3 0) 
13 8 ( 6 9) 
12 0 ( 6 2) 
12 7 ( 5 9) 
15 0 ( 4 7) 
12 6 ( 5 8) 
θ 1 (3 4) 
6 8 (7 5) 
40 (55) 
β 3 (6 4) 
10(14) 
Usual care 
1 8 (3 0) 
13.0(7.5) 
10 7(5 1) 
11 7 (7 0) 
15 3(5.9) 
11 1 (5 6) 
7.6(2 5) 
5 8 (7.3) 
18 (53) 
7 3 (6 4) 
5(15) 
Ρ value 
ρ = 0β3 
ρ = 0β6 
p = 0 2 2 
ρ = 0.68 
p = 0 3 9 
p = 0 4 6 
ρ = 0 63 
p = 0 5 7 
ρ = 0 81 
p = 0 63 
p = 071 
Abbreviations CBT, cognitive-behavioural therapy, GHQ-12, General Health Questionnaire 12-item version , BWSQ, 
Benzodiazepine Withdrawal Symptom Questionnaire7, 
1 Based on Ihe sum score of the lisi of Cornel3 
Doctor and patient views of the tapering-off strategy 
Participants (n=103) who entered the withdrawal programme visited their general practitioner an 
average of 5.6 times (sd 1.4, range 1 - 9). The average number of visits did not differ between the 
participants assigned to tapering off alone and those assigned to tapering off combined with group 
CBT, and there was no difference between the participants who successfully discontinued 
benzodiazepine use and those who did not. 
A total of 43 out of the 58 participating doctors actually supervised the patients during the 
tapering off proces; 42 of them returned the postal evaluation questionnaire. Analyses of these 
questionnaires showed that 37 doctors (88%) found the protocol feasible at their own practice, 35 
(83%) would encourage other general practitioners to taper off long-term benzodiazepine use with the 
aid of the withdrawal protocol, and 22 (52%) had already started using this protocol for patients not 
included in the trial. No major adverse event during the reduction period (such as epileptic seizures or 
psychotic episodes) was reported in the case record forms. 
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A total of 91 (88%) of the 103 participants who entered the withdrawal programme returned the 
postal evaluation questionnaire. The results showed that 78 (86%) of those who responded were 
satisfied with the 'treatment' received; 66 (73%) would be willing to follow the same treatment again 
if necessary. With respect to their supervision, 65 (76%) preferred treatment by their own GP, 6 (7%) 
preferred referral lo a specialised treatment setting, 12 (14%) preferred no support with tapering-off 
and 3 (3%) had no preference. 
Attrition rates and participant's views on group CBT 
Seven (10%) of the 73 participants assigned to CBT discontinued their benzodiazepine use before the 
start of the intervention. In order to prevent relapse, we invited these participants lo the therapy 
sessions; however, only two actually participated. Of the participants who began the tapering-off 
proces combined with group CBT, only 34 (65%) attended three or more sessions (figure 1). The 
discontinuation success rates did not differ significantly between the patients who were compliant 
with CBT and those who were not: 20/31 (65%) v. 6/15 (40%), p=0.12. The postal evaluation 
questionnaire was returned by 30 (88%) of the 34 compliant participants: 14 (47%) of them would 
have preferred more sessions; 28 (93%) were satisfied with the group therapy in general. The degree 
of satisfaction with group CBT was not related to taper success. 
Discussion 
Tapenng off was an effective strategy for the discontinuation of long-term benzodiazepine use, even 
after pre-selection with a letter containing advice to stop, achieving its highest success rates in 
patients using less than 10 mg diazepam equivalents. Adding group CBT did not increase the 
proportion of those who successfully discontinued. Although the study was marginally lacking power 
for some analyses, this is irrelevant since the success rate for patients receiving group CBT was 
numerically lower than that for the group assigned to tapenng off alone. Of those who failed to 
discontinue benzodiazepine use, those assigned to additional group CBT reduced their dosage 
significantly more than the participants in the control group. Both withdrawal programmes proved to 
be feasible in general practice. After the intervention, we did not find any significant differences 
between the three groups in the presence and severity of withdrawal symptoms, symptoms reflecting 
psychological distress and mood disturbances between the three groups. Neither the prevalence of 
problem drinking or alcohol use, nor the amount of alcohol consumed, was influenced by the 
intervention type or tapering off, which indicates that none of our participants replaced their 
benzodiazepine use with alcohol. 
101 
Chaplcf 6 
Efficacy of tapering off 
This was the first study to show the efficacy of tapering off long-term benzodiazepine use by 
including a 'usual care' control condition Although we pre-selected patients by sending a letter 
advising them to stop their use, our success rates were comparable with those of other benzodiazepine 
withdrawal studies ,<' In the control group, 21% of the participants stopped their benzodiazepine use 
spontaneously In addition, 23 (16%) of the 146 participants assigned to the experimental groups 
discontinued benzodiazepine use without any professional help while waiting for the interventions to 
start At first we considered this to be a methodological, but inevitable problem of our study, because 
it look some time to fill the therapy groups However, it appeared to be a cost-effective strategy in 
view of the 60% success rate among those still using benzodiazepines, as was shown by the per 
protocol analysis The proportions of participants who stopped spontaneously were much higher than 
the estimated 6% Several explanations can be put forward First, actually taking part in a 
discontinuation trial could provide an extra incentive to discontinue benzodiazepine use 
independently, even if a previous attempt was not successful Second, owing to selection processes, 
the proportion of participants in discontinuation trials who are able to stop their use without any 
professional help might be higher than in long-term users in general 
Generalisibility 
A participation rale of 17 4% presumes significant selection processes Although the people gave a 
vanety of reasons for non-participation, dependence on benzodiazepines might have played an 
important part Kan et al (1997) found that 40% of all those prescribed benzodiazepines in general 
practice were dependent on benzodiazepines according to DSM-III-R criteria, and Linden et al (1998) 
found that two- thirds of those who were long-term benzodiazepine users rejected a drug 
'holiday' ' ' Reluctance to enter group therapy as well as reluctance to hold interview sessions at 
home might have also contributed to the small number of participants In clinical practice a higher 
recruitment rate might be achieved if the patients are not asked to participate in a randomised 
controlled trial As participants were representative with respect to not only age and gender, but also 
to the (only) independent predictor of success, benzodiazepine dosage, it is unlikely that we excluded 
treatment-resistant patients As we identified all patients who were long-term users before we 
recruited participants, it is not possible to compare our attrition rate with that of other studies that 
recruited referred participants from specialised settings or by advertisement 
Efficacy of group CBT 
In our study, adjunctive group CBT focused on the management of withdrawal symptoms did not have 
any additional value Previous studies evaluating simultaneous psychological treatment to improve 
these success rates have considerable methodological problems Two studies did not compare the 
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efficacy of additional CBT ν tapenng off alone1'' '5, the other studies did not use a controlled design 
19, did not randomise participants over the conditions2" or studied a sample of fewer than 10 
participants2'22 The two studies without these methodological problems were restricted to 
participants who met the cntena for panic disorder, here the addition of CBT to tapenng off 
significantly increased the proportion who successfully discontinued benzodiazepine use These 
results are difficult to generalise, as the prevalence of panic disorder among those who are long-term 
benzodiazepine users has been estimated to be at most 27% 24 Our success rate for CBT might have 
been increased by a prion selection on psychiatnc morbidity and by introducing disorder-specific 
elements A disadvantage of this strategy is that the programme cannot then be used easily in general 
practice 
The lack of additional value might also be due to the limited number of sessions provided 
However, the efficacy of brief psychotherapy in alcohol dependence and somatisation disorder in 
general practice has been supported by the results of randomised controlled trials In view of the 
relapse rate in the benzodiazepine withdrawal study by Zitman & Couvée (2001), and the delayed 
effects of psychotherapy in the treatment of cocaine dependence and in the tapenng off of alprazolam 
in panic disorder, a long-term follow-up study is planned 3 5 27 Another possibility is to give CBT after 
instead of during tapenng-off In our opinion, however, this strategy is of limited value in clinical 
practice only two of the seven participants who stopped their use before the intervention could be 
motivated to attend the therapy sessions to help them remain benzodiazepine-free in the future 
Adherence to group CBT 
Adherence to group therapy was poor, which may reflect an overall resistance to group therapy among 
people who are long-term benzodiazepine users This is in line with findings in other studies and with 
our interpretation of the personal reasons why patients refused to attend group therapy sessions 1821 
Moreover, individual CBT sessions to restructure dysfunctional cognition might be more successful 
However, the poor adherence cannot explain the lack of success, as the success rate of patients who 
were compliant to CBT (n=34) was 65% Although sub-analyses lack statistical power, it is unlikely 
that this would be supenor to the 57% success rate of tapering off alone 
Feasibility in general practice 
Tapenng off was tolerated well in general practice the general practitioners did not report any major 
adverse event dunng or after the tapenng-off process The good compliance and high level of 
satisfaction with the programme among both doctors and participants further strengthen the feasibility 




• This study is the first to evaluate additional psychotherapy in a randomised, controlled fashion. 
• Gradual tapering off is an effective way of discontinuing benzodiazepine use. 
• Additional psychotherapy does not seem to increase the success rate of the gradual tapering-off 
approach. 
Limitations: 
• Only one in six patients in this study were willing to take part in a withdrawal programme. 
• Treatment adherence in psychotherapy was limited. 
• Patients received no diagnostic psychiatric screening, which made sub-analyses in specific 
diagnostic groups impossible. 
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Anton J L.M van Balkom, Eloy H van de Lisdonk, Cees C Kan, Frans G Zitman 
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Abstract 
Introduction 
















The Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ) measures the severity of 
benzodiazepine dependence on four domains awareness of problematic use, preoccupation with the 
availability of benzodiazepines, lack of compliance with the therapeutic regimen, and withdrawal 
Although promising results of the Bendep-SRQ have been obtained in cross-sectional studies, 
no attention has been paid to its clinical relevance dunng benzodiazepine withdrawal, ι e , predictive 
validity and time course We performed cross-validation and evaluated the predictive validity and time 
course on 180 long-term benzodiazepine users who were taking part in a general practice 
benzodiazepine discontinuation trial 
Three of the four domains had good scalability Some concerns arose about the preoccupation 
scale, which emphasizes the need for cross-validation in clinically relevant populations All scales 
showed excellent reliability (subject discnminabihly, item discnminabihly), while construct and 
discriminant validity were adequate 
All four scales contributed significantly to the prediction of whether complete abstinence would 
be achieved directly after taking part in the discontinuation programme This prediction was 
independent of the other prognostic variables, except for those in the domain problematic use The 
scales problematic use and preoccupation showed good sensitivity to changes dunng follow-up The 
insensitivity of the scale lack of compliance can be explained by low baseline scores in our population, 
while the insensitivity of the withdrawal scale was probably the result of the study design In 
conclusion, our study indicated the clinical relevance of the Bendep-SRQ before and dunng a 
benzodiazepine discontinuation inai We recommend the use of the Bendep-SRQ in discontinuation 
therapy and research into the field of benzodiazepine addiction 
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Introduction 
Although people have been aware that withdrawal symptoms occur following discontinuation of 
benzodiazepines since their introduction in the early 1960s , it took until the early 1980s to develop 
symptom-rating scales to measure the nature and severity of the benzodiazepine withdrawal 
syndrome410 Unfortunately, most of these scales have only been tested in small patient populations, 
without evaluating their psychometric properties or their predictive validity in benzodiazepine 
withdrawal Recently, the Benzodiazepine Withdrawal Symptom Questionnaire (BWSQ) developed 
by Tyrer et al (1990)", was evaluated psychometncally within a benzodiazepine discontinuation 
programme '2 This study design enabled evaluation of its clinical utility, ι e , predictive validity The 
mean scores could differentiate between "successes" and "failures", while lower scores in the last 
phase of tapenng-off predicted no or limited use of benzodiazepines at follow-up, which increased the 
percentage of correct predictions from 56% to 65% 
It has been shown that benzodiazepine dependence may not be reduced to a withdrawal 
syndrome on the basis of discontinuation alone 13 The BZ dependence criteria of the DSM-III-R and 
ICD-10 only met the requirements of the Rasch model after the removal of particular items The 
remaining items were considered to probe BZ dependence at its general core, but not reflect BZ 
dependence comprehensively, because criteria related to BZ withdrawal were omitted It is possible 
that these withdrawal criteria reflected a separate dimension, which means that BZ dependence might 
be a multidimensional concept These findings are in line with the results of a factor analysis reported 
by Bailhe and Mattick (1996) that yielded three factors during the development of the Benzodiazepine 
Dependence Questionnaire (BDEPQ) general dependence, pleasant effects and perceived need9 
However, these researchers did not adopt multidimensionahty, as they considered the BDEPQ total 
sum score to be a proper measure to reflect the seventy of BZ dependence comprehensively 
In contrast with Bailhe and Mattick (1996), Kan et al (1999) adopted a multidimensional 
approach to develop the Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ) H In 
order to construct adequate scales. Rasch modelling was applied to the dimensions suggested by factor 
analyses The scalability, reliability and validity of the four resulting Bendep-SRQ scales (problematic 
use, preoccupation, lack of compliance and withdrawal) proved promising in a subsequent cross-
validation study on outpatient benzodiazepine users ' 4 1 5 However, it remains unclear whether these 
results can be generalised to long-term benzodiazepine users who are taking part in a discontinuation 
programme Moreover, as a result of the cross-sectional designs of these studies, predictive validity 
and time course during benzodiazepine withdrawal have not been evaluated yet It can be expected 
that users with higher scores on any of the four dependence scales will be less successful in their 
tapenng-off attempts than users with low scores 
The aim of the present study was to cross-validate the Bendep-SRQ in a group of long-term 
benzodiazepine users who were taking part in a general practice benzodiazepine discontinuation 
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programme The following questions were adressed (a) Can previously found psychometric results be 
generalised to long-term benzodiazepine users who are seeking discontinuation treatment9, (b) What is 
the predictive value of the Bendep-SRQ regarding the achievement of complete abstinence by 
tapenng-off benzodiazepine use9 and (c) Can the Bendep-SRQ monitor the time course of 
benzodiazepine dependence9 
Method 
Setting and design 
This study was conducted as part of a benzodiazepine discontinuation inai at 30 general practices 
throughout the Netherlands The Bendep-SRQ (and other measures) were administered at baseline and 
outcome to 180 subjects randomised over three conditions gradual tapenng-off (n=73), gradual 
tapenng-off combined with group therapy (n=73) and a control condition consisting of usual care 
(n=34) In the two tapenng-off conditions, subjects were tapered-off by 25% a week after being 
transferred to an equivalent dose of diazepam, in the control condition, no attention was paid to the use 
of benzodiazepines The outcome of this programme has been reported elsewhere 
Subjects 
Subjects were at least 18 years of age, fulfilled the cntena for chronic use (i e , benzodiazepine use for 
at least three months with an amount sufficient for at least 60 days of consumption according to the 
prescription rules) and were not able to discontinue their use of their own accord having received 
wntten advice from their general practitioner Exclusion cntena were current psychiatric treatment, 
current treatment for drug or alcohol dependence, psychosis, epilepsy, insufficient mastery of the 
Dutch language, or suffenng from a terminal illness 
The Bendep-SRQ 
The Bendep-SRQ is a 20-item self-report questionnaire that measures the seventy of benzodiazepine 
dependence l4 All of the items are rated on a five-point scale The items of the scales problematic use, 
preoccupation and lack of compliance are rated according to the degree to which they applied over the 
past three months, while the items of the withdrawal scale are rated according to the subject's latest 
attempt to reduce or discontinue their benzodiazepine use Analogously to earlier reports, the items 
were dichotomized between response options 2 (this is not true for me) and 3 (this is partly true, partly 
false for me), in order to apply Rasch analysis 
Analysis 
Data gathered at the baseline assessment were used to cross-validate the Bendep-SRQ, while data 
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gathered at the outcome assessment three months after the start of discontinuation treatment were used 
to assess the predictive validity and time course 
Scalability of the Bendep-SRQ stales - Rasch analysis was applied to the items in the four Bendep-
SRQ scales Problematic use, Preoccupation, Lack of Compliance, and Withdrawal The surplus of 
Rasch modelling to the 'classical test theory' is the justification of the use of the sum score as a 
sufficient statistic for the underlying construct (i e the latent trait) by means of goodness of fil tests 
denved from the Rasch scaling model Although the use of sum scores is generally accepted in 
psychiatric research, this is only justified if the Rasch model holds true, as reflected by the goodness 
of fit statistics Rl and R2 '7 If Rl is not significant at the 1% significance level (P>0 01) the null 
hypothesis that all items have equal discriminative power cannot be rejected and equi-discnmmability 
can be assumed Similarly, unidimensionahty and local stochastic independence hold true when R2 is 
not significant (P>0 Ol) Rasch homogeneity holds true when both statistics are non-significant Kan et 
al (2001) reported that the latent trail for three of the four scales had a normal distribution "t 
Therefore, we applied the Rasch model under the assumption that the latent trait has a normal 
distribution by including the R0 statistic (marginal maximum likelihood method)17 '9 Nonrejection of 
this additional assumption implies that standard scores can be denved that correspond with estimates 
of the latent subject trait instead of the observed scores This is preferable, because the primary aim of 
a scale is to reflect the latent subject trail as accurately as possible The statistics Rl and R2 can then 
be computed on the basis of a normally distributed latent trait For more detailed information on the 
assumptions from which the Rasch model can be denved and Ihc required additive structure 
underlying the observed data, we referto Fischer et al (1995) and Kan et al (2001) l 8 2 0 
Reliability - Reliability is the degree to which a measurement can be repealed and the same values can 
be obtained To evaluate the reliability of the Bendep-SRQ scales we assessed subject discriminabihty 
and item discriminabihty 
Subject dfiiriminability (Internal Consistency) Subject discnminabihty implies that the subjects differ 
systematically, ι e , the vanation between subjects is larger than the vanalion due to random error 
Subject discnminabihty of the Bendep-SRQ scales was evaluated by means of the KR-20 coefficient, 
analogous to Cronbach's alpha for continuous variables 
Item discnminabihty Item discnminabihty implies that the items differ systematically, ι e , the 
vanation between items is larger than the variation due to random error This was tested by Cochran's 
Q test If the Q value is significant, items can be considered to occupy distinct points on the scale 
Additionally, analogous to the concept of reliability as desenbed by Hoyt (1941), which is a measure 
of intersubject discnminabihty, a measure of intentem discnminabihty has recently been developed 
the item discnminabihty coefficient (IDC) 1 4 2 1 On the premises that the underlying item response 
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model holds true, the IDC will show the extent to which the differences between items are systematic 
The higher the IDC (range, 0 to 1), the more powerful the predictions about the item scale 
Validity - A measurement is valid when the scale measures what it is intended to measure The validity 
of the Bendep-SRQ scales was assessed in terms of construct, discriminant, and predictive validity 
Construct validity Construct validity refers to the degree to which inferences can legitimately be made 
from the operationahzations in the questionnaire regarding the theoretical constructs on which the 
operationahzations were based To establish the construct validity of the Bendep-SRQ scales, 
theoretical rationales have been formulated to explain the specific item orders based on increasing 
Rasch scale values, which reflects increasing severity levels of the constructs To comply with the 
postulated theoretical rationales, the estimates of the Rasch scale values in the present study should 
approximately replicate the specific item orders of the Bendep-SRQ scales in the former study This 
would confirm the construct validity of the Bendep-SRQ scales 
Discriminant validity Discriminant validity means that the measure can discriminate between groups, 
e g, between subjects with and subjects without a particular disorder To estimate discriminant 
validity, we factor-analysed the following scale scores The Benzodiazepine Withdrawal Symptom 
Questionnaire version 2 (BWSQ-v2) that assesses BZ withdrawal symptoms during discontinuation of 
benzodiazepines in pharmacologically dependent patients" 12, the Dutch shortened Profile of Mood 
States (POMS), a 32-item self-report questionnaire that measures five short-term changeable mood 
stales22, the Short Form-36 that assesses quality of life on eight domains2126, and the Dutch Shortened 
Minesota Multiphasic Personality Inventory (MMPI) that assesses personality charactenslics 27 All of 
these questionnaires have proven to have good reliability and validity 
Predictive validity Predictive validity refers to whether a psychological measure is correlated with a 
particular type of behavior that occurs at a later point in time, in this case, whether or not a subject 
successfully discontinued their BZ use after participating in our benzodiazepine discontinuation 
programme This was estimated for each scale separately by logistic regression analysis to predict the 
outcome (successfully discontinued or failed to discontinue) adjusted first only for treatment condition 
(tapenng-off with or without group cognitive-behavioural therapy or usual care) and second for 
treatment condition and all baseline characteristics umvanaiely discnminating between subjects who 
successfully discontinued and those who did not 
Longitudinal monitoring - Previous reports on the Bendep-SRQ showed good test-retest reliability To 
descnbe treatment effects, an instrument also has to have good sensitivity to change We evaluated 
sensitivity to change using a repeated measures design with one within-subject factor with two levels 
(sum score at baseline and sum score at outcome) and one between-subject factor with two levels 
(treatment success and failure) 
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Data analysis program - Rasch analyses were conducted using the Rasch Scaling Program. Other 
data analyses were conducted using SPSS 10.0.5 (SPSS Ine, Chicago, IL). 
Results 
Sociodemographic features and pattern of BZ use 
The baseline charactenstics of all the subjects are presented in table 1, because there were no 
differences between the three conditions. Mean daily benzodiazepine dosage was relatively low (6.4 
mg diazepam a day). Sociodemographic and benzodiazepine usage characteristics were comparable 
with those in the sample studied by Kan et al (2001).18 The scores on the Bendep-SRQ in our sample 
were the same as those in the previous sample on the problematic use scale (p=0.26), but significantly 





Gender (Iemale) η (%) 
Age (years) mean (s d ) 
Marital status η (%) 
No relationship 
Marned / steady relationship 
Divorced 
Widowed 
Living alone η (%) 




Benzodiazepine usage characteristics. 
Dosage· mean MDD/DDD (s d ) 



























Abbreviations' MDD/DDD, mean daily dose / defined daily dose 
Scalability 
Table 2 shows that the R0, Rl and R2 test results of the Rasch analyses on the scales problematic use, 
lack of compliance, and withdrawal were all non-significant (p>0.01). This implies that the latent trait 
had a normal distribution and that Rasch homogeneity can be assumed. However, the latent trait of the 
preoccupation scale did not appear to be normally distributed (p=0.013) and removing this 
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Table 2 
Scalability of the Bendep-SRQ scales by means of the Rasch Scaling Program using the Marginal Maximum Likelihood (MML) method 
Scale I RO df RI df 9 R2 df 
- Problematic use 5 79 012 7 74 0 36 9 59 12 0 65 171 
- Preoccupation* 
CML method" 
















• Lack of Compliance" 22 49 0 03 171 
- Withdrawal 1 91 0 59 7 92 0 34 13 43 0 34 163## 
ABBREVIATIONS R0, test statistic of Rasch analysis with regard to a normal distnbution of the latent trait, R1, test statistic of Rasch analysis with regard to equidiscriminability, R2, test statistic of 
Rasch analysis with regard to unidimensionality and local stochastic independence, ι, number of items in the scales, df, degree of freedom, p, p-value, g, number of subgroups formed by Rasch 
analysis, n, number of subjects left in the analysis, CML, conditional maximum likelihood 
As the statistic R0 reached significance using the marginal maximum likelihood method, the conditional maximum likelihood method was also applied to this scale 
As the conditional maximum likelihood method does not assume a normally distributed latent trait, the R0 is not calculated 
Due to the small proportion of subjects who loaded on the scale, only the R2 could be computed 
# R1 and R2 statistics were calculated after excluding subjects with the minimum or maximum sum score that did not lead to vanance 
## Excluding the subjects who had not attempted to reduce or cease Iheir benzodiazepine use before Ihe assessment (n=B) 
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assumption from the Rasch model by using the conditional maximum likelihood (CML) method 
showed that the scale was not Rasch homogeneous. Removing one of the items "Just before I take my 
medication, that is the only thing I can think about" or "I spend a great deal of lime thinking about 
medicine" yielded a Rasch-homogeneous scale by using the CML method. The MML method, 
however, yielded a highly significant RO-statistic. 
Reliability 
Subject discriminability and item discriminability (table 3) indicated good reliability of the 
preoccupation, lack of compliance, and withdrawal scales. The problematic use scale yielded a 
moderate to good KR-20 value. Very good Cochran's Q and IDC results were found. 
Table 3 
Reliability of the Bendep-SRQ scales in terms of subject and item discnminabilily 
Parameter Problematic use Preoccupation Lack of Compliance Withdrawal* 
KR-20 56 74 73 76 
CQ" 235 151 30 36 
IDC 99 98 87 89 
ABBREVIATIONS KR-20, Kuder-Richardson-20 coefficienl of internal consistency, CQ, Cochran's Q (in rounded figures), IDC, 
item discriminability coefficient. 
Excluding all subjects who had not attempted to reduce or discontinue their BZ use before the assessment 
" All CQ p-values ρ < 0 001 
Construct validity 
The item orders based on increasing scale value estimates yielded by the Rasch analyses were only 
identical to the item orders found in the original study on the development of the Bendep-SRQ for the 
preoccupation scale (table 4).M The item order in the other three scales differed from the original study 
by 1 item. In our sample the item 'Other people have urged me to use less medication' had a lower rank 
order on the problematic use scale, while the item "tiredness" had a lower rank order on the 
withdrawal scale. In the lack of compliance scale, the item 'I take more medication than is written on 
the label' had a higher rank order. The Rasch scale estimate of the 'deviating' item only exceeded 
twice the standard error of the Rasch scale estimate of the preceding and following item in the 
problematic use scale. 
Discriminant validity 
The results of the principal axis factor analyses with varimax rotation are shown in table 5. A three-
factor solution was recommended by the scree plot, showing a substantial decrease and a gradual 
decline in the eigenvalue of additional factors. Moreover, two- and four-factor solutions were less 




Construct validity (item order based on the Rasch scale values) 
•1 63 (0 18) 
•0 97 (0 16) 
•0 40 (0 15) 
1 47 (0 16) 
1 53 (0 16) 
2 4 (1 5) 
-1 12 (0 19) 
-0 72 (0 19) 
-0 49 (0 19) 
0 18 (0 20) 
2 15 (0 33) 
-1 80 (0 25) 
-1 08 (0 22) 
-0 34 (0 23) 
1 15 (0 24) 
2 06 (0 52) 
2 0 (1 6) 
-0 73 (0 39) 
-1 60 (0 39) 
-1 21 (0 36) 
1 60 (0 36) 
1 95 (0 52) 
Bendep-SRQ scale (Item) Original study" Trial sample 
Problematic use: 
I have been thinking about giving up the medication -141 (0 15) -2 67(0 24) 
At present, the medication is less effective than il used to be 0 01 (0 14) -0 04(0 19) 
Other people have urged me to use less medication 0 11 (0 14) -0 67(0 19) 
I think the medication is destroying my life 0 64 (0 15) 1 40 (0 25) 
The medication is getting me into trouble 0 66(0 15) 2 00(0 29) 
Sum score PROBLEMATIC USE mean (s d ) 15(13) 1 5 (1 2) 
Preoccupation: 
I take another dose of medication on time because otherwise I 
would suffer from complaints 
I feel safe when I have my medication with me 
I get nervous if my medication is out of reach 
Just before I take my medication, that is the only thing I can 
think about 
I spend a great deal of time thinking about medication 
Sum score PREOCCUPATION mean (s d ) 
Lack of Compliance: 
I take more medication than is written on the label 
My medication is gone too quickly 
I go and get a new prescription before the appointed time 
I take a lot of medication in one go 
I alter what is wntten on the prescription 
Sum score LACK OF COMPLIANCE mean (s d ) 0 6 (16) 0 4 (0 9) 
Withdrawal: 
Restlessness -0 88(0 19) -0 50(0 19) 
Feeling depressed -0 29(0 18) -0 04(0 21) 
Tiredness -0 21 (0 18) -0 74(0 20) 
Irritability 0 38 (0 18) 0 01 (0 21) 
Shaking 1 00 (018) 1 27 (0 25) 
Sum score WITHDRAWAL mean (s d ) 2 0 (19) 1 4 (1 6) 
it is the most plausible The first factor appeared to be a dimension of the psychopathological status, as 
four of the five scales of the POMS and three of the five scales of the MMPI showed the highest 
loadings on this factor However, the Bendep-SRQ scale 'lack of compliance' and the BWSQ-v2 also 
loaded moderately on this factor The 'vigour' scale of the POMS and all scales of the Short-Form 36 
loaded highest on the second factor, representing quality of life The highest loadings of the Bendep-
SRQ scales were observed on the third factor that reflected a dimension of benzodiazepine 
dependence. No other scale loaded substantially on this factor, which indicated good discnrmnant 
validity 
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Table 5 
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Pnncipal axis factor analysis with vanmax rotation on a matnx of scale scores of all participants (n=180) 
Withdrawal scale excluded lo avoid the selection of palienls with previous attempts to discontinue of 
reduce their use (n=15) 
Predictive validity 
As shown by the crude odds ratios in table 6, all scales of the Bendep-SRQ showed significant 
predictive validity in a logistic regression analysis after correcting for treatment condition. The lack of 
compliance and preoccupation scales appeared to have the highest predictive values: both scales 
achieved an improvement of the prediction of the model from 63% to 70% correct. To assess the 
independent predictive value of the scales, we also calculated the odds ratios after correcting for all 
baseline measurements that univariately discriminated between successfully treated subjects and 
failures. These were dose (p = 0.001), sum score on the BWSQ-2 (p = 0.003), use of nicotine (p = 
0.009), negativism of the Dutch shortened MMPI (p = 0.043) and tension of the POMS (p = 0.048). To 
calculate the adjusted odds ratio for 'withdrawal', the BWSQ-2 sum score was a priori left out of the 
analysis, as the two scales tend to measure the same. Except for the problematic use scale, all of the 
scales still had significant independent predictive value. 
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Table 7 
Time course of mean benzodiazepine dependence scores dunng benzodiazepine discontinuation therapy 
Treatment oulcome 
1. Problematic use 




1 5 ± 1 2 
1 9 ±1.3 
0 6 ±0.8 
1.7 ±1.3 
2. Preoccupation 
Time of assessment 
Baseline Outcome 
1 6 ±1 5 
2.7 ±1 7 
0 5 ±09 
2 4 ±14 
3. Lack of Compliance 
Time of assessment 
Baseline Outcome 
0 1 ±04 
0.7 ±1 3 
0 0 ±02 
0 6 ±1.1 
4. Withdrawal 
Time of assessment 
Baseline Outcome 
1 1 ±1.5 
2.1 ±1.7 
0 9 ±13 
1 8 ± 1 7 





0 003 (F=9 13, df=1,138) 
0.000 
0 000 
0 002(F=9 86, df=1,13e) 
0.302 
0.000 
0 769 (F=0 09, df=1,138) 
0.047 
0.000 
0.963 (F<0 01,df=1,125) 
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Table 6 
Predictive validity of the Bendep-SRQ scales during benzodiazepine discontinuation therapy 
Bendep-SRQ scale Crude OH [ 95% C.I. ]· p-value Ad|. OR [95% C.I.]" p-value 
Problematic use 1 39 [1 04 -1 85 ] 0 025 1 11 [ 0 79 - 1 55 ] 0 540 
Preoccupation 1 62 [ 1 27 - 2.07 ] 0 000 1 38 [ 1 04 -1 84 ] 0 025 
Lack ol Compliance 2 89 [ 1 53 - 5.47 ] 0 001 2 3 7 ( 1 1 0 - 5 1 3 ] 0028 
Withdrawal 1 55 [ 1 22-1.9B] 0 000 1 48 [ 1 06 - 2 05 ] · " 0 020 
Abbreviations OR. odds ratio, C I, confidence interval, adj, adjusted 
* ORs for the scale score at baseline in successful and unsuccessful subjects, only corrected for treatment condition (n=141) 
*" Other significant independent predictors were treatment condition (p=0.001), dose (p=0 003) and use o) nicotine (p=0 013) 
*" Adjusted odds ratio calculated after removing the BWSQ-2 score 
Time course 
The longitudinal course showed significant time-effects in the scales problematic use, preoccupation, 
and withdrawal, which indicated a decrease in the severity of dependence after taking part in the 
benzodiazepine withdrawal program (table 7). Time χ treatment outcome interactions were only 
significant for the scales problematic use and preoccupation, which indicated a greater decrease in 
dependence severity in subjects who successfully discontinued compared to those who did not. 
Discussion 
The Bendep-SRQ was cross-validated in pnmary care patients who were taking part in a 
benzodiazepine discontinuation programme in order to evaluate the generalisability of previous results 
to this population and to assess the predictive validity and time course of dependence. In general, our 
results provide further support for the scalability, reliability and validity of the Bendep-SRQ scales. 
The main difference from previous studies was that our population comprised subjects who had 
the intention to quit their benzodiazepine use. They expressed this intention by giving informed 
consent to participate in a benzodiazepine discontinuation trial. Our sample was comparable with that 
studied by Kan et al (2001) with respect to the socioeconomic variables, benzodiazepine dosage and 
duration of use.18 However, our sample had significantly lower scores on the Bendep-SRQ scales 
preoccupation, lack of compliance, and withdrawal, which indicated selective recruitment. 
In our sample, Rasch homogeneity was confirmed in the problematic use, lack of compliance, 
and withdrawal scales. In line with a previous report, the latent trait was not normally distributed in 
the preoccupation scale, but in contrast, the Rasch model did not hold true for this scale.18 Removing 
one of the items "Just before I take my medication, that is the only thing I can think about" or "I spend 
a great deal of time thinking about medicine" yielded a Rasch homogeneous scale. This implies that 
the assumption of local stochastic independence was threatened for these items and not the 
unidimensionality. In both cases however, the latent trait was not normally distributed, as indicated by 
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a highly significant RO (p< 0 01) As the item parameter estimates in the Rasch model are independent 
of the subject parameters, this finding cannot be explained by recruitment selection Further research is 
required to shed more light on whether this scale can be properly used during withdrawal 
Surprisingly, a literature search to find information on the relationship between long-term 
benzodiazepine use and preoccupation with the availability of benzodiazepines, more specifically 
craving, revealed a gap in craving research in the field of benzodiazepine addiction, as only two 
reports were found 
The KR-20, IDC, and Cochran's Q showed excellent results, even better than those of 
previously research, which confirms the high reliability of all scales of the Bendep-SRQ The factor 
analytic results shown in table 5 could be interpretated the same way as those found in earlier studies 
on the Bendep-SRQ, which also supports discriminant validity In contrast with earlier studies, no 
information could be provided on concurrent validity, because we did not include any other 
dependence measurements 
The item orders for the scales problematic use, lack of compliance, and withdrawal were 
different form those in the original study However, the difference between the items based on 
increasing scale value estimates yielded by the Rasch analysis only exceeded the range of twice the 
standard error of the scale value estimate in the problematic use scale This suggests that we have 
found the definitive rank order Following the same reasoning, the item orders found for the scales 
'lack of compliance' and 'withdrawal' might be based on coincidence, because these differences did 
not exceed twice the standard error of the scale value estimate, whereas in the study by Kan et al 
(1999) they did '4 So for these scales, the rank order found by Kan et al holds true In conclusion, the 
approximate replication of previous item-orders supports the construct validity of the Bendep-SRQ 
scales 
As Rasch homogeneity was confirmed for three of the previous established scales, it was 
justified to use the sum scores for predictive analyses and follow-up measurements Although the 
'preoccupation' scale was not Rasch homogeneous, we used the sum score of the original 5-item scale 
to evaluate the clinical relevance of the previously developed and repeatedly confirmed scale The 
predictive validity of the Bendep-SRQ scales was supported by significant odds ratios (table 6) 
Moreover, three out of the four scales had predictive value independent of the daily dose, withdrawal 
symptoms, smoking status, personality traits and psychopathology, which shows the relevance of the 
benzodiazepine dependence level in clinical practice 
Tapenng-off benzodiazepine use significantly reduced the severity of the dependence 
characteristics problematic use, preoccupation, and withdrawal Patients who discontinued their 
benzodiazepine use completely had significantly greater decreases of the scale scores problematic use 
and preoccupation compared to subjects who did not The insensitivity of lack of compliance for 
stopping benzodiazepine use was probably due to the fact that the subjects who were able to stop had 
very low scores on this scale at baseline, so a significantly lower score at outcome was almost 
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impossible. More importantly, it might be argued that a high score on this scale reflects therapy 
resistance. We expected the sum score of the withdrawal scale to be higher at outcome, with a 
significant time χ treatment outcome interaction, because the experience of more severe withdrawal 
symptoms has been associated with an inability to achieve complete abstinence. However, we found 
a small but significant decrease in the sum score and no interaction effects. This could be explained by 
the study design, because the patients filled out the withdrawal scale four weeks after completing the 
intervention. The sum score would probably have been more sensitive if the scale had been 
administered during withdrawal. 
The present study on the psychometric properties of the Bendep-SRQ provided further support 
for the scalability, reliability and validity of the scales problematic use, lack of compliance, and 
withdrawal. However, some concerns arose about the preoccupation scale. The different rank orders 
found in the other scales did not threaten Rasch homogeneity, but the rank order of the scale 
problematic use suggests that we should reconsider the theoretical rationales that underlie the 
construct validity in long-term benzodiazepine users who seek discontinuation therapy. These results 
clearly show the limitations of generalizing psychometric properties of questionnaires if they are 
administered in other populations and thus the need for cross-validation in the different populations of 
clinical interest. The predictive validity and longitudinal course of the Bendep-SRQ were promising. 
Therefore we recommend its use in all treatment regimens in the field of benzodiazepine addiction. 
Further research is recommended to investigate whether particular profiles of the Bendep-SRQ scores 
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Background - Long-term studies of benzodiazepine discontinuation are scarce and inconclusive due to 
the lack of controlled comparisons with non-intervention 
Objective - To investigate longitudinally the 18-month outcome of benzodiazepine discontinuation in 
general practice with respect to benzodiazepine use, psychotropic drug use and psychological 
functioning 
Methods - In an 18-month prospective follow-up study, tapenng off with group cognitive-behavioural 
therapy (CBT) and tapenng-off alone were compared with a non-intervention control group in a 
randomised controlled design as strategies to discontinue long-term benzodiazepine use in 180 
patients who were not able to discontinue after receiving a letter from their general practitioner 
advising cessation by themselves 
Results - At follow-up, tapenng off alone resulted in higher abstinence rates compared to the control 
group (36% vs 15%, p=0 03), while simultaneous group CBT had no additional value to tapenng off 
alone Although patients were suffenng from mild anxiety and depressive symptoms, neither 
intervention type nor outcome affected psychological functioning Patients did not switch from 
benzodiazepines to other psychotropic drugs, nicotine, or alcohol 
Conclusion - This is the first long-term outcome study that provides evidence that tapenng-off 
benzodiazepine use is an effective strategy to discontinue benzodiazepine usage in motivated patients 
who are not able to quit after receiving a letter advising cessation by themselves Moreover, no 
negative effects were found on psychological functioning or psychotropic drug use Additional 
psychotherapy dunng the discontinuation programme did not improve success rates or psychological 
functioning 
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Introduction 
About 60% of long-term benzodiazepine users who take part in benzodiazepine discontinuation 
programmes are able to achieve complete abstinence in the short term When usage has lasted 
several years, however, short-term effects cannot be seen the ultimate goal of treatment To the best of 
our knowledge, five long-term evaluations of benzodiazepine discontinuation programmes have been 
described with a follow-up period ranging from ten months to five years However, none of these 
studies compared the outcome of the discontinuation programmes with the natural course of long-term 
benzodiazepine use in a randomised controlled fashion These studies therefore remain inconclusive 
with respect to discontinuation rates and the effect on psychological functioning 
When reviewing these follow-up studies, it appears that outcome largely depends on the type of 
measurement used With cross-sectional measurements, the studies yielded abstinence rates of 54% 
and 58%5 In contrast, studies longitudinally monitonng their patients reported abstinence rales of 
only 16%6 or 18%8 The findings of a fifth study, however, were very different, showing a continued 
abstinence rate of 82% 3 This study differed from the other four because (a) it was an evaluation of a 
patient-tailored withdrawal programme leading to taper-off periods up to 15 months, and (b) the 
specialised setting, which was a third-line Clinical pharmacology Unit 
Four long-term outcome studies evaluated psychological functioning at the end of follow-up 6 
The results were contradictory, probably because of differences and shortcomings in methodology 
Golombok et al (1987) reported significant mental problems after successful discontinuation, while 
Ashton (1987) suggested improved functioning of patients remaining benzodiazepine-free14 
However, both studies did not report baseline functioning nor made a companson between abstinent 
and non-abstinent patients Holton et al (1992) and Rickeis et al (1991) differentiated between 
abstinent and non-abstinent patients The former did not find significant differences between these 
two groups, while the latter found better functioning in abstinent patients 5 6 This difference may be 
due to the fact that Rickels et al (1991), contrary to Holton et al (1992), corrected for baseline values 
and used another assessment period (one month before follow-up versus the last year of follow-up)5 
Interpretation is also hampered by the fact that, as mentioned before, all these studies lacked a non-
intervention control group 
This study deals with the above mentioned issues, because it presents an 18-month follow-up of 
a randomised controlled trial (RCT) comparing tapenng off long-term benzodiazepine use, with or 
without cognitive-behavioural therapy (CBT), with a non-intervention control group 9 We aimed to 
answer the following questions (a) what are the longitudinal effects of the two lapenng-off 
programmes on benzodiazepine usage and the use of other psychotropic drugs and (b) what long-term 
effects can be expected for psychological functioning9 We hypothesised that tapering off with group 
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CBT would be superior to tapenng off alone, which would be superior to the control group, with 
higher continued abstinence rates and better psychological functioning at the end of follow-up 
Methods 
Design and short-term results of the randomised controlled trial 
The results of the RCT are descnbed in detail elsewhere , but they can be briefly summansed as 
follows of the 2964 identified long-term benzodiazepine users in pnmary care (i e , patients who had 
used benzodiazepines for over three months), 2004 met the cnteria for, and were included in, the 
minimal intervention (i e , a letter from their GP advising benzodiazepine discontinuation), which was 
used to select patients unable to stop by themselves All 2004 patients were invited by letter to visit 
their GP for an evaluation of the effect of the minimal intervention Of the 1321 patients who visited 
their GP, 1036 were still using benzodiazepines and were asked to participate in the RCT Finally, 
180 patients participated and were randomised over tapering off with CBT (n=73), tapering off alone 
(n=73), and a non-intervention control group (n=34) Patients assigned to one of the two active 
treatment groups were tapered off by the GP in weekly steps of 25% after being transferred to an 
equivalent dose of diazepam Patients assigned to tapenng-off with CBT attended five 2h weekly 
sessions of group CBT starting halfway through the taper-off programme Patients in the non-
intervention control group did not receive any help with benzodiazepine reduction during the 
intervention penod 9 
Both active treatment groups yielded significantly higher proportions of patients who 
successfully discontinued their use compared with the control group, based on the intenl-to-lreat 
analysis of the RCT self-report outcome assessment tapenng-off with CBT, 58% (33/57), tapenng-
off alone, 62% (37/60), and non-intervention, 21% (5/24) The two active treatment groups did not 
differ significantly 
Design and assessments follow-up study 
This 18-month prospective follow-up study consisted of (a) a computensed extract of all drug 
prescnption data from the GP information system (= computensed medical records) of the 30 
participating practices, and (b) a self-report follow-up assessment at 18 months identical to the 
baseline and outcome assessment of the RCT All patients gave wntten informed consent for the 
follow-up study The study received ethical approval from the University Medical Centre Nijmegen, 
and was earned out between 1998 and 2001 
Drug prescription data were extracted at a patient level and contained date of issue. Anatomical 
Therapeutic Chemical classification code (ATC-code)" and name of the drug, number of tablets and 
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dose, and prescription rules Gender, date of birth, and the administration number of individual 
patients were extracted to link prescription data with the results of the RCT and the 18-month follow-
up assessment For patients who left the practice before the end of the follow-up penod, the date and 
reason for leaving the practice were recorded 
The primary outcome measure was defined as the proportion of long-term benzodiazepine users 
who did not receive any benzodiazepine prescriptions after the intervention period of the RCT 
according to the prescription data records We calculated the daily dosage over predefined periods 
based on the sum of the total dosage of all issued benzodiazepine prescriptions Dosages were 
expressed in mg diazepam equivalent according to Zitman & Couvée (2001)7 The following periods 
were defined period -1 consisted of the three months before the minimal intervention, ι e , the letter 
from the GP (baseline period) Penod 0 was defined as the time between the sending of the letter and 
the RCT, which vaned in length between 5 and 15 months (mean ±sd was 7 6 ± 1 9 months) In this 
period, the minimal intervention was evaluated and patients were recruited and randomised for the 
RCT Penod 1 consisted of the intervention penod, and was defined as the three months after the 
start of the RCT Penods 2 to 6 were the follow-up penods, each covenng a 3-month period As 
prescnptions for benzodiazepines in the Netherlands have a restneted duration of one month, periods 
of at least three months provided reliable estimates of the daily dosage 
Patients' prescnption patterns dunng follow-up were classified according to Couvée et al 
(2002) to provide detailed information for those patients who could not discontinue or relapsed This 
classification system is based on general guidelines for the adequate maximum duration of treatment 
with benzodiazepines It systematically describes 14 prescription patterns, with pattern 1, 
benzodiazepine-free, to pattern 14, benzodiazepine use dunng more than 95% of the follow-up penod 
at a higher dosage than at the beginning of the study Based on these prescnption patterns, four 
outcome categones were established A, success, B, partial success, C, minor success, and D, failure 
(see table 2) 
Secondary outcome measures were the use of psychotropic drugs other than benzodiazepines, 
as extracted from the GP information system, and psychological functioning as measured at the end of 
follow-up The prevalence rates of psychotropic drug use other than benzodiazepines were analysed 
over 6-month penods because, in contrast with the prescnptions for benzodiazepines, these 
prescnptions were for quantities sufficient for three months The following categones were analysed 
separately (i) antidepressants (N06A), (n) anxiolytic or hypnotic drugs other than benzodiazepines 
(N05A and N05C without N05AB and N05CD), (m) pain medication (NOI, N02 and MOIA), and (iv) 
other psychotropic drugs, such as antipsychotics and antiepileptic drugs (N03, N04, N05A, N07 and 
N06 without N06A) The six-month period before the minimal intervention was defined as the 




The outcome assessment was earned out at the end of the follow-up penod by a research 
assistants who visited the patients at home Self-report questionnaires were used for use of 
benzodiazepines in the month pnor to the assessment (as Rickels el al, 1991 and Golombok et al, 
1987)45, the use of alcohol (including the number of problem drinkers based on the 18-item list of 
Cornel)12, psychological well-being (GHQ 12-item version)1\ mood (the scales depression, anger, 
fatigue, vigour and tension of the 32-item shortened profile of mood stales, POMS)14, the number and 
seventy of benzodiazepine withdrawal symptoms (benzodiazepine withdrawal symptom questionnaire 
version 2, BWSQ-V2)1 , and the seventy of benzodiazepine dependence (the scales problematic use, 
preoccupation, lack of compliance and withdrawal of the Bendep-SRQ)16 All questionnaires showed 
good reliability and validity for the Dutch population 
Sample size 
Expecting longitudinally measured abstinence rates of 20% in the TOA condition and of 50% in the 
TO+CBT condition, the required sample size per group was 44 patients based on a Yates's corrected 
chi-square lest (two-sided a=0 05, ß=0 20) 
Statistical analysis 
All outcome parameters were first analysed for the three groups Significant mam effects were further 
analysed with pairwise compansons All analyses were performed on an intent-to-treat basis 
The prevalence of benzodiazepine use in the predefined follow-up penods and the prescnption 
patterns according to Couvée et al (2002) were analysed by chi-square tests In addition, survival 
analyses (i e , the life table method of Kaplan and Meier and the Breslow test) were applied to receive 
the time-dependent survival (unrelapse) probabilities of the three groups and to compare their courses 
Of those who failed to achieve continued abstinence after the RCT, the daily dosage was 
compared for the three groups by repeated measures analysis, with condition as between-subjects 
factor and time as within-subject factor, corrected for baseline dosage and waiting time for the start of 
the RCT 
The secondary outcome measures were analysed by chi-square tests in the case of dicholomous 
vanables and with repeated measure ANOVA's in the case of continuous vanables All secondary 
outcome measures were analysed for the three groups as well as for the different benzodiazepine 
outcome cntena, to evaluate the relationship between psychological functioning and benzodiazepine 
usage during follow-up Time (baseline vs follow-up assessment) was used as within subject factor 
and treatment group as a three-level or outcome as a two-level between subject factor in the repeated 
measure ANOVA's Outcome was analysed twice dichotomised as continued abstinence versus 
benzodiazepine use dunng follow-up, and outcome category A2 - Β (at least partial success, excluding 
those achieving continued abstinence) versus category C + D (failure) (see table 2) 
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Results 
Patient flow 
The dropout rate differed for the various outcome measures. Prescription data were available for 170 
of the 180 patients (94%). Data of 10 patients could not be extracted because 9 moved to another city 
and 1 patient was lost to follow-up. On the other hand, the 18-month follow-up assessment was 
completed by 143 patients (dropout 37 patients, 21%). Reasons for dropping out were: dissatisfied 
with the 'treatment' (n=6), somatic or psychological problems (n=8), and unknown (n=23). The 
number of dropouts was equally distributed over the three groups (χ =1.85; df=2; p=0.40). This 
dropout rate was not related to benzodiazepine prescription dunng follow-up (p=0.52). Patients who 
dropped out had significantly lower benzodiazepine dependence profiles based on their Bendep-SRQ 
scores (problematic use, p=0.02; preoccupation, p<0 01; withdrawal, p=0.02). 
Patient characteristics (n=170) did not differ significantly at baseline between the three groups. 
Patients were prescribed benzodiazepines for a mean (±sd) duration of 13.5 (±9.6) years in a mean 
daily dosage of 8.4 mg diazepam equivalent during period -1 before the minimal intervention ^ i = 
4.1 mg; P50 = 6.3 mg; P75 = 9.9 mg) and 5.9 mg diazepam equivalent in period 0, the baseline of the 
RCT (P21 = 1.7 mg; P50 = 3.8 mg; P75 = 6.5 mg). The mean (±sd) age was 63 (±12) and 70% were 
female. For more detailed information see Oude Voshaar et al. 
Table 1 
Benzodiazepine abstinence rates based on prescriptions per 3-month period 
Period: 
Recruitment* RCT Follow-up 
0 1 2 3 4 5 6 
Condition: (n=170) (n=170) (n=170) (n=170) (n=170) (n=170) (n=170) 
Tapering oft + CBT (n=66): 
Point prevalence (%) 
Continued abstinence rate (%) 
Tapering off alone (n=69): 
Point prevalence (%) 
Continued abstinence rate (%) 
No intervention (n=33): 
Point prevalence (%) 
Continued abstinence rale (%) 
6% " 








6 1 % " 
2 1 % 




5 1 % " 






2 1 % 
15% 
46%" 











* Time between the sending of the letter and the start of the RCT in which the effect of the letter (minimal intervention) was 
evaluated and patients were recruited for the RCT 
" 12 patients received no prescnptions after the minimal intervention while waiting lor the RCT, although they reported not to 
have stopped These patients have stopped usage of their own accord while waiting for the RCT 
" Differed significantly with the non-intervention control group (p<0 05) 




Table 1 shows the abstinence rates based on the computerised benzodiazepine prescription data. The 
continued abstinence rate for the tapering off with CBT group was not significantly supenor to the 
non-intervention control group (p=0.12), while the opposite was the case with the tapering off alone 
group (p=0.03). The two active treatment groups only differed significantly in period 2, i.e., three to 
six months follow-up (p=0.03), in favour of tapering off alone. Survival function estimates for each 
group are shown in figure 1. Of those patients restarting benzodiazepine treatment during follow-up, 
90% (113/126) restarted within the first 9 months. During follow-up, the three groups differed 
significantly (Breslow lest: 9.31; df=2; p=0.19). Pair-wise comparisons showed that tapering off alone 
was significantly superior to the non-intervention control group (p=0.003), while tapering off with 
CBT was not (p=0.12). In line with these findings, tapering off with group CBT did not lead to 
significantly better prescription patterns during follow-up compared to the non-intervention control 
group (p = 0.11), while tapering off alone on the other hand did (p=0.03) (table 2). 
Figure 1 
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Benzodiazepine dosages in failures 
The mean (±sd) daily dosage of patients who failed to achieve continued abstinence decreased from 
10.3 ±6.6 mg before the minimal intervention (penod -1) to 6.9 ±4.5 mg thereafter (period 0) and 
finally to 5.2 ±6.7 mg diazepam equivalent at the end of follow-up (period 6). The repeated measures 
ANOVA showed that among patients who did not achieve continued abstinence, those receiving 
active treatment used significantly lower dosages at follow-up compared to those assigned to the 
control group (F=6.5; df=l; p=0.01). A significant time χ group interaction (active treatment vs. non­
intervention; F=5.3; df=l; p=0.02) indicated that this difference was not constant over time, but 
decreased during follow-up (see figure 2). 
Table 2 
Benzodiazepine (BZ) prescription patterns according to Couvée et al (2002) during follow-up 
Tapering off + Tapering off Control group Whole sample 
CBT alone 
Ourcome categories Ν (%) Ν (%) Ν (%) Ν (%) 
A Success 
1 BZ-free 
2 BZ use one episode < 15 days 
3 BZ use > one episode < 15 days 
4 BZ use one episode > 15 days and < 30 days 
5 BZ use > one episode > 15 days and < 30 days 
Β Partial success 
6 BZ use one episode > 30 days and < 60 days 
7 BZ use > one episode > 30 days and < 60 days 
Β BZ use one episode > 60 days and < 90 days 
9 BZ use > one episode > 60 days and < 90 days 
C Minor success 
10 BZ use > 90 days no use at time of follow-up 
11 BZ use > 95% of follow-up time, lower dose 
D Failure 
12 BZ use > 90 days and use at time of follow-up 
13 BZ use > 95% of follow-up time, same dose 
14 BZ use > 95% of follow-up time, higher dose 
1 Companson ol the lour outcome categones A, B, C and D 
- TO+CBT versus CC. χ2=6 1 ; ctf=3, p=0 11 
- TOA versus CC χ2=9 2; df=3, p=0.03 
2 Companson of outcome after dichotomising between category A versus the categories B, C and D-
- TO+CBT versus CC χ2 = 5 6, df=1,p=0.02 
- TOA versus CC χ2 = β 0, df=1, p=0 01 
3 Companson of outcome after dichotomising between category A and Β versus category C and D 
- TO+CBT versus CC χ2 = 4 8, df=1,p=0 03 



















































































































Mean daily dosages in mg dia7epam equivalent for patients not able to achieve continued abstinence 
12 
Condition 
^ ^ A c l i v e trealment 
| [Control 
3 4 5 6 
Time (3-month periods) 
No significant differences between the three groups were found regarding the self-reported abstinence 
rate the month before the follow-up assessment (χ2=3.3; df=2; p=0.19). Fifty-two percent (30/58) of 
the patients assigned to tapenng-off with CBT reported no use, 63% (37/59) of those assigned to 
tapenng-off alone, and 42% ( 11/26) of those assigned to the control group. 
Psychotropic drugs and agents 
The prevalence of prescribed antidepressants remained stable (baseline 18%; 12-18-month follow-up 
20%), and was independent of treatment group or outcome. Among patients who achieved continued 
benzodiazepine abstinence, the prevalence of pain medication decreased from 52% al baseline to 38% 
at 12-18-monlh follow-up, while it remained stable (43% versus 41%) in the other patients. The use of 
antipsychotic and antiepileptic drugs was negligible at baseline and follow-up. No significant 
switches to hypnotic or anxiolytic drugs other than benzodiazepines were observed in patients who 
remained abstinent: one patient received /opiclone 7.5 mg for daily use during follow-up; another 
patient received 30 tablets valerian extract 45 mg once, and finally a third patient was prescribed 10 
tablets of hydroxyzine 25 mg once At baseline, 67% of the patients consumed caffeine, 47% nicotine, 
and 54% alcohol. These prevalence rales and the mean amount consumed per user remained stable 
during follow-up independent of trealment group or outcome 
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Psychological functioning 
At baseline, the mean (±sd) score on the GHQ-12 was 2.6 ±3.3. Based on a cut-off rate of 2/3, 34% of 
the patients could be classified as 'psychiatric cases'. Based on the sex-adjusted norm scores of the 
POMS for the Dutch population, the proportion of patients in the fifth quintile was 46% for 
depression, 27% for anger, 41% for fatigue, 36% for having no vigour, and 29% for anxiety. The 
repeated measures ANOVA's yielded significant time factors for the scores regarding psychological 
well-being (GHQ-12, p<0.01), problematic use (Bendep-SRQ, p<0.01), preoccupation (Bcndep-SRQ, 
p<0.01), withdrawal (Bendep-SRQ, p<0.01), depression (POMS, p=0.02), anger (POMS, p<0.01), 
shyness (POMS, p=0.01), and tension (POMS, p<0.01). All time effects showed an improvement in 
functioning at follow-up. No significant time χ group interactions for any of the secondary outcome 
measures were found (seventy of withdrawal symptoms (BWSQ-v2), profile of benzodiazepine 
dependence (Bendep-SRQ), psychological well-being (GHQ-12), mood (POMS), and problematic 
alcohol use (Gomel)). This indicated that for all parameters the change from baseline to end of 
follow-up was comparable over the three groups. 
Comparing patients who achieved continued abstinence with those who did not resulted in 
significant time χ outcome interactions for the dimensions problematic use (p=0.05) and 
preoccupation (p=0.02) of the Bendep-SRQ. This indicated that the severity of benzodiazepine 
dependence decreased more for patients achieving continued abstinence compared with those who did 
not. Using the outcome criteria of Couvée et al (2002) no significant time χ outcome interactions 
were found for any of the variables, including the dimensions of the Bcndep-SRQ. 
Discussion 
Long-term efficacy of tapering-off 
Our main result is that at 18-month follow-up, 29% of those assigned to tapering off with group CBT, 
and 36% of those assigned to tapering off alone, were still benzodiazepine-free. Only tapenng off alone 
differed significantly from the non-intervention control group, in which 15% remained benzodiazepine-
free. Actively treated patients who failed to achieve continued abstinence lowered their dosage 
significantly more than patients in the non-intervention control group. The average dose reduction is 
partly explained by intermittent usage, since prescription patterns showed that 47% percent of the 
patients receiving additional CBT, and 54% of those receiving tapering off alone used benzodiazepine 
intermittently for periods shorter than 60 days. Similar to the short-term results, which have been 
discussed elsewhere10, simultaneous group CBT had no additional value to tapenng off alone for the 
effects during long-term follow-up. During the first 3-6-month follow-up, the combination with group 
CBT was even inferior to tapering off alone. 
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Contrary to Holton et al (1992) and Zilman & Couvée (2001)67, we included patients with an 
intervention immediately before tapermg-off Nevertheless, our abstinence rates were higher It is 
unlikely that this is due to a shorter follow-up penod, because it is shown that most relapses (>90%) 
occurred within the first nine months6 Two feasible explanations can be put forward Firstly, differences 
in the populations studied, as Holton et al (1992) included referred patients in a psychiatric setting, and 
Zitman & Couvee exclusively included a subgroup of depressed long-term benzodiazepine users in 
primary care<'7 Several publications suggested that depressive patients have greater difficulty in stopping 
benzodiazepine use " Secondly, due to the prospective nature of our study, both GPs and patients were 
aware that they would be followed up, while the follow-up in the other studies was performed 
retrospectively This suggests that a closer monitoring of patients after tapenng-off might prevent 
relapse 
The self-reported abstinence rate over the last month of follow-up yielded success rates of 52% 
for tapenng off with CBT, and 63% for tapenng off alone These success rates replicate the findings of 
Rickels et al ( 1991 ) and Golombok et al (1987), who found self-reported cross-sectional success rates of 
58% and 54% 45 Due to the intermittent usage of benzodiazepines dunng follow-up, cross-seclional 
success rates overestimate the longitudinal effects Moreover, the significance of self-reported cross-
sectional success rates is questionable, since we, having included a control group (contrary to Rickeis et 
al 1991 and Golombok et al 1987), did not find significant differences in success rate with the control 
group 
Psychotropic drugs and agents 
In line with Couvée et al (2002), patients were not prescnbed more antidepressants or other psychotropic 
drugs by their GP8 This contrasts with the results of Rickels et al (1991), who found an increase in the 
use of antidepressants by those taking part in their tapenng-off programme 5 This might reflect a 
difference in the settings because their study was conducted in a psychiatnc department where more 
diagnostic and alternative treatment strategies were available Neither the prevalence of caffeine, 
nicotine, or alcohol consumption, nor the amount of these agents taken by consumers, were influenced 
by intervention type or outcome, which indicates that none of our long-term users switched from 
benzodiazepine use to one of these agents 
Psychological functioning 
No increase in the presence or seventy of withdrawal symptoms was found dunng follow-up The nsk of 
a prolonged withdrawal syndrome is therefore not a cntical issue '8 The seventy of benzodiazepine 
dependence declined significantly in patients who achieved continued abstinence, but not in patients 
who shifted to better prescnption patterns dunng follow-up This suggests that for low-dose 
138 
Long term outcome of a three Londmon usual care controlled benzodiazepine discontinuation study 
benzodiazepine dependence, prescnption patterns or dosage levels have little influence on the seventy of 
dependence 
We did not find significant differences in symptoms for psychological distress and mood 
disturbances between the three groups or between patients who achieved continued abstinence and those 
who continued their use Thus, our patients did not detenorate dunng follow-up after tapenng-off their 
benzodiazepine use This finding contrasts with Rickels et al (1991)5, who found improved functioning 
in abstinent patients This discrepancy can be explained by the increase in the use of antidepressants by 
abstinent patients in the study of Rickels et al (1991), and by the low benzodiazepine dosages used by 
patients in our study Patients who achieved continued abstinence used a mean dosage of 6 0 mg 
diazepam equivalent before the minimal intervention (penod -1) and 3 3 mg at the start of the RCT 
(period 0), while successful patients in the study of Rickels et al (1991) used a mean dosage of 8 3 mg 
diazepam equivalent Nonetheless, it was somewhat disappointing to find that because tapenng-off long-
term benzodiazepine use does not significantly improve psychological functioning, our patients still 
suffered from mild mixed affective symptoms that might require medical treatment Moreover, adequate 
treatment after tapenng-off might also prevent restart of benzodiazepine use 
Critical remarks 
Prescnption data should be interpreted with caution Firstly, not all patients fill their prescription, 
secondly, there is no guarantee that the patient actually takes the filled prescnption, thirdly, a doctor 
might wnte a prescnption but fail to enter it in the medical records, and finally, there is a possibility that 
patients may obtain benzodiazepines from other sources However, we measured the self-reported 
benzodiazepine usage as well, while previous studies have been limited to either prescnption data or 
self-reported use Consequently, reliable compansons can be made with previous studies 
Conclusion 
Although a substantial number of patients restart benzodiazepine therapy dunng follow-up, tapenng-off 
benzodiazepine use effectively reduces long-term benzodiazepine consumption compared with a non-
intervention control group Moreover, the psychological functioning of patients did not detenorate after 
tapenng-off, which might indicate a history of non-effective treatment Despite the fact that the dosages 
used by our patients appear rather low, these patients were not able to stop their use by themselves after 
a minimal intervention, and thus really needed more support The identification of all long-term 
benzodiazepine users and the consecutive pre-selection used in this study show the difficulty of 
motivating patients (and doctors9) to taper-off benzodiazepine use Further research should therefore not 
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Objective - To identify predictors of long-term taper success in chronic benzodiazepine users unable 
to stop after written advice who participated in a benzodiazepine discontinuation programme in 
general practice. 
Methods - One hundred and eighty benzodiazepine users were prospectively followed-up for 18 
months through their medical records after they had participated in a randomised controlled trial 
comparing two tapering-off strategies and a non-intervention control group. Cox-regression analyses 
was performed to correct for the time until relapse. Potential predictors included benzodiazepine 
(usage) characteristics, psychopalhological symptoms, personality traits, and characteristics of 
(benzodiazepine) dependence. 
Results - A complete follow-up was achieved for 170 (94%) patients, of whom 50 (29%) achieved 
long-term success, defined as no use of benzodiazepines during the whole follow-up period. 
Independent predictors of success were: offering a taper-off programme with group therapy (RR=2.4; 
95% CI: 1.5-3.9) or without group therapy (RR=2.9; 95% CI: 1 8^.8), a lower daily dosage at the 
start of tapering-off (RR=1.5; 95% CI: 1.2-1.9), a substantial dose reduction by themselves 
immediately before the start of tapering-off (RR=2.1; 95% CI: 1.4-3.3), a low score on 'lack of 
compliance' of the benzodiazepine dependence self-report questionnaire (RR=2.4; 95% CI: 1.1-5.2), 
and no use of alcohol (RR=1.7; 95% CI: 1.2-2.5). Patients who used over 10 mg of diazepam 
equivalent, who had a score of three or more on the scale Lack of compliance of the Bendep-SRQ, or 
drank more than 2 units of alcohol per day failed to achieve long-term abstinence. 
Conclusion - Long-term tapering-off outcome appears to be influenced by non-specific addictive 
characteristics. A subgroup of chronic benzodiazepine users could be identified that was not a priori 
able to achieve long-term taper success in general practice. 
142 
Predictors of long term taper success after a benzodiazepine withdrawal programme 
Introduction 
Although benzodiazepines are effective drugs for the short-term treatment of insomnia and anxiety, 
their long-term efficacy remains questionable ' Adverse effects of long-term use arc becoming 
increasingly clear, such as development of dependence , increased risk of falls (leading to injuries) 
and traffic accidents'15, and cognitive decline69 The majority of chronic benzodiazepine users receive 
their prescriptions in general practice '" Therefore, the general practitioner (GP) is the first physician 
to make decisions about rational use and reduction of unwarranted chronic use Chronic 
benzodiazepine use can effectively be discontinued by tapermg-off strategics Identifying 
predictors of long-term taper-off outcome would make the management of chronic use more efficient 
Several factors have been related to successful benzodiazepine discontinuation in the short-
term The most reliable predictor for successful taper outcome is a lower benzodiazepine dosage al the 
start of tapermg-off '4 2125 No differences have been reported between individual benzodiazepines 
dunng gradual discontinuation,29 although after abrupt cessation a shorter elimination half-life 
resulted in a lower abstinence rate ,116 There is no consistent pattern for the influence of demographic 
variables For example, successful taper outcome has been linked to both male10 and female sex" l4, 
and to both younger1214 and older age groups ,227 In contrast, it has been repeatedly demonstrated thai 
a high level of psychopathological symptoms, especially anxiety and depressive symptoms, resulted in 
lower abstinence rates, as well as the personality traits neuroticism, dependence, and 
vulnerability M 1 ' i2122242527293132 jj, addition, these personality traits also led to the experience of a 
more severe benzodiazepine withdrawal syndrome following discontinuation2229 Whether 
benzodiazepine withdrawal symptoms during discontinuation independently affect taper outcome 
remains inconclusive25'" Moreover, neither the severity of benzodiazepine dependence, nor the 
diagnosis of benzodiazepine dependence, have been examined in relation to taper outcome 14 
The few follow-up studies of benzodiazepine discontinuation programmes carried out have 
used different selections of potential predictors ' ' In addition, the predictors found did not show a 
consistent pattern due to small sample sizes and the lack of multivariate analyses The two follow-up 
studies that did carry out a multivanate analysis, however, reported that successful short-term taper 
predicted a benzodiazepine-free outcome at follow-up ]4 " 
In this paper, we performed a multivariate prediction analysis of long-term taper outcome in 
180 patients included in a benzodiazepine discontinuation trial in general practice As potential 
predictors, we evaluated benzodiazepine (usage) characteristics, personality traits, psychopathological 
symptoms, characteristics of benzodiazepine dependence, including the severity of dependence, and 
the use of psychoactive agents and drugs Our purpose was to identify independent predictors of taper 
outcome and, if possible, to identify which patients do or do not benefit from lapenng-off with respect 





The sludy is part of a two-step treatment study aimed at the reduction of chronic benzodiazepine use 
(> 3 months) in 30 general practices in the Netherlands. The clinical outcome of both interventions 
has been described elsewhere. ' 
A total of 180 chronic benzodiazepine users who were not able to stop their benzodiazepine use 
after the first step, i.e., a letter from their general practitioner (GP) containing advice to stop, gave 
informed consent for the second step, which consisted of a randomised controlled trial on the 
differential efficacy of tapering-off with group therapy (n=73), tapering-off alone (n=73), and a non-
intervention control group (n=34). Patients assigned to one of the two active treatment groups in the 
second step visited their GP 6 times to taper their benzodiazepine dosage in steps of 25% per week, 
after being transferred to an equivalent dose of diazepam for two weeks. Patients assigned to the first 
group additionally received five weekly sessions of group psychotherapy starting halfway through the 
tapering-off. Patients in the control group were treated as usual and did not receive any help on the 
reduction of benzodiazepine use. The study received ethical approval from the University Medical 
Centre Nijmegen and was earned out between 1998 and 2001. 
The mean (±sd) age of the 180 patients was 63 (±12), and 70% were female. Patients used 
benzodiazepines for a mean (±sd) duration of 13.5 (±9.6) years. The mean daily dosage significantly 
decreased from 8.4 mg diazepam equivalent (P25 = 4.1 mg; P50 = 6.3 mg; P75 = 9.9 mg) before the first 
(minimal) intervention (i.e., the letter containing advice to stop their use) to 5.9 mg (P2'i= 1.7 mg; P50 
= 3.8 mg; P75 = 6.6 mg) thereafter. At 18-month follow-up, the continued abstinence rate for tapering-
off alone was significantly superior to the non-intervention control group (36% versus 15%, p=0.03). 
In contrast, outcome for tapering-off with brief psychotherapy was not significantly better than the 
control group (29% versus 15%, p=0.12).'7 
Measurements 
Benzodiazepine use was monitored prospectively in the GP medical records for 18 months. Success 
was defined as receiving no prescriptions for a benzodiazepine from the GP during the whole 18-
monlh follow-up period. Drug prescription data were extracted at patient level from the GP 
information system (= computerised medical records). Extracted were dale of issue, Anatomical 
Therapeutic Chemical classification code (ATC-code)37 and name of the drug, number of tablets and 
dose, and prescription rules. Gender, date of birth, and the administration number of individual 
patients were extracted to link prescription data with the additional assessments (see below). For 
patients who left the practice before the end of the follow-up, the date and reason for leaving the 
practice were recorded. 
144 
Predictors of long terni taper success after a benzodiazepine withdrawal programme 
In addition, patients were assessed at baseline, at outcome three months after the start of the 
second intervention and at 18-month follow-up These assessments took place at the participants' 
homes by trained research assistants The following variables were measured exclusively hypnotic 
use of the benzodiazepine (yes/no), use and amount of caffeine, nicotine and alcohol (including the 
number of problem drinkers according to the 18-item list of Cornel)38, psychological well-being 
(GHQ 12-item version)39, mood (the scales depression, anger, fatigue, vigour and tension of the 32-
item shortened profile of mood states, POMS)40, the number and severity of benzodiazepine 
withdrawal symptoms (benzodiazepine withdrawal symptom questionnaire version 2, BWSQ-v2) , 
four dimensions of the seventy of benzodiazepine dependence (problematic use, preoccupation, lack 
of compliance, and withdrawal, Bendep-SRQ)34, and five personality traits (negativism, somatisation, 
shyness, psychopathology and extraversion, Dutch Shortened MMPI)42 Although the Dutch 
shortened MMPI does not assess separately dependent or neurotic personality traits that have been 
related to taper outcome, psychometnc studies showed no decrease in informational value compared to 
the original MMPI4344 
Statistical analysis 
Predictors of continued abstinence were analysed by means of Cox-regression analysis using forward 
and backward elimination procedures45 with time to the first prescnption after the intervention pcnod 
as the dependent vanable, and the following independent variables more than 50% dose reduction 
after the minimal intervention (yes/no), benzodiazepine dosage at the start of tapenng-off, half-life of 
benzodiazepine (dichotomised at 24 hours), use of a high potency benzodiazepine (yes/no, based on 
presence of a 4-aryl group), self-reported hypnotic or anxiolytic use, use of more than one 
benzodiazepine (yes/no), use of antidepressants (yes/no), use of pain medication (yes/no), and all 
clinical status variables measured at the baseline assessment Vanables with nsk ratios of p<0 10 after 
correction for the intervention received (i e , the crude risk ratios) were entered into the multivanale 
Cox-regression analyses to identify independent predictors of long-term successful taper outcome 
(i e , the adjusted nsk ratios) 
Results 
The follow-up was completed for 170 of the 180 patients (94%) Patients lost to follow-up (moved 
home, n=9, unknown, n=l) were analysed until the moment of lost to follow-up (range 1 - 456 days) 
as censored observations 
Table 1 presents all vanables associated (p<0 10) with outcome dunng follow-up after 
correction for the intervention received We did not find significant differences in success rate 
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between individual benzodiazepines in patients who used exclusively one benzodiazepine (147/170, 
86%). oxazepam, 21/53, lemazepam 9/34, diazepam, 6/18, nitrazepam, 2/9, lorazepam, 1/6, 
lormetazepam, 2/5, benzodiazepines used by less than 5 patients put together, 3/22 Although the use 
of high potency benzodiazepines (n=27) was associated with a less successful outcome, this 
association was not detected for individual high potency benzodiazepines due to low patient numbers 
within these subcategories 
Table 1 
Prediclors oflong-term benzodiazepine abstinence (n=180) 
Variables Crude HR' [95% CI] p-value Ad). RR [95% Cil p-value % variance 
1 49 [0 94 2 36] 0 09 2 38 [1 46 - 3 85] <0 001 
1 9 2 ( 1 1 9 - 3 08] 0 007 2 92(178 4 78] <0 001 
Treatment group (vs no intervention)" 
Taper-off + group therapy 
Taper-off alone 
Lower BZ dosage at the start of lapenng-off 1 68 [1 43 - 1 98] <0 001 1 52 [1 22 -1 89] <0 001 
(per 10 mg diazepam eqv ) 
Dose reduction by themselves 2 25 [1 51 - 3 34] <0 001 2 13 [1 40 - 3 25] <0 001 
(O^less, 1=more than 50% dose reduction) 
Shorter duration of use 
(per 10 years) 
Potency of the benzodiazepine 
(0 = high potency 1 = low potency) 
Use of nicotine 
(0=yes, 1=no) 
Use of alcohol 
(0=yes, 1=no) 
Withdrawal symptoms al baseline 
(BWSQ-V2, range 0-42) 
Preoccupation scale of Bendep-SRQ 
(0=3 or higher 1=less than 3) 
Lack of compliance of Bendep-SRQ 
(0=3 or higher, 1=less than 3) 




1 73 [1 19 2 52] 0 004 
1 24 [1 04 - 1 48] 0 02 
1 70 [1 06 - 2 73] 0 03 
1 47 [1 0 3 - 2 10] 0 03 
1 47 [1 0 2 - 2 10] 0 04 
1 04 [1 01 - 1 06] 0 007 
1 85 [1 28 - 2 68] 0 001 
4 52(2 3 2 - 8 80] <0 001 2 39(110-5 19] 0 03 
1 03 [1 01 - 1 06] 0 01 
1 04 [1 00 - 1 07] 0 03 
18 9% 
13 7% 
12 5 % 
8 2 % 
4 8 % 
Model χ = 74 1, df=6 p<0 001 58 % 
Only corrected for treatment group 
Treatment group is a variable with three categories and therefore two nsk ratios are calculated 
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Of the 12 variables, the multivariate Cox-regression analysis identified five independent 
predictors of continued abstinence using a stepwise forward procedure: (1) a low benzodiazepine 
dosage at the start of tapenng-off, (2) active treatment instead of no intervention, (3) a dose reduction 
of more than 50% by themselves after the minimal intervention immediately before tapenng-off, (4) 
no use of alcohol, and finally (5) a low score on the dimension 'lack of compliance with the 
therapeutic regime' of the Bendep-SRQ. These results were confirmed by a second multivariate Cox-
regression analysis using a backward elimination (Wald) procedure. Figure 1 shows the survival 
curves of the three intervention groups corrected for the five independent predictors. 
Figure 1 
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Visual inspection of the data of the independent predictors revealed some interesting findings. 
With respect to the benzodiazepine dose at the start of tapering-off, we found that of the 22 patients 
who used more than 10 mg diazepam equivalent a day (the recommended therapeutic dose), only two 
patients were able to achieve continued abstinence (9%). None of the nine patients who scored three 
or more on the dimension 'lack of compliance with the therapeutic regime' of the Bendep-SRQ 
achieved continued abstinence, and finally, none of the 14 patients who consumed over two units of 
alcohol per day were able to achieve an 18-month benzodiazepine-free state. With the aid of these 
three variables 38 patients in our sample could be identified, of which only 2 patients (5%) were able 
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to achieve long-term taper success. For the variables 'intervention' and 'dose reduction after the 
minimal intervention', we found no clear cut-off rates for achieving continued abstinence. No cut-off 
rates were identified that guaranteed successful long-term taper outcome for any of the independent 
predictors. 
Negativism (personality trait) and tension (psychopathology) did not enter the multivariate 
analysis, which could be explained by their correlation with 'lack of compliance' (negativism: 
r=0.33, p<0.001; tension: r=0.2&, p<0.001). Also the benzodiazepine dependence characteristic 
'preoccupation with the availability of benzodiazepines' of the Bendep-SRQ did not enter the 
multivariate analysis. This variable was highly correlated with benzodiazepine dosage at the start of 
tapering-off, (r = 0.39, p< 0.001), dose reduction after the minimal intervention (r= 0.40, p< 0.001), 
and 'lack of compliance' (r = 0.33, p< 0.001) (see table 2). 
Table 2 
Correlation matrix of baseline values of the univariate predictors (n=l 80) 
Dose reduction by 
themselves (%) 
Duration of use 
(per 10 years) 
High potency 
(yes/no) 
Use of nicotine 
(yes/no) 
















-0 6 9 " 
0.2Θ " 
0 1 6 -
-0 09 
0 12 
0 1 5 * 
0.39 " 
0 . 3 4 " 
0 1 4 










-0 4 0 " 
-0.22 ' 











0 1 1 







































0 2 9 " 
0 20 * 
0 41 " 













0 . 3 3 " 
0.28 " 
I 
0 . 5 6 " 
Significant al ρ < 0.05 
Significant at ρ < 0.001 
148 
Predictors of long-term taper success after a benzodiazepine wuhdrawal programme 
Discussion 
In this study, five variables were independently related to long-term taper outcome of benzodiazepine 
discontinuation in general practice. These variables accounted for 58% of variance in outcome: 18.9% 
for active treatment (intervention type), 13.7% for dose reduction by patients themselves after the 
minimal intervention immediately before tapering-off, 12.5% for benzodiazepine dosage at the start of 
tapering-off, 8.2% for the use of alcohol, and finally 4.8% for lack of compliance. For the purpose of 
interpretation, Cohen46 considers 1% variance as a small effect, 9% as a medium effect, and 25% as a 
large effect. These variables will be discussed systematically below. 
Active treatment 
Patients motivated to cut down their benzodiazepine use, but unable to do so by themselves by minimal 
intervention, were 2.4, respectively 2.9 limes more likely to achieve long-term taper success when 
offered a taper-off programme compared with treatment as usual. Rickels et al (1991) and Couvée et al 
(2002) found successful cessation immediately after the taper-programme predictive for long-term taper 
success.1"16 Their prediction models, however, could not analyse the impact of offering a taper-off 
programme to patients motivated for tapering-off as they did not randomise these patients between 
tapenng-off and a non-intervention control group. 
Benzodiazepine dosage 
After treatment group, benzodiazepine dosage at the start of tapering-off was the next variable selected 
in the multivariate regression analysis. Benzodiazepine dose level at baseline is one of the most reported 
predictors of successful discontinuation in literature.14 2I"" A dose reduction of more than 50% after the 
minimal intervention immediately before the tapering-off programme also independently contributed to 
a successful long-term outcome. Although dose reduction during the minimal intervention correlated 
positively with benzodiazepine dosage at the start of tapering-off, the results of the multivariate analysis 
showed no confounding between these two variables in relation to taper outcome. 
Use of alcohol 
We found that no use of alcohol independently predicted a successful long-term taper outcome in 
contrast to previous research.1222526 Schweizer et al (1990) found, however, that mild-to-moderate 
alcohol use predicted a more severe benzodiazepine withdrawal syndrome upon discontinuation. The 
effect of alcohol consumption on taper outcome might be explained by addictive behaviour in chronic 
benzodiazepine users, because in social drinkers the abuse liability of benzodiazepines has been related 
to the use of alcohol.47'48 Moreover, high-dose benzodiazepine users are more often alcohol dependent, 
and use more caffeine and more nicotine compared to control subjects.49 This association might have a 
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biological basis, as alcohol potentiates the effect of benzodiazepines on the GABAA receptor in the 
central nervous system 
Benzodiazepine dependence 
Although benzodiazepine dependence is frequently mentioned as an adverse effect of chronic 
benzodiazepine use, it has never been diagnosed according to ICD or DSM criteria in chronic 
benzodiazepine users taking part in a discontinuation programme In this study, we administered the 
Bendep-SRQ, a multidimensional self-report questionnaire that comprehensively establishes the seventy 
of benzodiazepine dependence M A low score on the scale 'lack of compliance with the therapeutic 
regime' independently predicted good taper outcome Although the score for 'preoccupation with the 
availability of benzodiazepines' was umvanately associated with taper outcome, it did not enter the 
multivariate analysis due to its high correlation with the amount of dosage reduction after the minimal 
intervention, making these two variables interchangeable in the multivariate model These findings 
suggest that diagnosing benzodiazepine dependence might be relevant in patients discontinuing chronic 
benzodiazepine use Most benzodiazepine discontinuation trials have only evaluated benzodiazepine 
withdrawal symptoms during the discontinuation process as proxy for benzodiazepine dependence ' " 
The association between the seventy of these symptoms and taper outcome, however, remains 
inconsistent51 The relationship between personality and taper outcome may partly explain this 
inconsistency 22 29 Schweizer el al (1998) found that patients who dropped out at an early stage of the 
benzodiazepine discontinuation process, when withdrawal symptoms were relatively mild, were the 
main cause of the association between personality traits and taper outcome ,2 As we tried to identify 
predictors for taper success before the start of tapenng-off, we did not assess benzodiazepine withdrawal 
symptoms during the discontinuation phase However, a further study exploring the role of withdrawal 
symptoms during tapenng-off and pre-treatment dependence charactenstics is in progress 
Some negative findings 
Although some personality traits, as well as the level of anxiety and depressive symptoms, have been 
reported to (independently) affect taper outcome141'52122242527 2931 }2t we only found significant 
univanate relationships for negativism and tension As the vanablcs negativism and tension were both 
correlated to factors of benzodiazepine dependence (withdrawal, preoccupation, lack of compliance) it 
supported the claim that personality traits are important in influencing the dependence potential of the 
patient The level of psychopathology also was of limited interest We did not find any relationship 
between depression or psychological distress and outcome, despite the many assertions that depressed 
chronic benzodiazepine users have more difficulty in benzodiazepine discontinuation "',2 The univanate 
association of tension with taper outcome was relatively weak In addition, whether the benzodiazepine 
was used as a hypnotic or anxiolytic drug was irrelevant 
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Although in the population chronic benzodiazepine use is associated with female sex and a high 
age 5\ these factors did not influence benzodiazepine discontinuation outcome, which was in line with 
previous research. In our study, shorter duration of benzodiazepine use was only umvariatcly associated 
with better outcome. The follow-up studies of Rickels et al (1991) and Couvée et al (2002) found a 
relationship between a shorter benzodiazepine usage and successful taper outcome, whereas Holton et al 
(1992) found the opposite to be the case.M l6 
We did not observe significant differences between individual benzodiazepines, which might have 
been because some benzodiazepines were only used by a few patients. In line with previous research of 
gradual benzodiazepine discontinuation, the elimination half-life of the drug did not influence taper 
outcome. The use of high potency benzodiazepines was univariately associated with a less successful 
outcome, although this finding did not reach statistical significance in the multivariate analyses. As only 
27 patients in our population used a high potency benzodiazepine, wc would suggest a more detailed 
study of this aspect in future research. 
Final conclusions 
We can conclude that active treatment increases the likelihood of long-term abstinence in a general 
practice population of chronic benzodiazepine users motivated lo cut down their benzodiazepine 
consumption. In addition, the outcome of tapering-off depends on the dosage used by these patients and 
the ability of patients to lower their dosage first by themselves. Moreover, our data suggest that 
dependence characteristics are more important for taper outcome than the level of psychopathology, 
personality traits or benzodiazepine type, since all independent predictors can be considered as indicators 
of non-specific addictive behaviour.45 M A subgroup of patients could be identified that failed to achieve 
continued abstinence. It included patients using more than two units of alcohol per day, patients scoring 
three or more on the dimension 'lack of compliance with the therapeutic regime' of the Bendep-SRQ, 
and patients using more than 10 mg diazepam at the start of tapering-off afier the minimal intervention. 
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Background - Benzodiazepine (BZ) discontinuation has never been evaluated in economic terms 
Atm - To compare the relative costs and outcomes of tapenng-off long-term BZ use combined with 
group cognitive-behavioural therapy (TO+CBT) and tapenng-off alone (TOA) with usual care (UC) 
Design of the study - A randomised controlled tnal incorporating a cost-effectiveness analysis from a 
societal as well as a pharmaceutical perspective in general practice 
Method - The cost of treatment, prescnbed drugs, healthcare services, productivity loss, and patients' 
costs were measured using drug prescnption data and cost-dianes The pnncipal outcome was the 
proportion of patients able to discontinue BZ dunng the 18-month follow-up Secondary outcome 
measures were the quality of life (SF-36 and HUB) 
Results - One hundred and eighty patients were randomised over TO+CBT (n=73), TOA (n=73), and 
UC (n=34) Treatment costs were €172 99 for TO+CBT and €69 50 for TOA Both conditions 
significantly reduced BZ costs during follow-up compared to UC The incremental cost-effectiveness 
ratios (cost per percent abstinence) showed that, depending on the study perspective, TO+CBT cost 
€10 70 to €56 82 and TOA €0 77 to €41 24 for an incremental one percent successful benzodiazepine 
discontinuation compared to UC 
Conclusions - TO+CBT and TOA both led to a significant reduction in BZ costs However, it remains 
uncertain which healthcare utilisation has a causal relationship with long-term BZ consumption or its 
treatment Although the incremental cost-effectiveness ratios were better for TOA than for TO+CBT, 
the differences were relatively small Extrapolation of our data showed that the investment in TOA 
was paid back after 20 months when corrected for treatment gain in the UC condition 
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Introduction 
The prevalence of long-term users of benzodiazepines in the population has been estimated at 3% ' 
This finding contrasts sharply with current guidelines, which advise prescription of these drugs for 
short-term penods only 4 8 In the Netherlands, the pharmaceutical cost of benzodiazepine usage is 
estimated at €100 million per year9 In addition, the treatment of associated adverse effects generates 
costs related to benzodiazepine usage For example, the cost of hip fractures related to benzodiazepine 
usage has been estimated at €16 4 million per year '0 Therefore, conformity with the guidelines for 
primary care would not only imply better care for patients, but might also result in a more efficient 
mental healthcare 
It has been reported that tapenng-off long-term benzodiazepine use might lead to an increase in 
medical consumption and consequently a higher workload for physicians " Empincal studies, 
however, suggest the opposite effect Despite a temporary increase in psychiatnc contacts in the year 
of withdrawal, Holton et al (1992) found a significant reduction in the mean number of both GP and 
psychiatnc contacts in the five years after withdrawal ' Furthermore, detoxification of high-dose 
benzodiazepine users significantly reduced GP contacts from 17 5 to 3 1 per year, and visits to mental 
health specialists from 7 6 to 2 1 per year 13 Finally, Bashir et al (1994) did not find an increase in GP 
contacts after a minimal intervention to reduce benzodiazepine use in pnmary care l4 
This paper presents an economic evaluation based on a randomised controlled design companng 
two benzodiazepine tapenng-off strategies with a usual care control group in pnmary care The main 
purpose of the study was to reduce unwarranted long-term benzodiazepine use, and consequently a 
reduction of associated side-effects (dependence, falls, traffic accidents, and cognitive impairmenl) 
Additionally, we measured the quality of life at baseline and follow-up No deterioration or even an 
increase in quality of life after benzodiazepine discontinuation was considered a prerequisite for 
tapenng-off The cost-effectiveness analysis was performed from a societal perspective (including all 
costs possibly associated with benzodiazepine usage) as well as from a pharmaceutical perspective 
Methods 
Study design 
A randomised controlled tnal in pnmary care that compared tapering off long-term benzodiazepine 
use combined with group cognitive-behavioural therapy (TO+CBT) and tapenng off alone (TOA) with 
a usual care control group (UC) was performed Patients were randomised in a ratio of 2 2 1 
respectively to achieve maximum discnminative power between the two active treatment groups, and 
were followed up for 18 months after the start of the trial Patients assigned to TO+CBT or TOA were 
tapered-off in 6 visits to their general practitioner (GP) by dosage reduction m steps of 25% a week, 
after being transferred to an equivalent dose of diazepam Patients assigned to TO+CBT attended in 
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addition five weekly two-hour sessions of group CBT starling halfway through the taper programme 
The study received ethical approval from the University Medical Centre Nijmegen and was earned out 
between 1998 and 2001 
Patients and recruitment 
We identified all long-term benzodiazepine users (i e , use for over three months) by means of a 
computensed search for benzodiazepine prescriptions at 30 general practices in rural and urban areas 
of the Netherlands, in which 58 GPs delivered pnmary care to about 118,000 patients In order to 
include patients unable to stop, all long-term users were sent a letter by their GP advising 
discontinuation of benzodiazepine use l 5 The exclusion cntena were current psychiatric treatment, 
current treatment for drug or alcohol dependence, medical history of psychosis, epilepsy, insufficient 
mastery of the Dutch language, or terminal illnesses Furthermore, people were excluded specifically 
at the GP's request because of severe co-morbidity or psychosocial reasons Three months after the 
letter was sent, patients were invited to visit the GP in order to evaluate the effect of the letter Patients 
still using benzodiazepines were asked to participate in the present study A total of 180 patients gave 
wntten informed consent 
Benzodiazepine usage 
The main outcome parameter measure was the percentage continued abstinence during the follow-up 
penod, ι e , 3 to 18 months after the start of the intervention according to the prescnption data of the 
GP The mean daily benzodiazepine dosage presenbed after sending the letter advising discontinuation 
and before the start of the tnal was considered the baseline benzodiazepine consumption 
The clinical outcome of this study has been described elsewhere , 6 1 7 Briefly, the 180 patients, of 
which 70% were female, had a mean (±sd) age of 63 (±12) Patients used benzodiazepines for a mean 
(±sd) duration of 13 5 (±9 6) years The mean daily dosage was 8 4 mg diazepam equivalent (P25= 4 1 
mg, P50 = 6 3 mg, P75 = 9 9 mg) before receiving the letter advising discontinuation , and 5 9 mg (P25 = 
1 7 mg, P-io = 3 8 mg, P7, = 6 6 mg) at the start of the tnal No differences were observed at baseline 
between the three conditions with respect to socio-demographical vanables, benzodiazepine usage, or 
psychological functioning At the end of the 15-month follow-up period, TOA (n=69) resulted in a 
significantly higher abstinence rale compared to UC (n=33) (36% vs 15%, p=0 03), in contrast to 
TO+CBT (n=68) (29% vs 15%, p=0 12) 
Quality of life 
Patients were assessed on three occasions before treatment (baseline), after treatment completion 
(three months after the start of the tnal), and at 18 months (outcome) Structured interviews were 
conducted at the patients' homes by research assistants The questionnaires included the Medical 
Outcome Study Short-Form 36 (SF-36) and the Health Utility Index-Mark-III (HUI-3)18 ' 9 
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The SF-36 is a genene descriptive instrument measuring a spectrum of function, disability, and 
distress It consists of eight domains (physical functioning, social functioning, role limitation due to 
physical problems, role limitation due to emotional problems, mental health, vitality, pain, and general 
health perception) The Dutch version of the SF-36 was previously tested and validated The HUI-3 
is a multi-attnbute health-state classification system frequently applied for the economic evaluation of 
healthcare programmes It is a self-administered questionnaire for determining 8 functional aspects 
(i e, attributes) of quality of life (vision, hearing, speech, emotion, pain, ambulation, dexterity, and 
cognition) These attributes are summansed into a utility score ranging from 0 (death) to 1 (perfect 
health) 
Costs 
Costs were elicited from a societal perspective in which all costs generated within the healthcare 
sector, patient and family costs, as well as costs generated in other sectors (productivity losses), were 
evaluated over the 15-month follow-up period Because underlying diseases and reasons for taking 
benzodiazepines may be heterogeneous and largely unknown, costs were measured broadly regardless 
of whether they could be related to the use of benzodiazepines Since the causal relationship between 
most costs and the status of benzodiazepine use remained unclear, the cost-effectiveness analysis was 
performed from a societal as well as a pharmaceutical perspective 
The intervention costs (GP contacts and psychotherapy sessions) were obtained from the case 
record forms Pharmaceutical costs were calculated based on the drug prescription database (including 
ATC-code , number and dose of tablets and prescription rules) of the GP, which was monitored 
longitudinally Other costs were obtained by four 3-week cost-diaries completed at 3, 6, 12, and 18 
months after the start of the trial, and were extrapolated for the 15-month follow up penod assuming 
lineanly Dianes comprised regular and non-regular healthcare utilization, over-the-counter (OTC) 
drugs, productivity loss at work as well as housekeeping activities, and costs related to the status of 
benzodiazepine use Healthcare utilisation comprised a number of visits to the GP, first aid medical 
ward, medical specialists and paramedical specialists (physiotherapists, psychologists, and social 
workers), non-regular medical care, and days of hospital admissions The first week of each diary was 
filled in retrospectively with help from a research assistant The next two weeks had to be filled in by 
the patients themselves The completed dianes had to be returned by post A research assistant phoned 
patients in the event dianes were incomplete or not returned on time 
To determine cost pnees, several assumptions were made Cost prices for visits to GPs, medical 
specialists, medical first aid ward, psychologists and social workers were derived from the guidelines 
for pharmaco-economic research in the Netherlands 22 Costs for alternative medicine, over-the-counter 
medication, and costs of patients related to the status of benzodiazepine use ('extra costs') were priced 
according to the costs reported by patients in the cost-dianes The pnees for presenbed drugs were 
sourced from the Dutch Health Care Insurance Council, plus a standardised compensation per 
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prescnption for pharmacists in the Netherlands The costs of benzodiazepines were calculated 
according to the pnce for the genene agents in the Netherlands for individual benzodiazepines, ι e , the 
lowest pnce for an individual benzodiazepine " Prescnptions for drugs other than benzodiazepines 
were pnced exactly if issued more than 100 times dunng baseline and follow-up, while other 
prescnptions were pnced at €40 per 90-day treatment penod 23 All pnces are in euros and indexed at 
2001 pnces 24 
Analysis 
The pnmary outcome parameter was the percentage continued benzodiazepine abstinence dunng 
follow-up in the three groups according to the prescnption data of the GP To analyse the difference in 
costs between the three groups, the total costs dunng follow-up were calculated and expressed as mean 
amount per patient per condition As the distnbution of costs was skewed, non-parametric tests were 
performed 
The differential quality of life across the three conditions at follow-up was tested for each 
subscale of the SF-36, and for the utility score of the HUI-3 separately, with a repeated measure 
ANOVA with time (baseline vs follow-up assessment) as a two-level within subject factor, and 
treatment condition (TO+CBT, TOA, UC) as a three-level between subject factor 
Results 
Study participation and compliance 
Table 1 
Study adherence dunng follow-up for the different measurements in absolute number of patients per condition 







































180 patients were included and randomised over TO+CBT (n=73), TOA (n=73) and UC 
(n=34) The sample size differs for the different outcome measures (table 1) Prescnption data were 
available for 170 of the 180 patients (94%) for the whole follow-up penod The baseline assessment 
was available for all 180 patients, while 143 (79%) patients completed the 18-month follow-up 
assessment The number of dropouts for the 18-month assessment did not differ significantly across 
the three groups (χ2 = 1 85, df=2, p=0 40) and was not related to benzodiazepine use dunng follow-up 
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(p=0.52). Finally, the cost-diaries were completed by 171 patients at baseline and during follow-up by 
142 patients at 3 months, 130 patients at 6 months, 125 patients al 12 months, and 143 patients at 18 
months. 
Table 2 
Utility score (HUI-3) at baseline and at 18-month follow-up per condition (n=180) 
Health Utility Index - 3 
Intervention: Baseline * 18-month " 
TO + CBT Mean±sd (n) 61 ±25 (63) 66 ±22 (42) 
TOA Meantsd (n) 64 ±28 (63) 5B ±30 (49) 
UC Mean±sd (n) 61 ±27 (32) 69 ±26 (17) 
* No utility score could be denved for 22 (12%) of the 180 patients assessed at baseline based on the algorithm for the HUI-3 
" No utility score could be derived for 22 (15%) of the 143 patients assessed at outcome based on the algorithm lor the HUI-3 
Quality of life 
No differences were observed between the three groups at baseline with respect to quality of life 
(tables 2 & 3). The scores on the SF-36 were low compared to the norm scores for the general Dutch 
population.20 The repeated measures ANOVA comparing baseline and outcome scores over the three 
groups did not result in significant condition χ time (=baseline vs. outcome) interactions for any of the 
measures. A comparison between abstinent and non-abstinent patients did not show significant 
differences at follow-up. 
Table 3 
Quality of life (SF-36) at baseline and at 18-month follow-up per condition (n=180) mean ±s.d. 
Short-Form 36 
role role general 
physical social limitation limitation mental health 




End ol follow-up (n=58) 
TOA: 
Baseline (n=73) 
End of follow-up (n=59) 
UC: 
Baseline (n=34) 
End of follow-up (n=26) 
82 87 
67 ±26 61 ±21 
68 ±26 68 ±22 
66 ±25 64 ±24 
65 ±26 64 ±26 
68 ±25 66 ±19 
72 ±26 69 ±19 
79 84 
51 ±40 63 ±39 
57 ±44 67 ±41 
54 ±42 69 ±39 
54 ±42 76 ±39 
69 ±35 70 ±42 
76 ±36 81 ±29 
77 67 
64 ±18 55 ±23 
71 ±17 63 ±20 
66 ±20 57 ±23 
76 ±39 61 ±20 
64 ±23 56 ±24 
81 ±29 63 ±24 
80 73 
62 ±27 58 ±23 
67 ±26 62 ±19 
60 ±24 52 ±20 
61 ±27 57 ±20 
66 ±26 58 ±22 
69 ±22 55 ±22 
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Cost of the interventions 
The actual number of tapering-off visits to the GP contrasted with the standardised 6 consultations as 
patients assigned to TO+CBT and TOA visited their GP 4.2 (sd 2.7) and 3.9 (sd 2.6) times 
respectively. Patients assigned to TO+CBT attended on average 2.3 (sd 2.2) therapy sessions.16 This 
resulted in an actual cost for the interventions of €172.99 for TO+CBT, €69.50 for TOA, and nihil for 
UC. 
Cost of prescribed drugs 
The pharmaceutical costs for benzodiazepines at baseline were identical over the three conditions 
(χ2=0.5; df=2; p=0.80). The costs for benzodiazepines differed significantly during follow-up 
(TO+CBT, €68.73; TOA, €51.93; and UC, €94.04; χ2=9.8; df=2; p=0.01). Post hoc analyses showed 
that the cost of benzodiazepine usage in the UC group was significantly higher compared with the 
TO+CBT (p=0.05) and the TOA groups (p=0.002). TO+CBT and TOA did not differ significantly 
(p=0.17) from each other. The cost of prescribed drugs other than benzodiazepines did not differ over 
the three groups at baseline (χ2=2.8; df=2; p=0.24) nor during follow-up (χ2=3.4; df=2; p=0.18). 
Table 4 
Generated costs based on the 3-week cost-diaries per group during follow-up in euros indexed at 2001 
Time 
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p<0 05 compared to physiotherapist visit at baseline for patienls assigned to TOA and UC 
Significant difference (p<0 05) compared to baseline (Wilcoxon test) in the treatment condition 
General practitioner 
Medical specialist / first aid medical ward 





Cosls related to status of BZ use 
TOA (n=73): 
General practitioner 
Medical specialist / firsl aid medical ward 





Costs related lo status of BZ use 
UC (n=34): 
General practitioner 
Medical specialist / first aid medical ward 





Costs related to status of BZ use 
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Cost-diaries 
Other costs were based on the cost-diaries (see table 4). The three groups differed at baseline as 
patients assigned to TO+CBT visited physiotherapists significantly more (χ2=7.0; df=2; p=0.03) 
compared to patients assigned to TOA or UC. 
During follow-up, the costs vaned widely both within and between the groups at the different 
follow-up assessments. The three groups differed at 3 months with respect to the costs of OTC drugs 
(p=0.04), and at 6 months with respect to the number of GP (p=0.02) and physiotherapist contacts 
(p=0.01), and the additional costs ('extra costs') of patients related to the status of benzodiazepine use 
(p=0.04). During follow-up, none of the patients were admitted to hospital due to falls or traffic 
accidents. 
Each follow-up assessment was pairwise tested (Wilcoxon test) with the baseline assessment to 
evaluate trends within each condition for the parameters examined. Ten of the 96 tests yielded 
significant p-values (p<0.05). Compared to baseline, patients in the TO+CBT group had significantly 
more visits to the GP at 6 months, and to the physiotherapist at 12 months, while patients in the TOA 
group had significantly more visits to the GP at 6 months, to the medical specialist at 6 and 18 months, 
spent less money on OTC drugs at 3 months, had more productivity loss at 3 months, and had 
increased 'extra costs' at 6 and 12 months. Patients in the UC group had significantly decreased 'extra 
costs' at 12 months compared to baseline. 
Table 5 






































































Baseline diary linearly extrapolated for a period of 15 months 




To assess the cost-effectiveness from a societal perspective, the costs assessed in the cost-diaries were 
extrapolated linearly over the follow-up penod. The cost of prescribed drugs other than 
benzodiazepines, and the costs of the separate categories in the diaries, were 5 to 15 times higher than 
the costs for treatment or benzodiazepine use. Table 5 shows the mean cumulative costs at baseline 
(extrapolated to a 15-month period) and during the 15-month follow-up period. Table 6 presents the 
(incremental) cost-effectiveness ratios from different perspectives compared with the UC group based 
on the mean change between baseline and follow-up. UC resulted in the lowest cost per unit success 
(proportion of patients able to discontinue) independent of the study perspective, while the differences 
in costs per unit success were small between the two taper strategies. The incremental cost-
effectiveness ratios show that for every percent abstinence above that achieved by usual care, TOA is 
cheaper than TO+CBT. 
Table 6 
Costs (C), effectiveness (E), cost-effectiveness ratio (C/E), incremental cost (AC), incremental effectiveness 
(ΔΕ), and incremental cost-effectiveness ratio (AC/AE) per patient based on the mean change score reported in 
table 5 for TO+CBT and TOA compared to UC during 18-month follow-up 
Perspective: C E CE AC ΔΕ AC/E 













The data for the pharmaceutical perspective showed that when corrected for UC, TO+CBT 
saves €25.02 during follow-up and TOA €54.31 due to the reduction in benzodiazepine usage. 
However, these savings were less than the cost of the treatment (investment). The savings in the last 6 
months of follow-up were €8.40 for TO+CBT, and €17.20 for TOA when corrected for treatment gain 
by UC. Carrying the results of the last 6 months of follow-up linearly forward showed that the 















































Economic evaluation of tapenng off benzodiazepine usage m long term users 
Discussion 
Up until now, benzodiazepine taper-off studies have not included an economic evaluation This study 
estimated the hypothesised 'added value' of both tapering-off with group CBT (TO+CBT) and 
tapenng-off alone (TOA) compared to usual care (UC) during an 18-monlh follow-up in relation to the 
associated costs As most benzodiazepine users receive prescriptions from their GP, the study was 
carried out in primary care Since GPs treated their patients themselves, our results are representative 
for daily practice, and do not have to be corrected when implemented 
The costs of benzodiazepine usage during follow-up were significantly lower among patients 
assigned to TO+CBT or TOA compared with patients receiving UC The incremental cost-
effectiveness ratios showed that TOA was associated with the lowest incremental costs per percent 
patients able to discontinue over the success rate of UC, independent of the applied study perspective 
An increase of one percent successful discontinuation cost €41 24 from a societal perspective, €10 37 
from a comprehensive pharmaceutical perspective, and €0 77 from a limited pharmaceutical 
perspective when treating patients by tapering-off alone instead of usual care The question is whether 
policy makers at different levels are prepared to pay an extra €0 77 to €41 24 for a one percent 
successful discontinuation of benzodiazepine usage The addition of group CBT does not increase the 
success rate and the treatment costs are higher When corrected for usual care, TO+CBT resulted in 
comparable or inferior incremental cost-effectiveness ratios than TOA (depending on the study 
perspective) 
Compared to the general population, our population had a low quality of life, which 
corresponded with surveys of long-term benzodiazepine users in the population " " However, the 
quality of life did not change significantly as a result of our interventions, nor as a result of treatment 
outcome Consequently the prerequisite for conducting a cost-effectiveness analysis was met, since 
patients did not detenorate after benzodiazepine discontinuation 
A limitation typical of many economic analyses in mental healthcare28, is the lack of pilot study 
service data for this patient group, together with the skewed distribution of observed economie data in 
this trial Our decision to measure healthcare utilisation with four 3-week cost-dianes during an 18-
month follow-up was based on numerous assumptions Nonetheless, despite these shortcomings, our 
study is one of the largest benzodiazepine discontinuation trials published29 32 and included far more 
patients than previous evaluations of taper programmes with additional psychotherapy, which had a 
maximum of 20 patients per group " 37 However, our sample size was still relatively small considering 
the high prevalence of benzodiazepine use, and was also too small to evaluate the incidence of hospital 
admissions resulting from falls and traffic accidents since no such incidents were observed in our 
study 
In contrast to the cost-diary data, the drug prescription data were longitudinally monitored and 
were available for 94% of the patients However, the causal relationship between prescribed drugs 
165 
Chapter 10 
other than benzodiazepines and benzodiazepine use and discontinuation remained unclear A previous 
report of this study showed that the use of psychotropic drugs did not significantly change as a result 
of benzodiazepine discontinuation", which has also been reported by others 1e For these reasons, 
additional cost-effectiveness analyses were performed from two pharmaceutical perspectives a 
comprehensive one including all prescnbed drugs, and a limited one exclusively looking at the cost of 
treatment and benzodiazepine usage 
Application of the limited pharmaceutical perspective, and extrapolation of the results for the 
last 6 months of follow-up, showed that treatments costs were paid back after 141 months for 
TO+CBT, and 20 months for TOA when corrected for treatment gain by UC Since most relapses 
occurred within the first 6 to 9 months of follow-up, extrapolating our follow-up over 20 months 
seemed reasonable, while extrapolation over 141 months might be questionable ' 
We recommend motivating patients to taper-off long-term benzodiazepine use in general 
practice, as these programmes result in significantly higher abstinence rates compared with usual care, 
and no loss in quality of life The additional cost of tapermg-off alone per percent success is low and 
vanes between É0 77 and €41 24 depending on the economic perspective applied We preferred 
application of the limited pharmaceutical perspective, resulting in an incremental cost-effectiveness 
ratio of 0 77 €/%, because we did not find a clear association between the measured healthcare 
utilisation charactenslics and benzodiazepine usage, while these costs exceeded those for treatment 
and benzodiazepine usage Furthermore, tapenng off benzodiazepine use might lead to a reduction in 
the cost for mental healthcare since treatment costs would be paid back after 20 months of follow-up 
The addition of group CBT to tapenng-off had no clinical or economical advantages 
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The focus of this thesis is an evaluation of the outcome of different strategies to discontinue long-term 
benzodiazepine use in general practice The study started with a systematic review and meta-analysis 
of the literature in order to summarise the available knowledge on benzodiazepine discontinuation 
strategies systematically (Part I) Thereafter, three strategies were evaluated using data obtained from 
a larger research project the Benzoredux project (Parts II, III, and IV) 
In this chapter, the findings will be summarised for all of the four Parts of the thesis 
Subsequently, some methodological issues of the Benzoredux project will be discussed in order to 
establish the strengths and limitations of the results Finally, the key conclusions will be summarised, 
as will the implications for clinical practice and a suggested approach for future research 
Summary 
Part I: Literature review 
In chapter 3 a systematic review and meta-analysis is carried out of the literature on discontinuation 
strategies of long-term benzodiazepine use Sixty original papers were identified by a systematic 
literature search, which yielded four types of discontinuation strategies a minimal intervention, a 
systematic discontinuation programme without additional treatment, a systematic discontinuation 
programme in combination with psychotherapy, and a systematic discontinuation programme in 
combination with pharmacotherapy Success rates were calculated at a patient level for each 
intervention type per coded vanable The effects of the coded variables were analysed by means of 
Pearson's chi-square tests and controlled for possible two-way interaction effects using additional 
Pearson chi-square tests over the confounding variables Review papers, double publications, animal 
research, clinical trials evaluating the efficacy of benzodiazepine treatment for a fixed period, and case 
reports less than five cases were excluded 
Minimal interventions were defined as simple interventions applied for large groups of patients 
advising them to stop benzodiazepine use by themselves The effect of these interventions was 
examined in five studies, three using a randomised controlled design by including a non-intervention 
control group receiving usual care The mean success rate of 22% at 6 to 9 months follow-up was 
significantly supenor to the 9% success rate in the control group All minimal interventions were 
earned out in general practice 
Systematic discontinuation strategies were defined as treatment programmes guided by a 
physician Two-thirds of patients managed to discontinue long-term benzodiazepine use directly after 
systematic discontinuation The success rate could be increased by tapenng off after transfer to a long-
acting benzodiazepine if patients were treated as outpatients or if they used more than 15 mg diazepam 
equivalent per day The theoretical advantage of transfer to a long-acting agent before tapenng-off is 
170 
Summary and general discussion 
the occurrence of less severe withdrawal symptoms caused by a more gradual blood level decrease. 
Inpatient treatment resulted in a higher success rate than outpatient treatment The success rate for the 
inpatient group was independent of dose level, while in the outpatient group a high dose level (more 
than 30 mg diazepam equivalent) was associated with lower success rates Although symptom-guided 
taper methods indicated to result in the highest success rate and fixed taper-off schemes seemed 
supenor to abrupt discontinuation, firm conclusions could not be made due to lack of head-to-head 
compansons of these methods In addition, the impact of the underlying disease could not be evaluated 
properly, although multiple drugs users and insomniacs seemed to have inferior success rates We 
failed to detect any influences on the success rate of publication year, duration of benzodiazepine use, 
and setting 
The addition of psychotherapy to facilitate discontinuation did not result in higher success rates 
However, low patient numbers (i e , less than 20 patients per group), as well as the lack of randomised 
controlled compansons, made any firm conclusion difficult Two well-designed randomised controlled 
tnals, however, suggested different efficacy in different diagnostic patient groups The addition of 
CBT proved to be efficacious in patients diagnosed with panic disorder, but not in substance abusers 
The addition of the psychoactive drugs carbamazepine and Imipramine resulted m significantly higher 
success rates than systematic discontinuation alone 
The lack of long-term data (longer than one year) was a major limitation in the evaluation of 
minimal intervention strategies Only five studies reported long-term follow-up results of systematic 
discontinuation programmes Aggregation of these data was difficult because the success rates vancd 
widely (from 16 - 82%) due to the different outcome cntena for benzodiazepine use Finally, a two-
step approach used in the Benzoredux project had never been applied before 
Part II: Minimal intervention 
The Benzoredux project was earned out in 30 general practices in the Netherlands, where 58 general 
practitioners (GPs) delivered pnmary healthcare to 118082 patients A computensed search identified 
all the patients who had received at least one benzodiazepine prescnption dunng the previous year Of 
these, 2964 were identified as long-term benzodiazepine users (more than three months), and 2004 
fulfilled the inclusion cntena for the Benzoredux project These patients received the first intervention 
of the project, namely a letter from their GP advising discontinuation of benzodiazepine use 
In chapter 4, the effect of this minimal intervention is evaluated over a 21-month follow-up 
penod Three practices were excluded from the analyses because prescription data could not be 
extracted from them In addition, some patients were lost to follow-up due to moving homes, dead or 
technical problems with extraction of follow-up data The sample therefore comprised 2248 long-term 
benzodiazepine users (in stead of the 2964 identified at study start), for which complete follow-up was 
available Of this group, 1601 patients met the inclusion cntena and actually received the minimal 
intervention The short-term evaluation, 3 to 6 months after the initial letter was sent, showed that 28% 
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(446/1601) of patients did not receive benzodiazepine prescriptions anymore This success rate was 
superior to the mean success rale of the minimal interventions described in chapter 3 During the 21-
month follow-up period, the success rate for continued abstinence dropped to 16% (251/1601) 
In order to avoid Hawthorne effects, we recruited retrospectively a blinded control group of 
2061 long-term benzodiazepine users in 16 additional practices, of which 1585 patients were available 
for analysis The in- and exclusion cnteria for receiving the minimal intervention were not applied for 
these patients in order to prevent recall bias A comparison between the 1585 control subjects with the 
2248 long-term users in the experimental practices revealed significantly higher dosage reductions in 
the experimental practices (24% versus 5%, p<0 01) Moreover, 24% of the patients in the 
experimental group did not receive any benzodiazepine prescription 4 to 6 months after receiving the 
discontinuation letter (quitters), versus 12% of the patients in the control group (p<0 01) Quitters used 
significantly lower dosages before receiving the discontinuation letter compared to non-quitters Of 
the quitters, 42% in the control group and 56% in the expenmental group remained benzodiazepine 
prescription abstinent till the end of follow-up (p<0 01) The patients who relapsed used significantly 
lower benzodiazepine dosages at 21 months compared with their baseline level 
In chapter 5, a more extensive follow-up is presented of users who stopped in the short term and 
who gave informed consent for a more intensive follow-up Of the 2004 long-term benzodiazepine 
users who originally received the minimal intervention, 1321 patients responded to a second letter 
asking them to visit their GP Of the 1321 visitors, 285 said they had slopped their benzodiazepine use, 
and 109 (38%) gave informed consent for the follow-up study After a mean follow-up period of more 
than two years, 49% were still completely abstinent from benzodiazepines Furthermore, 60% of those 
patients who relapsed showed better usage patterns during follow-up, ι e, using benzodiazepines 
intermittently for penods of less than 90 days Benzodiazepine consumption during follow-up was not 
related to psychological functioning Patients did not change their benzodiazepine use for other 
psychotropic drugs Two independent predictors of relapse were indentified use of more than 10 mg 
diazepam equivalent a day before receiving the initial letter and a poor general health perception 
Part ΠΙ: Short-term results of taper-off strategies 
Of the 1321 patients that visited the GP three months after the minimal intervention, 1036 patients said 
they were still using benzodiazepines, of which 180 agreed to participate in the second stage, a 
randomised controlled tnal (RCT) The patients were randomised over tapenng-off combined with 
simultaneous group cognitive behavioural therapy (CBT) (n=73), tapenng-off alone (n=73), and a no-
intervention control group (n=34) The short-term results presented in Part III are based on self-report 
outcome measures 
In chapter 6, we describe the short-term effect of the RCT based on intenl-to-treal analysis, on 
self-report abstinence rates, and psychological functioning at the end of treatment (available for 141 
patients, 78%) Both taper programmes yielded significantly higher abstinence rates compared with 
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the no-intervention control group tapenng off combined with group CBT, 58%, tapenng off alone, 
66%, and non-intervention, 21% Contrary to our hypothesis, the addition of group CBT did not 
increase the success rate of the tapenng-off programme 
Some interesting findings were noted (a) patients did not suffer adverse effects from (trying to) 
taper-off since neither intervention type nor treatment outcome critically affected any of the secondary 
outcome parameters (seventy of withdrawal symptoms, psychological distress, mood swings, or the 
use of psychoactive agents), (b) the participation rate was poor 17% (180/1036) of the eligible 
patients gave informed consent to participate in the tnal, (c) although these patients did not respond to 
the minimal intervention, 23 of the 146 patients (20%) assigned to one of the taper-off strategies 
slopped their benzodiazepine use after giving informed consent while wailing to join the programme, 
(d) attendance at group CBT was poor 65% attended three or more sessions, (e) the programmes 
showed good feasibility in general practice, and (0 the majonty of patients were satisfied with the 
treatment received 
In chapter 7, the Benzodiazepine Dependence Self-Report Questionnaire (Bendep-SRQ) was 
cross-validated to establish its usefulness in daily practice The Bendep-SRQ is a self-report 
questionnaire that measures the seventy of benzodiazepine dependence on four domains 'awareness 
of problematic use', 'preoccupation with the availability of benzodiazepines', 'lack of compliance 
with the therapeutic regime', and 'withdrawal' Three out of the four domains had good scalability 
Some concerns arose about the scalability of the preoccupation scale, which emphasized the need for 
cross-validation in clinically relevant populations All scales showed excellent reliability (subject 
discnminability, item discnminabihty), while construct and discnminant validity were adequate All 
four scales contnbuled significantly to the prediction of complete abstinence after the tapenng-off 
programme This prediction was independent of the other prognostic vanables (baseline 
benzodiazepine dosage and smoking status), except for those in the domain 'problematic use' The 
scales 'problematic use' and 'preoccupation' showed good sensitivity to change during follow-up 
Part IV: Long-term results of taper-off strategies 
The 18-monlh prospective follow-up study consisted of (a) a computensed extract of all drug 
prescription data from the GP information system, (b) a self-report follow-up assessment at 18 months 
identical to the baseline and short-term outcome assessment, and (c) five three-week cost-dianes at 
baseline and at 3, 6, 12 and 18-month follow-up 
In chapter 8, the clinical outcome study is presented longitudinally investigating the 18-monlh 
outcome of benzodiazepine discontinuation with respect to benzodiazepine use, psychotropic drug use, 
and psychological functioning The drug prescnplion data were available for 170 of the 180 patients 
included in the tnal (94%) Fifty patients (29%) did not receive benzodiazepine prescnptions during 
follow-up Tapenng-off alone resulted in a significantly higher continued abstinence rate compared to 
the control group (36% versus 15%, p=0 03), while simultaneous group CBT had no added value for 
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tapenng-off alone In addition, actively treated patients who failed to discontinue benzodiazepine use 
lowered their dosage significantly more than the patients receiving usual care Moreover, 47% of 
patients receiving tapenng-off combined with group CBT, and 54% of those receiving tapenng-off 
alone used benzodiazepines intermittently for penods of less than 60 days Patients did not switch 
from benzodiazepines to other psychotropic drugs, nicotine, or alcohol Although patients were 
suffenng from mild anxiety and depressive symptoms, neither intervention type nor outcome 
adversely affected psychological functioning 
Chapter 9 presents a Cox-regression analysis used to identify independent predictors of long-
term taper success Potential predictors included benzodiazepine (usage) charactenstics, 
psychopathological symptoms, personality traits, and charactenstics of (benzodiazepine) dependence 
Independent predictors of success included offenng a taper-off programme with or without group 
CBT, a lower daily dosage at the start of tapenng-off, a substantial dose reduction after a minimal 
intervention immediately before tapenng-off, a low score on the 'lack of compliance' scale of the 
Bendep-SRQ and no use of alcohol Patients who used over 10 mg of diazepam equivalent, who had a 
score of three or more on the 'lack of compliance' scale of the Bendep-SRQ, or who drank more than 
two units of alcohol per day failed to achieve long-term abstinence 
Chapter 10 presents the economic evaluation of the follow-up study This study examined the 
incremental cost-effectiveness ratios (= costs per unit extra effect) of tapenng-off benzodiazepine 
usage with and without group CBT compared to usual care We planned a prion a cost-effectiveness 
analysis from a societal perspective for the condition that the quality of life increased or remained 
stable This prerequisite was confirmed as neither intervention type, nor outcome, affected the quality 
of life 
The medical consumption, as measured with five 3-week cost-diaries, did not significantly 
change during follow-up, and was independent of intervention type or treatment outcome However, 
fluctuations within, and between, groups questioned the reliability of these measures Moreover, these 
costs and the costs for prescribed drugs other than benzodiazepines exceeded the intervention costs 
and the pharmaceutical costs for benzodiazepines, while the causal relationship with benzodiazepine 
usage remained uncertain Therefore, the cost-effectiveness ratios were also calculated from two other 
perspectives a pharmaceutical perspective limited to intervention costs and benzodiazepine usage, and 
a comprehensive pharmaceutical perspective also including the costs of prescnbed drugs other than 
benzodiazepines Both tapenng-off strategies led to a significant reduction in benzodiazepine costs 
Although the incremental cost-effectiveness ratios were better for tapenng-off alone than for tapenng-
off with group CBT, when compared with usual care, the differences were small Extrapolation of our 
data showed that the costs for tapenng-off alone were paid back after 20 month follow-up when 
corrected for treatment gain in the usual care group 
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Methodological issues of the Benzoredux project 
The results - summarised above - have already been discussed in the vanous chapters In this general 
discussion, the methodological strengths and limitations of the Benzoredux project are discussed 
together with the implications for interpretation of the results The following aspects will be discussed 
setting, subjects, attrition rate and effect size of the minimal intervention, attrition rate and 
randomisation procedure of the RCT, interventions of the RCT (taper protocol and group CBT), the 
primary outcome parameter, benzodiazepine dosage levels, and finally the measurements 
Setting 
The Benzoredux project was earned out in general practice as most long-term users (89%) receive 
benzodiazepine prescnptions from their GP The high prevalence of benzodiazepine use and the daily 
practice of a GP gave the opportunity to evaluate a two-stage treatment approach starting with a 
minimal intervention Moreover, in general practice, long-term benzodiazepine use is often taken for 
granted and hardly evaluated anymore 2 Furthermore, most long-term users do not receive additional 
treatment for anxiety or insomnia anymore that would be interrupted by the minimal intervention 
Previous minimal interventions were also conducted in general practice, while the more 
intensive tapenng-off strategies were mainly conducted in psychiatric inpatient or outpatients clinics, 
which limits generahsabihty to general practice A ' ' These discontinuation studies contrast with the 
pragmatic nature of the Benzoredux project that concentrates on the effectiveness of tapenng off in 
daily practice Moreover, 76% of the patients in our study preferred treatment by their GP, while only 
7% preferred referral to other specialists (see chapter 6), which is in line with survey data of 
benzodiazepine users ' A large benzodiazepine discontinuation study in general practice found 
comparable short-term success rates (66%) and a somewhat lower long-term success rate This study 
was restneted to depressive long-term benzodiazepine users, while no pre-selection was carried out 
through a minimal intervention ' 
Subjects 
The main purpose was to reduce long-term benzodiazepine consumption in general practice by 
recruiting as much as possible long-term benzodiazepine users We therefore identified a prion all 
long-term benzodiazepine "users to provide detailed information on the effect of our approach in an 
'average Dutch general practice' However, two factors might limit the generahsabihty of our results 
to the 'average long-term benzodiazepine user in the population' First, 12% of the long-term 
benzodiazepine users (297/2425) had to be excluded in order to prevent interference with the treatment 
they were receiving in psychiatnc or addiction outpatient clinics Secondly, the inclusion and 
exclusion cntena had to be checked by the general practitioner themselves, which was justified by the 
pragmatic nature of the Benzoredux project If a GP wanted to exclude a patient for a reason not 
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covered by our exclusion cntena, he/she had to motivate that decision and subsequently discuss it with 
one of the researchers Nevertheless, 10% of the patients (251/2425) were excluded specifically on 
instigation of the GP An interesting finding was that a substantial number of GPs excluded the oldest 
patients at the first check By discussing the checklist, most GPs were persuaded to include the elderly 
As the outcome of both treatment stages (minimal intervention / tapenng-off) was independent of the 
patient's age, this finding stresses the influence of prejudice on the patient's chances of discontinuing 
benzodiazepine use Moreover, these results indicate that especially the elderly should be included in 
the programme, since adverse effects increase with old age M 16 
In previous studies on minimal intervention strategies, the GP had not only to check the 
inclusion and exclusion cntena, but also to identify the long-term users in his/her practice17 ", while 
two studies did not provide information how long-term users were identified 20 ' 
Attrition rate of the minimal intervention 
Our study is the first study that identified all long-term benzodiazepine users before starting 
recruitment, and it therefore provides detailed information on the recruitment process To validly 
evaluate the effect of a letter containing advice to stop benzodiazepine use, gaining informed consent a 
priori was impossible Asking informed consent afterwards was not necessary, since the effect of the 
letter was evaluated using anonymous prescnption data that could only be linked to individual patients 
by the GP Therefore, the results of the minimal intervention were not hampered by non-respondent 
bias in contrast to the studies of Bashir et al (1994), Jones (1991) and O'Leary (1989)l7 '82 ' The study 
of Cormack et al (1994) on the efficacy of a discontinuation letter was also performed without 
informed consent of the patients " This study was earned out in three general practices with ten GPs 
and 209 long-term benzodiazepine users Therefore, the influence of individual GPs could not be ruled 
out and subgroup analyses could not be performed '9 
Thirty five percent of the patients who received the discontinuation letter did not respond to the 
invitation of the GP three months later to discuss the effect On the one hand, it might reasonably for 
GPs not to want to see everyone personally as participation in the study would than increase their 
workload substantially by 40 consultations over 4 to 10 weeks However, a busy surgery does not fully 
explain why 35% of the patients refused to visit the GP Drug-seeking behaviour or avoidance of 
patients combined with a non-restrictive policy or attitude of the GP might have played a role, which 
is also suggested by the personal reasons patients gave for not visiting the GP (see chapter 4) '2 " 
Effect size of the minimal intervention 
The effect of the minimal intervention was compared to a matched control group that was recruited 
retrospectively Of the seven previous studies evaluating a minimal intervention strategy, three studies 
did not include a control group17,12',, while the others recruited controls from the same general 
practices As participation in a benzodiazepine reduction trial is likely to influence the prescnption 
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behaviour of the GP (Hawthome-effect), the allocation of controls from non-intervention practices in a 
blinded fashion was preferable 2526 The proportion of patients who discontinued benzodiazepine use 
was 14 1% among users excluded for the minimal intervention in the expenmental practices (thought 
to have more difficulty in benzodiazepine discontinuation), while 11 7% discontinued in the matched 
control practices Although this finding could reflect a Hawthome-effect, it might also be caused by 
GP participation bias 
GPs in the control practices were not asked to apply the exclusion cnlena on the list of long-
term benzodiazepine users for two reasons First, the control practices were recruited retrospectively, 
which might lead to recall bias in applying the inclusion and exclusion cntena Second, the knowledge 
of really sending the letter (experimental practices) or the knowledge of not sending the letter (control 
practices) might influence the exclusion of patients specifically on instigation of the GP The long-
term effectiveness of this intervention was therefore evaluated by comparing all long-term users in the 
expenmental practices (whether or not they were excluded from the intervention) with all long-term 
benzodiazepine users in the control practices As no matched control group was available for the 
patients who actually received the letter, the exact effect size of the intervention remains unknown 
Attrition rate of the RCT 
The participation rate in the second stage was 17% Therefore, the results of the two tapenng-off 
strategies can not be generalised to all long-term benzodiazepine users in general practice Patient and 
GP related factors can be put forward to explain this finding GP-related factors are likely to have been 
influential since the number of patients included in the RCT ranges from 0 patients in 6 practices 
(group as well as solopractices) to 15 patients in a solo practice and 22 in a group practice This might 
reflect different attitudes among GPs regarding long-term benzodiazepine use On the other hand, GPs 
might have participated pnmanly in relation to the first stage, not being fully aware of the second 
stage or discouraged by the increased workload of evaluation visits after the minimal intervention 
Patient-related factors should also be considered As 40% of all benzodiazepine users in general 
practice are dependent according to the DSM-III-R cntena, dependence on benzodiazepines might 
have played a role28 In addition, Linden et al (1998) found that two-thirds of long-term low-dose 
benzodiazepine users rejected a drug holiday in general practice 29 According to Russell and Lader 
(1992), benzodiazepine withdrawal involves a preliminary penod of negotiation between patient and 
doctor, dunng which underlying fears and attitudes should be explored 30 The penod of negotiation in 
our tnal was limited to one or, on instigation of the patient, two consultations and some information 
sheets Furthermore, patients might have had a general resistance to taking part in an RCT, a specific 
reluctance to one of the treatment arms (for example the no-intervention control group or the group 
CBT), or a reluctance to be visited at home If this were the case, the participation rate would probably 
be higher in clinical practice However, we hypothesise that the participation rate in our study reflects 
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the daily practice in which GPs have to agree on a treatment with patients, and the participation would 
only increase substantially by exerting more pressure on patients 
Although the relative participation rate was rather low, our study is one of the largest 
benzodiazepine discontinuation trials ever published Because we identified all the long-term users 
before we recruited them, our attrition rate cannot be compared with that of other studies which 
recruited referred patients in specialised settings or through advertisements4"" A study conducted in 
general practice reported a recruitment rate of 47%, which was estimated retrospectively Moreover, 
this study was restncled to depressed long-term benzodiazepine users that were put on paroxetine or 
placebo, and were only tapered-off if their depression responded to that treatment 
Randomisation 
The benzodiazepine discontinuation study in the second stage of the Benzoredux project is the first 
study in which patients are randomised between tapenng-off and a no-intervention control group It is 
therefore the first study providing evidence for the efficacy of tapenng-off long-term benzodiazepine 
use Moreover, this design enabled a controlled evaluation of psychological functioning and 
psychotropic drug use during long-term follow-up 
An advantage of randomisation at a GP level might be a shorter waiting time for group CBT, 
since most patients of a particular practice were recruited within limited timelines We randomised at 
patient level and not at GP level to avoid bias due to different attitudes of the GPs and different taper-
off results in the different practices n The effect of the GP on outcome and recruitment was also found 
in our study and confirmed our choice (see chapter 4) In addition, GPs were not forced to apply 
different protocols to their patients as the protocol for both taper programmes (with and without group 
CBT) were identical for the GP The fact that GPs were not blinded whether patients received 
additional group CBT could be seen as a limitation, but reflects daily/clinical practice as GPs have to 
refer patients for additional treatment The knowledge of the GP concerning the possibilities and 
effects of the taper scheme might have enlarged the success rate in the control group, which made our 
results rather conservative 
Taper protocol 
The taper protocol was based on that of Schweizer et al (1990), namely a fixed taper scheme, 25% of 
the baseline dosage per week, in six consultations with the GP 4 In contrast with clinical studies using 
stncl protocols, patients in our study were treated within the daily practice of their GP Although the 
mean number of consultations was 5 8, the number varied widely (range 1-10) which showed the 
pragmatic nature of the trial As presented in chapter 6, our tapenng-off programme had good 
feasibility in general practice and patients were satisfied with the treatment received 
As reported in chapter 3, the different taper rates did not influence outcome Other published 
tapenng-off studies used fixed taper schemes, although one study that used patient-tailored taper 
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schemes reported very high long-term success rates ' Due to the pragmatic nature of the Benzoredux 
project, our treatment can be considered to he somewhere between a fixed and a patient-tailored taper 
scheme Patient-tailored taper schemes with taper penods of up to 15 months and combined with 
additional pharmacological and psychological treatment, as performed by Ashton (1987), are, 
however, difficult to carry out in general practice ' 
Group cognitive-behavioural therapy 
The extent to which the therapists abided by the protocols ('adherence') was investigated by 
overheanng the audiotapes of a selection of treatment sessions by an independent assessor Adequate 
adherence, however, does not mean that the treatment was received satisfactorily Of the 73 patients 
assigned to additional group CBT, only 34 patients attended three or more sessions, which at least 
partly explains why this therapy did not have any effect It might reflect an overall resistance to group 
psychotherapy among long-term benzodiazepine users This would be in line with findings in other 
studies and with our interpretation of the personal reasons why patients refused to attend group 
therapy sessions 20 To get enough patients to make the therapy programme feasible for first-line 
treatment, we could not select on psychiatric diagnoses or age group The heterogeneous nature of the 
group might therefore have affected the group process 
The content of the therapy also has to be considered For cognitive-behavioural therapy, five 
sessions is not very many Treatment comprised group support, psycho-education, relaxation exercises 
and cognitive restructuring of the dysfunctional interpretation of withdrawal symptoms As many 
patients, especially low-dose users, may experience limited withdrawal symptoms, the usefulness of 
the cognitive part could be questioned 11n addition, the tape recordings showed that this part of the 
programme was the most difficult, especially for elderly patients Since the therapy was given 
simultaneous with the tapenng-off visits to the GP, it might have been too much for some patients 
Therefore, tapenng-off within therapy sessions without consultations with the GP or psychotherapy 
afterwards to prevent relapse might improve the results The latter option, however, was not supported 
by preliminary analyses of our data 
Primary outcome parameter 
The pnmary outcome parameter was the use of benzodiazepines When discussing our data, we have to 
bear in mind that prescnption data should be interpreted with caution First, not all patients fill their 
prescnption, secondly, there is no guarantee that the patient actually takes the filled prescnption, thirdly, 
a doctor could fail to record a wntten prescnption in the medical record, and fourthly, there is a 
possibility that patients may obtain benzodiazepines from other sources The bias caused by prescnptions 
of other medical specialists is limited as 89% of all benzodiazepine prescnptions are issued by general 
practitioners and only 9% by medical specialists, half of those being psychiatnsts ' In our study, 
psychiatnc treatment was an exclusion cntenon In addition to prescnption data, we also measured the 
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self-reported benzodiazepine usage. In the light of the dependence liability of benzodiazepines, the 
validity of the self-report assessment might be questionable. Geiselmann & Linden (1991), however, 
found an average compliance-coefficient of 0.8, which was similar to non-compliance with other forms 
of medication. 
Available long-term studies have assessed benzodiazepine use exclusively by self-report 
measurements or prescription data, while we assessed both. One may argue whether it would be 
worthwhile to obtain also benzodiazepine plasma levels or urine collections as in some short-term 
discontinuation trials. Orchs et al. ( 1987) did not detect the reported drug in the plasma of 25 of the 77 
benzodiazepine users. Conversely, in 10 of the 225 patients, benzodiazepines which were not 
reported were delected (diazepam, flurazepam). The discrepancies can partly be explained by 
intermittent use rather than regular use. In our study, a substantial number of patients used 
benzodiazepines intermittently during follow-up, which would threaten the validity of benzodiazepine 
plasma levels and urine collection. Moreover, the pragmatic nature of the study, the general practice 
setting, and the interview assessments at the patients' homes limited the possibilities for such analysis. 
If the patients had to give blood or urine samples, as well visit the hospital for checks, it would 
decrease the participation rate of the trial or lead to bias due to selectively missing data. The kappa for 
the agreement of reported and recorded benzodiazepine consumption at the end of follow-up was 0.73 
(p<0.001) in our study. Although adequate, the kappa is supposed to be conservative due to different 
time windows for reported and recorded benzodiazepine consumption. Inspection of our data also 
showed that most discrepancies were found in patients using benzodiazepines intermittently during 
follow-up. 
Benzodiazepine dosage levels 
Although high-dose benzodiazepine users were not excluded at forehand in the Benzoredux project, 
the average benzodiazepine dose levels in our study were rather low and within the therapeutic range. 
The average dosages used by our patients, however, were comparable to the average dose levels of 
long-term benzodiazepine users in a Dutch general practice. Before sending the letter containing stop 
advice, patients used on average 7.9 mg diazepam equivalent a day, while the sub group of patients 
who participated in the second stage of the project used on average 8.4 mg diazepam equivalent at this 
stage of the study. The latter patients used 5.9 mg diazepam equivalent a day between sending the 
letter and the start of tapenng-off. The 103 patients who actually underwent lapering-off (see figure 1, 
chapter 6) were transferred to an equivalent dose of 7.8 mg diazepam equivalent at the start of 
tapenng-off programme. Although these dosages seem rather low, these patients were not able to 
discontinue by themselves and thus really needed more help. 
As dose level before the intervention was an important predictor of outcome in our study, our 
results do not apply to high dose users. Stratified analyses of the minimal intervention showed a sharp 
decrease in effect for patients using more than 10 mg diazepam equivalent. Moreover, patients using 
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more than 10 mg diazepam equivalent had a significantly higher risk of relapse in the long term The 
tapenng-off programme showed almost comparable results with patients using more than 10 mg 
diazepam equivalent having a 1 5 lower chance to discontinue in the long-term An interesting finding 
with respect to the dose level at the start of tapenng-off was that this result was not confounded by the 
dosage reduction of patients by the minimal intervention Therefore our results suggest that a minimal 
intervention immediately before tapenng-off add to the effects of tapenng-off 
Secondary assessments 
Psychiatric diagnosis - It has been suggested that patients with a depressive disorder or a panic 
disorder have less success in benzodiazepine discontinuation ' 1 6 These reports suggest that diagnosing 
patients would contnbute to more sophisticated conclusions and the identification of important 
predictors However, the categoncal nature of such data would lead to a relatively small sample size 
per diagnosis, limiting the statistical power to find a significant interaction effect between outcome 
and diagnosis Therefore, we decided to only measure the seventy of some psychopathological 
symptoms In addition, the GHQ-12 scores suggested that approximately one third of the patients 
fulfilled the cntena for a psychiatnc disorder according to DSM-cntena As presented in chapter 9, no 
influence of depressive symptoms was found on taper outcome, while tension was only univanately 
related to outcome 
Sleep parameters - Although 58% of our patients reported use of benzodiazepines exclusively as 
hypnotics, we did not assess sleep parameters How important is it to establish sleep parameters'' 
According to guidelines for hypnotic treatment, patients may only be treated with benzodiazepines if 
day-time functioning is hindered Day-time functioning was measured with the POMS, GHQ-12, and 
the SF-36 at baseline as well as at follow-up As shown in chapters 6 and 8, these parameters were not 
affected by tapenng-off Secondly, the reliability and validity of the available sleep questionnaires was 
doubtful 7 and sleep EEG or sleep/wake dianes would burden patients too much 
Cost-diaries - The medical consumption during follow-up was measured with four 3-wcek diaries and 
linearly extrapolated over the whole follow-up penod The reliability of these measurements is 
questionable as only 12 of the 65 weeks were measured and the dropout was about 30% at each 
measurement The high vanation within, and between groups, reflects low reliability Moreover, the 
relationship between healthcare utilisation and the use or non-use of benzodiazepines was uncertain, 
while these costs exceeded the costs of the interventions combined with the pharmaceutical costs of 
benzodiazepines Therefore, the cost-effectiveness analysis from a societal perspective must be 





Sending a letter to long-term benzodiazepine users advising them to discontinue their use is an 
effective strategy for reducing benzodiazepine usage in general practice in the long term About 28% 
of the patients discontinued benzodiazepine usage over the short term, while 16% remained 
benzodiazepine-free dunng the 21-month follow-up Both success rates, as well as the amount of 
reduction among patients continuing use, were significantly supenor to long-term benzodiazepine 
users in the control practices The biggest impact was on patients using 10 mg diazepam equivalent or 
less The main predictor of relapse was a benzodiazepine dosage of more than 10 mg diazepam 
equivalent before receiving the letter Pharmacological and patient factors had no or limited impact on 
relapse 
Patients who continued benzodiazepine usage after receiving the letter could be helped to slop 
using through a systematic taper strategy However, only one out of six patients were prepared to 
participate in such a programme In the short-term, 62% of the patients receiving tapenng-off alone, 
and 58% receiving tapenng-off combined with group CBT, discontinued benzodiazepine use The 
Bendep-SRQ was found to be a valid and reliable questionnaire to estbablish the seventy of 
benzodiazepine dependence in this population Moreover, low scores on three of the four subscales 
were independently related to successful discontinuation 
The short-term success rates dropped to 36% and 29% when longitudinally monitored for 18 
months, but remained significantly supenor to the non-intervention control group Because other 
benzodiazepine discontinuation studies lack such a control group, this is the first study that provides 
evidence for both the short-term and long-term effectiveness of tapenng-off In addition, patients who 
continued using used significantly lower dosages compared with patients in the control group Neither 
intervention type nor outcome affected psychological functioning or the use of psychoactive agents or 
drugs Offenng a tapenng-off programme to patients, a low dosage before tapenng-off, a marked 
reduction of the benzodiazepine dosage after receiving the discontinuation letter, no use of alcohol, 
and a low score on the Bendep-SRQ Lack of compliance scale, all independently contnbuted to a 
more favourable outcome of tapenng-off during follow-up 
In general, patients were satisfied with the treatment received, while GPs thought the tapenng-
off programme feasible in general practice The economic evaluation did not show an increase in 
workload for the GP or an increase in medical consumption after the discontinuation programme 
Extrapolating the financial consequences showed that a reduction in benzodiazepine usage saved the 
intervention costs for tapenng-off alone, conected for regular healthcare, within 20 months of follow-
up 
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Implications for clinical practice 
This study clearly showed the effectiveness of a two-step treatment approach as a strategy to 
discontinue long-term benzodiazepine use in general practice. The effectiveness was shown by the 
proportion of patients able to stop completely as well as by the significant dosage reduction among 
patients who continued using. GPs judged both interventions feasible in general practice. 
The long-term effectiveness of the first stage, the minimal intervention, justifies its use as a pre-
selection for the tapering-off strategy. Moreover, a dosage reduction after a minimal intervention 
independently contributed to a more successful outcome of the tapering-off programme. Therefore, the 
first step in clinical practice should be to identify all long-term benzodiazepine users, and to advise 
them to reduce their usage. This advise should be as personal as possible, but it should also be as 
simple as possible. We would recommend the use of our discontinuation letter at this stage. Patients 
using more than 10 mg diazepam equivalent, who stop using after receiving the letter, need to be 
monitored as there is a significant risk of relapse. 
Patients not able to stop by themselves (and perhaps patients who relapse after the minimal 
intervention as well) should be motivated to participate in a tapering-off programme to support them 
in this process. Especially, since we found that patients do not detenorate after tapering-off or switch 
from benzodiazepine use to alcohol, nicotine or other psychotropic drugs. Moreover, we estimated that 
the costs of this treatment will be saved within 20 months of follow-up when provided in general 
practice. Other reasons for tapering-off in general practice are: (a) discontinuation success rates are 
similar in the different settings, (b) patients prefer to be treated by their GP instead of being referred, 
and (c) both GPs and patients were satisfied with the tapering-off programme. 
Additional psychological interventions should not be applied simultaneously with the tapering-
off programme, because the meta-analysis and the results of the Benzoredux-project did not show any 
additional effect. Patients who do not manage to stop in the short-term can be supported in a second 
attempt with the addition of carbamazepine or Imipramine (see chapter 3). Patients who use more than 
10 mg diazepam equivalent, who drank more than two units of alcohol a day or who score three or 
more on the Lack of compliance scale of the Bendep-SRQ have a significantly higher risk of failing in 
the long term. Perhaps these patients should receive second-line treatment straightaway. There is no 
obvious appropriate treatment (after the adding carbamazepine or imipraminc) for patients in general 
practice who cannot stop in the short term or who relapse in the long term. In these cases, the GP and 
the patient should analyse together the pros and cons of long-term benzodiazepine usage. Psychiatric 
screening would probably help identify the appropriate solution. 
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Recommendations for future studies 
The major difficulty when dealing with the problem of long-term benzodiazepine use in general 
practice is motivating patients to stop using and preventing relapse in the long term. Our findings 
therefore not only suggest the need to optimise discontinuation strategies, they also stress the 
importance of preventing long-term use. 
Future discontinuation studies should focus on how to motivate patients (and GPs) to 
discontinue benzodiazepine use. For example, researching the effect of introducing the stages of 
change like those used to motivate patients with alcohol or drug dependency. Since almost 50% of 
patients relapse after successful discontinuation, relapse prevention strategies should be developed, for 
example, reminders or supporting consultations with a GP or psychologist. In addition, the effect of 
treating underlying psychiatric disorders after tapering-off benzodiazepines should be evaluated to see 
if this helps prevent relapse. Finally, stepped care approaches should be evaluated to examine the 
effect of other additional therapies on tapenng-off, especially in treatment-refractory patients, such as 
pharmacological treatment or individual psychotherapy. These programmes should not be limited to 
general practice, but should also include referrals for second-line treatment of patients who fail to stop 
benzodiazepine usage in general practice. 
184 
Summary and general discussion 
References 
I College voor zorgverzekeringen. Gebruik van benzodiazepinen 1993 - 1998 Ediled by Piepenbnnk JF Geneesmiddelen 
Informatie Project (GlP-signaal) 2000 
2. Van der Waals FW, Mohrs J, Foeis M Sex differences among recipients of benzodiazepines in Dutch general practice 
British Medital Journal 1993,307:363-366. 
3. Lagro-Jansen ALM, Liberton UW. Profielen van regelmatige gebruikers van benzodiazepinen in een huisartspraktijk 
Nederlands Tijdschrift voor Geneeskunde 1993, 137(39) 1969-1973 
4. Schweizer E, Rickels K, Case WG, et al. Long-term therapeutic use of benzodiazepines II Effects of gradual taper 
Archives of General Psychiatry 1990; 47:908-915 
5. Schweizer E, Rickeis Κ, De Martinis Ν, et al The effect of personality on withdrawal severity and taper outcome in 
benzodiazepine dependent patients. Psychoogical Medicine 1998; 28 713-720. 
6. Rickels K, DeMartinis N, Garcia-Espana F, et al Imipramine and buspirone in treatment of patients with generalized 
anxiety disorder who are discontinuing long-term benzodiazepine therapy. American Journal of Psychiatry 2000, 
157.1973-1979. 
7 Higgitt A, Golombok S, Fonagy P, et al Group treatment of benzodiazepine dependence Briti\h Journal of Addiction 
1987; 82 517-532 
8 Sanchez-Craig M, Cappell H, Busto U, et al Cognitive-behavioural treatment for benzodiazepine dependence· a 
comparison of gradual versus abrupt cessation of drug intake British Journal of Addiction 1987,82 1317-1327. 
9 Otto MW, Pollack MH, Sachs GS, et al Discontinuation of benzodiazepine treatment, efficacy of cognitive-behavioral 
therapy for patients with panic disorder. American Journal of Psychiatry 1993; 150:1485-1490 
10 Elsesser K, Sartory G, Maurer J. The efficacy of complaints management training in facilitating benzodiazepine 
withdrawal. Behavioural Research and Therapies 1996,34 149-156 
II Chamey DA, Paraherakis AM, Gill KJ. The treatment of sedative-hypnotic dependence: evaluating clinical predictors of 
outcome. Journal of Clinical Psychiatry 2000, 61 · 190-195 
12 Vissers FHJA Gebruik van slaap- en kalmeringsmiddelen in hel dagelijks leven Determinanten, gevolgen en de rol van 
de huisarts Dissertatie Universiteit van Maastricht, 1998 
13. Zilman FG, Couvée JE Chronic benzodiazepine use in general practice patients with depression an evaluation of 
controlled treatment and taper-off Report on behalf of the Dutch Chronic Benzodiazepine Working Group. British 
Journal of Psychiatry 2001, 178(4) 317-324 
14. Greenblatt DJ, Shadcr RI, Harmatz JS. Implications of altered drug disposition in the elderly Studies of 
benzodiazepines Journal of Clinical Pharmacology 1989; 29 866-872 
15 Pomara N, Stanley B, Block R, et al Increased sensitivity of the elderly to the central depressant effects of diazepam 
Journal of Clinical Psychiatry 1985: 46 185-187 
16. Lord SR, Anstey KJ, Williams P, et al Psychoactive medication use, senson-molor tunction and falls in older women 
British Journal of Clinical Pharmacology 1995;(39) 227-234 
17 O'Leary M: A novel approach to tackling the "benzodiazepine problem" in general practice. Pssihiatnc Bulletin 1989, 
13 180-181 
18 Bashir K, King M, Ashworth M Controlled evaluation of brief intervention by general practitioners to reduce chronic 
use of benzodiazepines British Journal of General Practice 1994, 44 408-412 
19 Cormack MA, Sweeney KG, Hughes-Jones H, Foot GA Evaluation of an easy, cost-effective strategy for cutting 
benzodiazepine use in general practice. British Journal of General Pracitice 1994, 44.5-8 
20 Cormack MA, Owens RG, Dewey ME The effect of minimal interventions by general practitioners on long- term 
benzodiazepine use Journal of the Royal College of Geneneral Practitioners 1989, 39:408-411 
21. Jones D Weaning elderly patients off psychotropic drugs in general practice' a randomised controlled Inai Health 
Trends 1990;22:164-166 
22. De Berk HAA. Over gebruik van benzodiazepmepreparaten in de huisartsenpraktijk Dissertatie 1988. Nijmegen ISBN 
90-9002477-8 
23. Vissers FHJA, Jongbloet AJ, Knottnerus JA, et al. Benzodiazepinen de gebruiker en zijn huisarts. Bijwerkingen, 
satisfactie, afhankelijkheid en sloppen gezien door de bnl van gebruiker en huisarts Huisarts en Wetenschap 1988, 
41(7).329-334. 
24. Tattersall ML, Hallslrom C Self-help and benzodiazepine withdrawal Journal of Affective Disorders 1992, 24193-198 
185 
Chapter 11 
25 Morgan J D , Wnght D J & Chryslyn H Pharmacoeconomic evaluation of a patient education letter aimed at reducing 
long term prescnbing of benzodiazepines Pharmacy World and Science 2002, 24 231 236 
26 De Brugh S, Mant A, Matlick RP, et al A controlled trial of educational visiting to improve benzodiazepine prescnbing 
in general practice Australian Journal of Public Health 1995, 19 142-148 
27 Holm M Intervention against long-term use of hypnotics/sedatives in general practice Scandinavian Journal of Primary 
Healthcare 1990, 8 113-117 
28 Kan CC, Breteler MH, Zitman FG High prevalence of benzodiazepine dependence in out-patient users, based on the 
DSM HI-Rand ICD lOcntena Acta Psychiatwra Scandinavita 1997,96 85-93 
29 Linden M, Bar T, Geiselmann Β Patient treatment insistence and medication craving in long-term low- dosage 
benzodiazepine prescnptions Psychological Medicine 1998,28 721-9 
30 Rüssel J, Lader ΜΗ Guidelines for the prevention and treatment of benzodiazepine dependence on behalf of the 
Substance Abuse Committee of the Mental Health Foundation Edited by Rüssel J, Lader ΜΗ The Mental Health 
Foundation, 1992 
31 Ashton Η Benzodiazepine withdrawal outcome in 50 patients Bilishr Journal of Addiction 1987,82 665-671 
32 Waltz J, Addis ME, Koemer K, et al Testing the integnty of a psychotherapy protocol Assessment of adherence and 
competence Journal of Consultative Clinical Psychology 1993,61 620-630 
33 Busto U, Sellers EM, Naranjo CA, et al Withdrawal reaction after long term therapeutic use of benzodiazepines Ν Engl 
J Med 1986,315 854 859 
34 Geiselmann Β, Linden M Prescnplion and intake patlerns in long-term and ultra-long term benzodiazepine treatment in 
pnmay care practice Pharmacopsychiatnca 1991, 24 55-61 
35 Orchs HR, Miller LG, Greenblalt DJ, et al Actual versus reported benzodiazepine usage by medical outpatients 
Euopean Journal of'Clinical Pharmacology 1987, (32) 383 388 
36 Lader M Anxiety or depression during withdrawal of hypnotic treatments Journal of Psychosonwlic Research 1994, 
(38) 113-123 
37 Van Diest R, Milius H, Markusse R, et al De Slaap-Waak Ervanng Lijst Tijdschrift voor Sociale Gezondheidszorg 
1989,67 343-347 
186 
Nederlandse samenvatting (Summary in Dutch) 
Inleiding 
Achtergronden van (langdurig) benzodiazepinegebruik 
Vraagstellingen en onderzoeksopzet 
Het Benzoredux project 
Samenvatting en conclusies Deel Ι Literatuur overzicht 
Deel II. Minimale interventie 
Deel III Korte termijn resultaten van gereguleerde dosisreductie 
Deel IV Lange termijn resultaten van gereguleerde dosisreductie 
Consequenties voor de klinische praktijk 
Aanbevelingen voor verder onderzoek 
187 
Nederlandse samenvatting (Summary in Dutch) 
Inleiding 
In deze Nederlandstalige samenvatting wordt kort ingegaan op de achtergronden van hel onderzoek en 
het onderzoeksdesign van het Bcnzoredux project waarop dit proefschrift grotendeels gebaseerd is 
Vervolgens worden de belangrijkste onderzoeksbevindingen van de 4 delen van het proefschrift 
samengevat Voor gedetailleerde bespreking van deze resultaten wordt verwezen naar de discussies 
van de afzonderlijke hoofstukken De samenvatting eindigt met enkele implicaties voor de klinische 
praktijk en suggesties voor verder onderzoek 
Achtergronden van (langdurig) benzodiazepinegebruik 
Benzodiazepinen is de verzamelnaam van een groep geneesmiddelen voor de behandeling van 
slaapstoornissen en angststoornissen Deze stoffen behoren tot de meest voorgeschreven 
geneesmiddelen in de Westerse samenleving Ten tijde van de start van dit onderzoek in 1998 kregen 
1 9 miljoen Nederlanders in totaal 11 6 miljoen recepten voor een benzodiazepine Negenentachtig 
procent van deze voorschriften werd afgegeven door de huisarts Een prevalentieschatting uitgaande 
van onze definitie van langdurig gebruik (gebruik meer dan 3 maanden) komt uit op ca 3%, 
overeenkomend met 72 patiënten in een gemiddelde huisartspraktijk 
Benzodiazepinen zijn uiterst effectieve geneesmiddelen voor een kortdurende behandeling van 
slaap- en angststoornissen Gerandomiseerd en gecontroleerd onderzoek naar de effectiviteit op lange 
termijn is echter nauwelijks voorhanden Enkele uitzonderingen daargelaten, geven zowel nationale 
als internationale richtlijnen betreffende het gebruik van benzodiazepinen dan ook aan dat deze 
middelen slechts kortdurend moeten worden voorgeschreven Daarentegen zijn de bijwerkingen van 
langdurig gebruik de afgelopen decennia steeds meer naar voren gekomen Zo blijkt dat 40%, 
respectievelijk 52% van de gebruikers m de Nederlandse huisartspraktijk afhankelijk is van deze 
middelen volgens de criteria van de DSM-III-R, respectievelijk ICD-10 Het gebruik van 
benzodiazepinen leidt lot een afname van de geheugenfunctie en mogelijk predisponeert het tot een 
versnelde cognitieve achteruitgang Bovendien hebben gebruikers een toegenomen kans op een 
verkeersongeluk en een verhoogd risico op vallen met als gevolg een heupfracluur Hoewel 
benzodiazepinen relatief veilig zijn bij overdosering, worden zij bij bijna de helft van alle 
suicidepogingen gebruikt Uit Engels onderzoek blijkt dat per miljoen prescnplies voor 
benzodiazepinen 5 9 mensen overlijden als gevolg van het gebruik Ondanks de relatieve lage prijs 
voor een benzodiazepine, lopen de farmaceutische kosten in Nederland door het frequente en 
langdung gebruik van deze middelen op lot meer dan 95 miljoen euro per jaar De behandeling van 
heupfracturen als gevolg van het gebruik van benzodiazepinen wordt geschat op meer dan 16 miljoen 
euro per jaar 
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De discrepantie lussen de relatief hoge prevalentie van langdung benzodiazepinegebruik en de 
richtlijnen voor het gebruik van deze middelen wordt multifactoneel veroorzaakt Zowel 
eigenschappen van het geneesmiddel zelf, als karakteristieken van de patient, arts en praklijkvoenng 
lijken een rol te spelen Deze discrepantie heeft geleidt tot de ontwikkeling van diverse 
behandelstrategieen om langdung benzodiazepinegebruikers te helpen hun gebruik te staken Deze 
behandelstrategieen kunnen worden onderverdeeld in minimale interventies en gereguleerde 
dosisreductie programma's Met behulp van minimale interventies worden patiënten uitgenodigd op 
eigen kracht te stoppen door hen bewust te maken van de bezwaren van langdung gebruik 
(bijvoorbeeld een brief met stopadvies of een voorlichtingsbijeenkomst) Hiermee lukt hel 1 op de 5 
patiënten het gebruik te beëindigen Lange termijn effecten van minimale interventies zijn echter nooit 
onderzocht Gereguleerde dosisreductie is een intensievere behandelingsvorm, waarbij de dosenng 
geleidelijk wordt verlaagd onder begeleiding van een arts Een dergelijk aanpak leidt bij 2 van de 3 
patiënten tot succes Omdat alleen gemotiveerde gebruikers deelnemen aan gereguleerde dosisrcductie 
en deze interventie nooit binnen een gerandomiseerde opzet is vergeleken met het natuurlijk beloop 
van benzodiazepinegebruik onder langdung gebruikers, is de werkelijke effectiviteit van deze 
behandeling feitelijk onbekend Bovendien is follow-up onderzoek schaars en spreken beschikbare 
resultaten elkaar tegen De economische consequenties van deze behandeling zijn zelfs nog nooit 
geëvalueerd Verder is het opvallend dat de meeste studies zijn uitgevoerd in de tweede lijn, terwijl de 
meerderheid van de langdung benzodiazepinegebruikers hun recepten via de huisarts verkrijgt 
Diverse psychotherapeutische of farmacologische behandelingen zijn voorgesteld om het effect van 
gereguleerde dosisreductie te vergroten Desondanks is de toegevoegde waarde van adjuvante 
psychotherapie nooit in een gerandomiseerd, gecontroleerd onderzoek geëvalueerd Tenslotte wordt in 
de praktijk herhaaldelijk aanbevolen te starten met een minimale interventie om vervolgens alleen 
patiënten die niet op eigen kracht kunnen stoppen gereguleerde dosisreductie aan te bieden Een 
dergelijke trapsgewijze aanpak is eveneens nog nooit onderzocht 
Vraagstellingen en onderzoeksopzet 
De hoofdvraagstelling van dit proefschnft ncht zich op het evalueren van verschillende 
behandelmethoden om langdung benzodiazepinegebruik te staken Specifieke vraag- en doelstellingen 
waren 
• Het op systematische wijze samenvatten van de huidige kennis om patiënten te helpen hun 
benzodiazepinegebruik te staken 
• Het evalueren van de lange termijn effecten op het voorschnjven van benzodiazepinen na een 
minimale interventie strategie in de huisartspraktijk 
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• Het evalueren van zowel de korte als lange termijn resultaten van gereguleerde dosisreductie 
met en zonder aanvullende psychotherapeutische ondersteuning onder patiënten die hun 
benzodiazepinegebruik niet konden stoppen met behulp van een minimale interventie. 
• Het verkrijgen van inzicht in enkele factoren die het effect van gereguleerde dosisreductie 
beïnvloeden, waarbij de male waarin mensen verslaafd zijn aan deze middelen in het bijzonder 
wordt onderzocht. 
• Het evalueren van de kosteneffectiviteit van de twee gereguleerde dosisreduclie programma's 
ten opzichte van een reguliere behandeling, dat willen zeggen geen interventie gericht op het 
staken van benzodiazepinegebruik. 
De studie startte met een meta-analyse van eerder onderzoek met betrekking tot het slaken van 
langdurig benzodiazepinegebruik (deel I). Daarna werden opeenvolgende behandelstratcgieën in de 
huisartspraktijk geëvalueerd (deel II, III en IV). Deze gegevens werden verkregen binnen een groter 
onderzoeksproject: hel Benzoredux project. 
Het Benzoredux project 
Het Benzoredux project werd uitgevoerd onder 58 huisartsen in Nederland, werkzaam in 30 praktijken 
met in totaal 118082 patiënten. In deze praktijken werden alle patiënten geselecteerd die het jaar 
voorafgaande aan het project een recept hadden ontvangen voor een benzodiazepine. Uit deze lijst 
werden 2964 langdurig benzodiazepinegebruikers (langer dan drie maanden) geïdentificeerd, waarvan 
uiteindelijk 2004 patiënten voldeden aan de criteria voor het Benzoredux project. Deze 2004 patiënten 
werden geïncludeerd in de eerste fase van het onderzoek en kregen allen een minimale interventie, te 
weten een persoonlijke brief van hun huisarts waarin zij gewezen werden op de bezwaren van 
langdurig gebruik en geadviseerd werden hun gebruik geleidelijk te staken (stopbrief)· Het 
medicatiegebruik van deze patiënten werd geëvalueerd met behulp van het elektronisch medisch 
dossier van de huisarts en vergeleken met het 'natuurlijk beloop' van het benzodiazepinegebruik van 
langdurig gebruikers in 16 retrospectief geworven controlepraktijken (zie hoofdstuk 4). 
Alle stopbrief ontvangers werden 3 maanden later uitgenodigd op het spreekuur van hun 
huisarts. Van de 1321 patiënten die hun huisarts daadwerkelijk bezochten, zeiden 285 patiënten 
gestopt te zijn en 1036 de benzodiazepinen nog te gebruiken. Aan de stoppers werd toeslemming 
gevraagd voor een intensievere follow-up studie bestaande uit een 'baseline' en een follow-up meting 
met behulp van zelfbeoordelingsvragenlijsten (zie hoofdstuk 5). Aan de niet-sloppers werd deelname 
gevraagd aan de tweede interventie van het Benzoredux project; een gerandomiseerde, gecontroleerde 
trial (RCT). In totaal werden 180 van 1036 patiënten (17%) gerandomiseerd over gereguleerde 
dosisreductie gecombineerd met gelijktijdige groeps cognitieve-gedragstherapie (CGT; n=73), 
gereguleerde dosisreductie alleen (n=73) en een controle groep waarin patiënten geen hulp kregen bij 
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hel staken van hun benzodiazepinegebruik (n=34) Het medicatiegebruik van deze patiënten werd 
eveneens geëvalueerd met behulp van het elektronisch medisch dossier Ter aanvulling kreeg deze 
groep drie inlervicwmetingen bestaande uit zelfbeoordelingsvragenhjsten welke werden afgenomen op 
baseline en 3, respectievelijk 18 maanden follow-up en hielden zij vijf keer een 'kostcndagboekjc' bij 
ter evaluatie van de medische consumptie gedurende 3 opeenvolgende weken (zie figuur 1, hoofdstuk 
2) 
Samenvatting en conclusies 
Deel I: Literatuuroverzicht 
Voor het bestuderen van de effecten van behandelingen gencht op hel staken van langdurig 
benzodiazepinegebruik (langer dan 3 maanden) werd een meta-analyse vemcht Met behulp van een 
systematische zoekstrategie werden 60 originele publicaties geïdentificeerd, betreffende vier typen 
interventies, te weten minimale interventies, gereguleerde dosisrcductie zonder aanvullende 
behandeling of gecombineerd met psychotherapie en/of farmacotherapie Overzichtsartikelen, 
dierexperimenteel onderzoek, effect onderzoek naar benzodiazepinen met een afbouwtraject nadien en 
casusbeschrijvingen met minder dan vijf patiënten werden geexcludeerd Na het poolen van data werd 
per behandelvorm de succeskans geschat en het effect van diverse variabelen en hun onderlinge 
interactie berekend met behulp van Pearson Chi-kwadraat toetsen 
Het effect van minimale interventies werd in 5 studies onderzocht, waarvan 3 studies het effect 
binnen een gerandomiseerd design vergeleken met een controlegroep bestaande uit reguliere medische 
zorg Zes tot negen maanden na de interventie had 22% van de gebruikers hun benzodiazepinegebruik 
volledig geslaakt, tegenover 9% in de controle groepen Minimale interventies waren alleen in de 
huisartspraktijk uitgevoerd 
Met behulp van gereguleerde dosisreductie kon tweederde van de patiënten hun 
benzodiazepine-gebruik staken Dit effect werd verbeterd door patiënten alvorens af te bouwen om te 
zetten op een langwerkend benzodiazepine indien zij poliklinisch werden begeleid of wanneer zij meer 
dan 15 mg diazepam equivalent per dag gebruikten Het theoretische voordeel van het omzetten van 
het gebruikte benzodiazepine naar een langwerkend middel is een stabielere bloedspiegel en een 
geleidelijker daling hiervan tijdens de behandeling Klinische behandeling leidde eveneens tot een 
hogere succeskans vergeleken met een ambulante behandeling Tijdens klinische behandeling bleek de 
hoogte van de dosering niet gerelateerd aan het behandelresultaat, terwijl ambulante behandeling tot 
een slechter resultaat leidde bij patiënten die hogere dosenngen gebruikten Hoewel dosisverrrundenng 
op gelelde van de symptomen van de individuele patient de beste resultaten gaf en gereguleerde 
dosisreductie weer supeneur leek ten opzicht van abrupt staken, moet worden vermeld dat deze 
behandelingen nooit binnen één studie met elkaar vergeleken zijn Hoewel de data te beperkt waren 
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om de succeskans voor de verschillende psychiatrische stoornissen apart te evalueren, werden 
aanwijzingen gevonden dat multipele drugsgebruikers en patiënten met een slaapstoornis moeilijker te 
behandelen waren. Wij vonden geen invloed van hel jaar van publicatie van de studie, de duur van het 
benzodiazepinegebruik, en de setting. 
Studies waarin psychotherapeutische ondersteuning naast een dosisreductie programma werd 
onderzocht toonden geen additioneel effect hiervan voor de 'gemiddelde' benzodiazepinegebruiker. 
Definitieve conclusies werden beperkt doordal de behandelgroepen klein waren. Ze bestonden uit 
maximaal 20 patiënten per behandelingsgroep. Slechts 2 studies hadden een gerandomiseerde, 
gecontroleerde opzet. De resultaten van deze twee studies suggereren dat het effect van adjuvante 
psychotherapie afhankelijk is van de onderliggende aandoening. Zo blijkt het de kans op een 
succesvolle afbouw voor patiënten met een paniekstoornis te verbeteren en voor patiënten met een 
afhankelijkheid van multipele middelen te verslechteren. Tenslotte resulteerde het toevoegen van de 
psychofarmaca carbamazepine en imipramine tot een hogere succeskans van gereguleerde 
dosisreductie. 
Een van de belangrijkste beperkingen met betrekking tot de huidige stand van zaken is het 
gebrek aan follow-up resultaten. De lange termijn effecten van minimale interventies zijn nooit 
onderzocht. Slechts vijf studies evalueerden follow-up resultaten (langer dan 1 jaar) van gereguleerde 
dosisreduclie. Aggregatie van deze data was echter niet mogelijk omdat succes percentages fors 
verschilden tussen de studies afhankelijk van de gehanteerde definitie van benzodiazepine abstinentie 
(range 16 - 82%). Tenslotte bleken trapsgewijze behandelingsprogramma's, zoals onderzocht in het 
Benzoredux project, nimmer te zijn geëvalueerd. 
Deel Π: Minimale interventie 
In hoofdstuk 4 zijn de lange termijn effecten van de eerste interventie van het Benzoredux-project, te 
weten de stopbrief, geëvalueerd gedurende een 21 maanden durende follow-up periode. In verband 
met computerproblemen in een drietal huisartspraktijken en uitval van een aantal patiënten door 
verhuizingen, overlijden en technische problemen bij de extractie van follow-up gegevens, omvatte de 
uiteindelijke onderzoekspopulatie 2248 langdurig benzodiazepinegebruikers (i.p.v. de aanvankelijk 
geïdentificeerde 2964). Van deze groep ontvingen 1601 patiënten daadwerkelijk de stopbrief (zie 
figuur 1, hoofdstuk 4). Drie tot zes maanden na verzending van de stopbrief kregen 28% (446/1601) 
van de stopbrief ontvangers geen recepten meer voor benzodiazepinen, hetgeen iets hoger was dan het 
gemiddelde succespercentage van een minimale interventie zoals gevonden in hoofdstuk 3. Na 21 
maanden bleek 16% van alle stopbriefontvangers (251/1601) volledig abstinent te zijn gebleven. 
Ter voorkoming van het Hawthome-effect werd retrospectief een geblindeerde controlegroep 
gerekruteerd in 16 huisartspraktijken met 2061 langdurig benzodiazepinegebruikers, waarvan 
uiteindelijk voor 1585 benzodiazepinegebruikers alle gegevens beschikbaar waren voor analyse. De 
in- en exclusie criteria, zoals gehanteerd voor het verzenden van de stopbrief, werden niet toegepast op 
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deze patiënten ter voorkoming van recall bias Vergelijking van de 1585 patiënten uit de 
controlepraktijken met de 2248 patiënten uit de experimentele huisartspraktijken, toonde een 
significant hogere mate van reductie van het totale benzodiazepinegebruik in de experimentele 
praktijken (24% versus 5%, p<0 01) Op korte termijn (4-6 maanden na verzending stopbnef) bleek de 
kans om te stoppen twee keer zo groot in de experimentele praktijken vergeleken met de 
controlepraktijken (24% versus 12%, p<0 01) Vergeleken met met-stoppers gebruikten stoppers 
significant lagere dosenngen op baseline Bovendien bleef van de stoppers uit de experimentele 
praktijken (24%, n=536) 56% volledig gestopt tijdens follow-up, tegenover 42% van de stoppers uit de 
controlegroep (12%, n=183) (p<0 01) De gemiddelde dosenng van stoppers die terugvielen was aan 
het eind van de follow-up significant lager dan de dosenng op baseline 
In hoofdstuk 5 wordt de follow-up studie gepresenteerd van de stoppers die toestemming gaven 
voor de aanvullende, prospectieve follow-up metingen Het doel van dit hoofdstuk was het beschnjven 
van prescnpliepatronen tijdens terugval, het evalueren van het gebruik van overige psychofarmaca, het 
identificeren van voorspellers van terugval, en tenslotte een evaluatie van het psychisch functioneren 
Van de 285 patiënten die dne maanden na ontvangst van de stopbnef aangaven gestopt te zijn 
gaven 109 (38%) toestemming voor deelname aan deze follow-up studie Na een gemiddelde follow-
up duur van meer dan 2 jaar bleef 49% volledig abstinent Dne van de vijf patiënten die terugvielen 
hadden tijdens follow-up betere gebruikspatronen dan voor ontvangst van de stopbnef, hetgeen wil 
zeggen dat zij nu intermitterend benzodiazepinen gebruikten in penoden van minder dan 90 dagen 
Het al dan niet gebruik van benzodiazepinen tijdens follow-up was niet gerelateerd aan het psychisch 
functioneren Bovendien trad geen verandenng op in hel voorschnjven van andere psychofarmaca 
Twee onafhankelijke predictoren voor terugval werden geïdentificeerd gebruik van meer dan 10 mg 
diazepam equivalenten per dag voor ontvangst van de stopbnef en een slechtere algemene 
gezondheidsbeleving door de patient 
Deel III: Korte termijn effecten van gereguleerde dosisreductie 
Deel III bespreekt het korte termijn effect van de tweede stap in het Benzoredux project, te weten de 
uitkomst van de gerandomiseerde, gecontroleerde vergelijking van gereguleerde dosisreductie met en 
zonder cogmtieve-gedragstherapie (CGT) met een controlegroep waann geen behandeling wordt 
gegeven gencht op het gebruik van benzodiazepinen De resultaten in deel III zijn gebaseerd op 
zelfgerapporteerde uilkomstmaten zoals verkregen uil de inlerviewmetingen bij patiënten thuis 
In hoofdstuk 6 worden de korte termijn effecten op zelfgerapporteerde benzodiazepinegebruik 
en psychologisch functioneren geanalyseerd op basis van een intention-to-treat principe (gegevens 
beschikbaar voor 141 patiënten, 78%) Beide expenmentele behandelingen gaven significant hogere 
succes percentages te zien dan de controlegroep 58% voor gereguleerde dosisreductie met CGT, 66% 
voor gereguleerde dosisreductie alleen, en 21% voor de controlegroep In tegenstelling tot onze 
hypothese, bleek toevoeging van CGT het succes percentage niet te verhogen 
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Daarnaast werden enkele interessante secundaire bevindingen gedaan Het psychisch 
functioneren van patiënten bleef onveranderd, ongeacht het al dan niet gebruiken van benzodiazepinen 
en ongeacht het al dan niet ontvangen van behandeling Bovendien bleek dat 23 van de 146 (16%) 
patiënten toebedeeld aan één van de experimentele behandelingen hun gebruik alsnog op eigen kracht 
slaakten tijdens de wachttijd voor de behandeling De bereidheid tot deelname aan gereguleerde 
dosisreduclie was laag slechts 17% (180/1036) van de beschikbare patiënten participeerde 
uiteindelijk Tevens was de opkomst tijdens de psychotherapie sessies laag 65% van de patiënten 
toebedeeld aan gereguleerde dosisreductie met CGT bezocht dne of meer sessies Desondanks was de 
overgrote meerderheid van de deelnemende patiënten tevreden met de verkregen behandeling en bleek 
gereguleerde dosisreductie goed uitvoerbaar in de huisartspraklijk 
In hoofdstuk 7 wordt een cross-vahdatie vemcht van de Benzodiazepine Dependence Self-
Report Questionnaire (Bendep-SRQ) om de bruikbaarheid hiervan in de klinische praktijk te testen 
De Bendep-SRQ is een zelfbeoordelingsvragenhjst die de ernst van de afhankelijkheid van 
benzodiazepinen meet op vier domeinen, te weten 'bewustzijn van problematisch gebruik', 
'preoccupatie met betrekking tot de beschikbaarheid van benzodiazepinen', 'gebrekkige trouw aan het 
therapeutisch regime', en 'onttrekking' Hoewel de psychometrische eigenschappen van deze 
vragenlijst in cross-sectioneel onderzoek veelbelovend zijn gebleken, is de predictieve validiteit en de 
sensitiviteit voor verandering tijdens benzodiazepine detoxificatie nooit onderzocht 
Rasch-analyse op de baselmegegevens van de Bendep-SRQ toonde voor dne van de vier 
subschalen een goede schaalbaarheid De schaalbaarheid van de preoccupatieschaal kon echter niet 
worden bevestigd, hetgeen het belang van cross-vahdatie in verschillende, klinisch relevante 
populaties onderstreept Alle subschalen hadden een zeer goede betrouwbaarheid (subject 
discnnunabiliteit, item discnminabihteit) en een adequate construct en discriminante validiteit 
Alle subschalen droegen significant bij aan het voorspellen of een patient al dan niet in staal was 
zijn gebruik te staken met behulp van gereguleerde dosisreductie Met uitzondering van de schaal 
'problematisch gebruik' was de voorspellende waarde onafhankelijk van andere prognostische 
vanabelen (dosering benzodiazepine en roken) De schalen 'problematisch gebruik' en 'preoccupatie' 
waren sensitief voor veranderingen tijdens follow-up Deze resultaten pleiten voor afname van de 
Bendep-SRQ voor en na benzodiazepine detoxificatie, zowel in onderzoek als in de klinische praktijk 
Deel IV: Lange termijn resultaten van gereguleerde dosisreductie 
De 18-maanden follow-up studie bestond uit (a) een geautomatiseerde extractie van alle prescriptie 
data uit het elektronisch medisch dossier van de huisarts, (b) een follow-up meting na 18 maanden met 
behulp van zelfbeoordehngsvragenlijsten, identiek aan de meting op baseline, en (c) vijf 
kostendagboekjes die een periode van 3 weken bestreken en ingevuld werden op baseline en na 3, 6, 
12 en 18 maanden follow-up 
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In hoofdstuk 8 wordt het longitudinale beloop van het benzodiazepinegebruik, het gebruik van 
overige psychofarmaca, en het psychologisch functioneren na 18 maanden geëvalueerd. De prescriptie 
data waren volledig beschikbaar voor 170 van 180 (94%) patiënten in de trial. Vijftig patiënten (29%) 
ontvingen geen enkele benzodiazepine prescriptie gedurende de follow-up. Na 18 maanden bleek 
gereguleerde dosisreductie zonder CGT een significant hoger succes percentage te hebben dan de 
controle groep (36% versus 15%, p=0.03). Evenals op de korte termijn had toevoeging van CGT aan 
gereguleerde dosisreductie geen meerwaarde. Patiënten die deelnamen aan één van de experimentele 
behandelingen maar die hun gebruik niet volledig slaakten, gebruikten significant lagere doseringen 
tijdens follow-up in vergelijking met patiënten uit de controle groep. Bovendien kregen 48% van de 
patiënten toegewezen aan gereguleerde dosisreductie met CGT en 55% van de patiënten toegewezen 
aan gereguleerde dosisreductie zonder CGT benzodiazepinen nu intermitterend voorgeschreven in 
perioden van minder dan 90 dagen. Patiënten kregen niet vaker andere psychofarmaca voorgeschreven 
en gingen ook niet meer nicotine of alcohol consumeren. Hoewel patiënten milde angst- en 
depressieve symptomen rapporteerden, had noch het type interventie, noch de uitkomst hiervan 
invloed op het psychologisch functioneren. 
Hoofdstuk 9 presenteert de uitkomsten van een Cox-regressic analyse ter identificatie van 
onafhankelijke voorspellers voor het kunnen staken van benzodiazepinen op lange termijn. Als 
potentiële voorspellers werden benzodiazepine (gebruiks)karakteristieken, psychopathologie, 
persoonlijkheidskenmerken en karakteristieken van (benzodiazepine) afhankelijkheid meegenomen. 
Onafhankelijke voorspellers van succes waren: (a) het aanbieden van een dosisreduclie programma 
met en zonder CGT, (b) een lagere benzodiazepine dosering bij aanvang van de gereguleerde 
dosisreductie, (c) een substantiële dosisreductie op eigen kracht na een minimale interventie direct 
voor aanvang van de gereguleerde dosisreductie, (d) een lage score op schaal 'gebrek aan 
therapietrouw' van de Bendep-SRQ, en (e) geen gebruik van alcohol. Slechts 2 van 38 patiënten die 
meer dan 10 mg diazepam equivalenten gebruikten, die drie of hoger scoorden op de schaal 'gebrek 
aan therapietrouw' van de Bendep-SRQ, of die meer dan 2 eenheden alcohol per dag consumeerden 
lukte hel om langdurig abstinent te blijven. 
Hoofdstuk 10 presenteert een economische evaluatie door de incrcmentele kostcn-effectiviteits 
ratios (= kosten per eenheid extra effect) van gereguleerde dosisreductie met en zonder CGT te 
bepalen ten opzichte van reguliere huisartsenzorg, dat wil zeggen het verlenen van normale medische 
zorg zonder gerichte interventie op hel slaken van benzodiazepinegebruik. A priori werd een kosten-
effectiviteits analyse vanuit maatschappelijk perspectief gepland, onder de voorwaarde dat de kwaliteit 
van leven zou verbeteren of constant zou blijven. Aan deze voorwaarde werd voldaan, aangezien noch 
het type interventie, noch de uitkomst enig effect had op de kwaliteit van leven zoals gemeten met 
twee zelfbeoordelingsvragenlijsten (Short-Form 36 en Health Utility Index 3). 
Gezien de fluctuaties in de medische consumptie zoals gemeten met de vijf koslendagboekjes, 
zowel binnen als tussen de drie condities, werden vraagtekens geplaatst bij de betrouwbaarheid van 
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deze gegevens Bovendien overstegen de kosten voor de medische consumptie zoals vastgesteld in de 
koslendagboekjes, alsmede de kosten voor medicatiegebruik anders dan benzodiazepines, vele malen 
de gezamenlijke kosten voor de interventie en het benzodiazepinegebruik tijdens follow-up, terwijl 
geen relatie met het gebruik van benzodiazepinen tijdens follow-up werd gevonden, noch met de 
verkregen behandeling Om deze redenen werden tevens incrementele kosten-effecliviteit ratios 
berekend vanuit twee andere perspectieven een beperkt farmaceutisch perspectief beperkt tol de 
interventiekosten en de kosten voor benzodiazepinegebruik sec en een uitgebreid farmaceutisch 
perspectief waarin ook de kosten van alle overige prescripties werden meegenomen Zowel 
gereguleerde dosisreductie met als zonder CGT leidde tot een significante reductie in kosten voor 
benzodiazepinen Hoewel de incrementele kosten-effectivileits ratios beter waren voor gereguleerde 
dosisreductie zonder CGT dan voor gereguleerde dosisreductie met CGT waren de verschillen klein 
Extrapolatie van onze data het zien dat na correctie voor de effecten van reguliere zorg, de kosten van 
gereguleerde dosisreductie zonder CGT na 20 maanden waren terugverdiend door reductie in de 
kosten voor benzodiazepinegebruik 
Consequenties voor de klinische praktijk 
Deze studie bewijst dat een getrapte aanpak ter reductie van langdurig benzodiazepinegebruik in de 
huisartspraktijk zowel effectief als goed uitvoerbaar is Deze effectiviteit betreft zowel de proportie 
patiënten die hun gebruik volledig stoppen alsmede een significante dosisreductie onder met-stoppers 
De effectiviteit van een minimale interventie (lees stopbrief) op lange termijn rechtvaardigt het 
gebruik als preselectie voor gereguleerde dosisreductie Bovendien blijkt dosisvermindenng naar 
aanleiding van een stopbnef het succes van gereguleerde dosisreductie onafhankelijk van andere 
prognostische factoren positief te beïnvloeden In de klinische praktijk moet daarom de eerste stap 
beslaan uit het identificeren van alle langdurig benzodiazepinegebruikers om hen vervolgens te 
adviseren dit gebruik op eigen kracht te staken Du advies moet zo persoonlijk mogelijk zijn, alsmede 
zo eenvoudig mogelijk Voor dit stadium raden wij onze stopbnef aan Patienten die ondanks gebruik 
van meer dan 10 mg diazepam equivalenten per dag stoppen, moeten intensiever vervolgd worden in 
verband met een verhoogd nsico op terugval 
Patienten die niet in staat zijn op eigen kracht te stoppen (en eventueel patiënten die terugvallen 
na een minimale interventie) moeten gemotiveerd worden voor gereguleerde dosisreduclie, mede 
gezien het feit dat patiënten met verslechteren door het slaken van benzodiazepinen en hun 
benzodiazepinegebruik niet verruilen voor alcohol, nicotine of andere psychofarmaca Bovendien 
wordt geschat dat de investenngskosten na ongeveer 20 maanden zullen zijn terugverdiend indien 
deze interventie plaatsvindt in de huisartspraktijk Andere redenen om gereguleerde dosisreductie in 
de huisartspraktijk uit te voeren zijn het feit dat (a) succespercentages in een andere settings 
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vergelijkbaar zijn (zie hoofdstuk 3), (b) patiënten voorkeur hebben voor behandeling door hun eigen 
huisarts en (c) zowel deelnemende huisartsen als patiënten tevreden zijn over deze behandeling 
Patienten die meer dan 10 mg diazepam equivalenten per dag gebruiken voor aanvang van 
gereguleerde dosisreductie, die meer dan 2 eenheden alcohol per dag nuttigen of een score van dne of 
hoger hebben op de schaal 'gebrek aan therapietouw' van de Bendep-SRQ, zouden reeds op voorhand 
verwezen kunnen worden naar een tweedelijns setting 
Additionele psychotherapeutische interventies gelijktijdig met gereguleerde dosisreductie 
moeten worden vermeden, aangezien zowel uit onze meta-analyse, als binnen onze eigen studie, geen 
meerwaarde hiervan werd gevonden Indien een patient zijn gebruik niet kan sloppen met behulp van 
gereguleerde dosisreductie, kan een tweede poging worden ondernomen na toevoeging van 
carbamazepine of Imipramine (zie hoofdstuk 3) Vooralsnog blijft echter onduidelijk wal de 
behandeling van eerste keus is voor patiënten die hun gebruik niet kunnen staken (ook na toevoeging 
van de eerder genoemde psychofarmaca) of terugvallen In deze gevallen zullen huisarts en patient 
samen de voor- en nadelen van langdurig benzodiazepinegebruik moeten afwegen Psychiatrische 
screening en/of advies kan een waardevolle aanvulling zijn bij het maken van een juiste beslissing 
Aanbevelingen voor verder onderzoek 
Belangrijke aandachtsgebieden bij het terugdringen van langdurig benzodiazepinegebruik in de 
huisartspraktijk is het motiveren van patiënten hun gebruik te staken en het voorkomen van terugval 
na succesvol slaken Het lijkt dan ook niet zinvol alleen te zoeken naar optimalisatie van de huidige 
behandelingsvormen, maar ook aandacht te besteden aan preventie van langdurig gebruik 
Toekomstig onderzoek moet zich richten op het motiveren van patiënten (en huisartsen ') voor 
benzodiazepine reductie Zo kunnen bijvoorbeeld de 'stages of change', zoals gebruikt in de 
verslavingszorg worden gebruikt Aangezien ongeveer 50% van de succesvol afgebouwde patiënten 
op termijn terugvalt, zullen terugvalpreventie programma's moeten worden ontwikkeld, bijvoorbeeld 
schriftelijke reminders of ondersteunende consulten door huisarts of psycholoog Daarnaast zal het 
effect van hel behandelen van onderliggende psychiatrische aandoeningen na afbouw geëvalueerd 
moeten worden, met name in het licht van terugvalpreventie Tenslotte zullen trapsgewijze studies 
moeten worden uitgevoerd om het effect te onderzoeken van adjuvante medicamenteuze of 
psychotherapeutische ondersteuning bij therapieresislente patiënten Deze programma's dienen niet 
beperkt te blijven tot de huisartspraktijk, maar zullen ook verwijzingen naar de tweede lijn moeten 
evalueren wanneer benzodiazepineafbouw in de eerste lijn faalt 
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1 Het vragen van informed consent kan valide klinisch onderzoek onmogelijk maken 
(dit proefschrift) 
2 Het is problematisch dat veel artsen benzodiazepine-prescripties continueren zonder dat ZIJ weet 
hebben van de redenen waarvoor het middel indertijd gestart is 
(dit proefschrift) 
3 Een hogere dosering benzodiazepinen is, ongeacht het type interventie, de belangrijkste 
voorspeller of iemand in staat is zijn gebruik te staken, alsmede voorgoed gestaakt te blijven 
(dit proefschrift) 
4 Voor een substantieel deel van de benzodiazepinegebruikers draagt het benzodiazepinegebruik 
niet in positieve zin bij aan hun psychisch welbevinden 
(dit proefschrift) 
5 Slechts 1 op de 6 langdurig benzodiazepinegebruikers is bereid onder begeleiding van zijn huisarts 
een poging te doen zijn gebruik te staken 
(dit proefschrift) 
6 Ziektekostenverzekeraars moeten benzodiazepinen voor maximaal 4 maanden per jaar vergoeden 
indien zij worden voorgeschreven in de eerste lijn 
(dit proefschrift) 
1 Vanwege de hoge prevalentie van psychiatrische co-morbiditeit zijn diagnose behandel 
combinaties, de zogenaamde DBC's, in de psychiatrie een ondoenlijke zaak 
8 Beweringen dat patiënten met een specifieke psychiatrische aandoening benzodiazepincgebruik 
moeilijker kunnen staken dan anderen kan niet wetenschappelijk worden onderbouwd 
9 Gereguleerde dosisreductie is een effectieve wijze om langdurig benzodiazepincgebruik op 
langere termijn te reduceren 
(dit proefschrift) 
10. De verslavende eigenschappen van benzodiazepinen spelen een belangrijke rol bij het niet kunnen 
staken van deze middelen 
(dit proefschrift) 
11 De idee dat een proefschrift een reflectie is van iemands levenswerk staat in schril contrast met de 
gemiddelde leeftijd van promovendi 
12 Geld maakt niet gelukkig, wel de relatieve hoeveelheid ten opzichte van je omgeving 
13 De hoogte van de impactfactor van het tijdschrift waarin een manuscript geplaatst wordt, wordt 
naast de wetenschappelijke kwaliteit van het onderzoek bepaald door de mate waarin een 
onderwerp wetenschappelijk in de mode is 
14 Het is eenvoudiger stelling te nemen dan een stelling te maken 

